EMDEON CORPORATION
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
Form 10-Q
|
|
|
þ
|
|
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
|
|
|
|
|
|
For the quarterly period ended
September 30, 2006
|
|
|
|
|
|
|
|
or
|
|
|
|
|
|
|
|
|
|
o
|
|
TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
|
|
|
|
|
|
For the transition period
from
to
|
Commission file number: 0-24975
EMDEON CORPORATION
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
|
|
94-3236644
|
(State of
incorporation)
|
|
(I.R.S. employer identification
no.)
|
|
|
|
669 River Drive, Center 2
Elmwood Park, New Jersey
|
|
07407-1361
(Zip code)
|
(Address of principal executive
office)
|
|
|
(201) 703-3400
(Registrants telephone
number including area code)
Indicate by check mark whether the registrant: (1) has
filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past
90 days.
Yes þ No o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, or a non-accelerated
filer. See definition of accelerated filer and large
accelerated filer in
Rule 12b-2
of the Exchange Act.
Large accelerated
filer þ Accelerated
filer o Non-accelerated
filer o
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Exchange Act).
Yes o No þ
As of November 3, 2006, there were 284,628,031 shares
of
Emdeon Common Stock outstanding (including unvested shares of
restricted Emdeon Common Stock).
EMDEON
CORPORATION
QUARTERLY
REPORT ON
FORM 10-Q
For the period ended September 30, 2006
TABLE OF
CONTENTS
WebMD®,
WebMD
Health®,
CME
Circle®,
dakota
imagingtm,
Emdeontm,
Emdeon Business
Servicestm,
eMedicine®,
Envoy®,
ExpressBill®,
Healthpayers
USA®,
MedicineNet®,
Medifax®,
Medifax-EDI®,
Medpulse®,
Medscape®,
MEDPOR®,
Medsite®,
POREX®,
Publishers
Circle®,
RxList®,
Select Quality
Care®,
Summex®,
theheart.org®,
The Little Blue
Booktm
and
ViPS®
are trademarks of Emdeon Corporation or its subsidiaries.
2
FORWARD-LOOKING
STATEMENTS
This Quarterly Report on
Form 10-Q
contains both historical and forward-looking statements. All
statements other than statements of historical fact are, or may
be, forward-looking statements. For example, statements
concerning projections, predictions, expectations, estimates or
forecasts and statements that describe our objectives, future
performance, plans or goals are, or may be, forward-looking
statements. These forward-looking statements reflect
managements current expectations concerning future results
and events and can generally be identified by the use of
expressions such as may, will,
should, could, would,
likely, predict, potential,
continue, future, estimate,
believe, expect, anticipate,
intend, plan, foresee, and
other similar words or phrases, as well as statements in the
future tense.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual
results, performance or achievements to be different from any
future results, performance and achievements expressed or
implied by these statements. The following important risks and
uncertainties could affect our future results, causing those
results to differ materially from those expressed in our
forward-looking statements:
|
|
|
|
|
the inability to successfully deploy new or updated applications
or services;
|
|
|
|
the failure to achieve sufficient levels of customer utilization
and market acceptance of new or updated products and services;
|
|
|
|
difficulties in forming and maintaining relationships with
healthcare industry participants, including healthcare payers
and providers and vendors of services to those payers and
providers;
|
|
|
|
the pending sale of a 52% interest in our Emdeon Business
Services segment and its effects on that segment and on our
company as a whole;
|
|
|
|
the inability to attract and retain qualified personnel;
|
|
|
|
the anticipated benefits from acquisitions or divestitures not
being fully realized or not being realized within the expected
time frames;
|
|
|
|
general economic, business or regulatory conditions affecting
the healthcare, information technology, Internet and plastics
industries being less favorable than expected; and
|
|
|
|
the other risks and uncertainties described in this Quarterly
Report on
Form 10-Q
under the heading Managements Discussion and
Analysis of Financial Condition and Results of
Operations Factors That May Affect Our Future
Financial Condition or Results of Operations.
|
These factors are not necessarily all of the important factors
that could cause actual results to differ materially from those
expressed in any of our forward-looking statements. Other
unknown or unpredictable factors also could have material
adverse effects on our future results.
The forward-looking statements included in this Quarterly Report
are made only as of the date of this Quarterly Report. Except as
required by law or regulation, we do not undertake any
obligation to update any forward-looking statements to reflect
subsequent events or circumstances.
3
PART I
FINANCIAL INFORMATION
|
|
ITEM 1.
|
Financial
Statements
|
EMDEON
CORPORATION
(In
thousands, except share and per share data, unaudited)
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
875,460
|
|
|
$
|
155,616
|
|
Short-term investments
|
|
|
71,943
|
|
|
|
267,387
|
|
Accounts receivable, net of
allowance for doubtful accounts of $1,283 at September 30,
2006 and $6,909 at December 31, 2005
|
|
|
101,217
|
|
|
|
195,317
|
|
Inventory
|
|
|
9,342
|
|
|
|
10,791
|
|
Prepaid expenses and other current
assets
|
|
|
39,889
|
|
|
|
30,936
|
|
Assets held for sale
|
|
|
949,693
|
|
|
|
|
|
Assets of discontinued operations
|
|
|
|
|
|
|
254,247
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
2,047,544
|
|
|
|
914,294
|
|
Marketable equity securities
|
|
|
2,668
|
|
|
|
4,430
|
|
Property and equipment, net
|
|
|
66,907
|
|
|
|
95,686
|
|
Goodwill
|
|
|
288,109
|
|
|
|
895,975
|
|
Intangible assets, net
|
|
|
125,969
|
|
|
|
235,271
|
|
Other assets
|
|
|
68,667
|
|
|
|
50,027
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
$
|
2,599,864
|
|
|
$
|
2,195,683
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
7,014
|
|
|
$
|
7,739
|
|
Accrued expenses
|
|
|
98,745
|
|
|
|
170,102
|
|
Deferred revenue
|
|
|
76,515
|
|
|
|
68,390
|
|
Liabilities held for sale
|
|
|
85,591
|
|
|
|
|
|
Liabilities of discontinued
operations
|
|
|
|
|
|
|
68,436
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
267,865
|
|
|
|
314,667
|
|
1.75% convertible subordinated
notes due 2023
|
|
|
350,000
|
|
|
|
350,000
|
|
31/8% convertible
notes due 2025
|
|
|
300,000
|
|
|
|
300,000
|
|
Other long-term liabilities
|
|
|
14,331
|
|
|
|
14,518
|
|
Minority interest in WebMD Health
Corp.
|
|
|
60,413
|
|
|
|
43,229
|
|
Convertible redeemable exchangeable
preferred stock, $0.0001 par value; 10,000 shares
authorized, issued and outstanding at September 30, 2006
and December 31, 2005
|
|
|
98,709
|
|
|
|
98,533
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock, $0.0001 par
value; 4,990,000 shares authorized; no shares issued
|
|
|
|
|
|
|
|
|
Common stock, $0.0001 par
value; 900,000,000 shares authorized;
438,018,221 shares issued at September 30, 2006;
428,624,239 shares issued at December 31, 2005
|
|
|
44
|
|
|
|
43
|
|
Additional paid-in capital
|
|
|
12,200,936
|
|
|
|
12,121,431
|
|
Deferred stock compensation
|
|
|
|
|
|
|
(3,699
|
)
|
Treasury stock, at cost;
157,625,719 shares at September 30, 2006;
150,296,414 shares at December 31, 2005
|
|
|
(1,022,325
|
)
|
|
|
(950,482
|
)
|
Accumulated deficit
|
|
|
(9,679,027
|
)
|
|
|
(10,100,164
|
)
|
Accumulated other comprehensive
income
|
|
|
8,918
|
|
|
|
7,607
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
1,508,546
|
|
|
|
1,074,736
|
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND
STOCKHOLDERS EQUITY
|
|
$
|
2,599,864
|
|
|
$
|
2,195,683
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
4
EMDEON
CORPORATION
CONSOLIDATED
STATEMENTS OF OPERATIONS
(In thousands, except per share data, unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Services
|
|
$
|
274,158
|
|
|
$
|
237,198
|
|
|
$
|
792,509
|
|
|
$
|
690,615
|
|
Products
|
|
|
25,574
|
|
|
|
23,824
|
|
|
|
76,048
|
|
|
|
72,096
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
299,732
|
|
|
|
261,022
|
|
|
|
868,557
|
|
|
|
762,711
|
|
Cost of operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Services
|
|
|
158,967
|
|
|
|
142,484
|
|
|
|
472,951
|
|
|
|
414,533
|
|
Products
|
|
|
10,743
|
|
|
|
9,582
|
|
|
|
32,974
|
|
|
|
30,562
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cost of operations
|
|
|
169,710
|
|
|
|
152,066
|
|
|
|
505,925
|
|
|
|
445,095
|
|
Development and engineering
|
|
|
9,243
|
|
|
|
8,912
|
|
|
|
27,164
|
|
|
|
26,595
|
|
Sales, marketing, general and
administrative
|
|
|
74,050
|
|
|
|
63,865
|
|
|
|
216,263
|
|
|
|
189,292
|
|
Depreciation and amortization
|
|
|
18,189
|
|
|
|
15,801
|
|
|
|
51,964
|
|
|
|
44,826
|
|
Legal expense
|
|
|
1,023
|
|
|
|
5,904
|
|
|
|
1,840
|
|
|
|
14,347
|
|
Advisory expense
|
|
|
2,126
|
|
|
|
|
|
|
|
4,198
|
|
|
|
|
|
Loss on investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,642
|
|
Loss on redemption of convertible
debt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,902
|
|
Interest income
|
|
|
6,599
|
|
|
|
5,124
|
|
|
|
15,450
|
|
|
|
13,380
|
|
Interest expense
|
|
|
4,723
|
|
|
|
2,996
|
|
|
|
14,082
|
|
|
|
11,670
|
|
Other expense
|
|
|
|
|
|
|
1,863
|
|
|
|
|
|
|
|
1,863
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
before income tax provision and minority interest
|
|
|
27,267
|
|
|
|
14,739
|
|
|
|
62,571
|
|
|
|
36,859
|
|
Income tax provision
|
|
|
3,474
|
|
|
|
1,851
|
|
|
|
12,082
|
|
|
|
3,567
|
|
Minority interest in WebMD Health
Corp., net of tax
|
|
|
140
|
|
|
|
38
|
|
|
|
(653
|
)
|
|
|
38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
23,653
|
|
|
|
12,850
|
|
|
|
51,142
|
|
|
|
33,254
|
|
Income from discontinued
operations, net of tax
|
|
|
358,048
|
|
|
|
1,257
|
|
|
|
370,171
|
|
|
|
6,868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
381,701
|
|
|
$
|
14,107
|
|
|
$
|
421,313
|
|
|
$
|
40,122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.08
|
|
|
$
|
0.04
|
|
|
$
|
0.18
|
|
|
$
|
0.10
|
|
Income from discontinued operations
|
|
|
1.25
|
|
|
|
0.00
|
|
|
|
1.29
|
|
|
|
0.02
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1.33
|
|
|
$
|
0.04
|
|
|
$
|
1.47
|
|
|
$
|
0.12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.08
|
|
|
$
|
0.03
|
|
|
$
|
0.17
|
|
|
$
|
0.09
|
|
Income from discontinued operations
|
|
|
1.19
|
|
|
|
0.01
|
|
|
|
1.25
|
|
|
|
0.02
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1.27
|
|
|
$
|
0.04
|
|
|
$
|
1.42
|
|
|
$
|
0.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares
outstanding used in computing income per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
287,967
|
|
|
|
356,091
|
|
|
|
286,749
|
|
|
|
339,576
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
300,012
|
|
|
|
370,313
|
|
|
|
297,409
|
|
|
|
351,875
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
5
EMDEON
CORPORATION
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(In thousands, unaudited)
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
Cash flows from operating
activities:
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
421,313
|
|
|
$
|
40,122
|
|
Adjustments to reconcile net income
to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
Income from discontinued
operations, net of tax
|
|
|
(370,171
|
)
|
|
|
(6,868
|
)
|
Depreciation and amortization
|
|
|
51,964
|
|
|
|
44,826
|
|
Minority interest in WebMD Health
Corp., net of tax
|
|
|
(653
|
)
|
|
|
38
|
|
Amortization of debt issuance costs
|
|
|
2,190
|
|
|
|
1,856
|
|
Non-cash advertising
|
|
|
4,454
|
|
|
|
6,999
|
|
Non-cash stock-based compensation
|
|
|
35,235
|
|
|
|
3,631
|
|
Bad debt expense
|
|
|
1,170
|
|
|
|
1,532
|
|
Loss on investments
|
|
|
|
|
|
|
3,642
|
|
Loss on redemption of convertible
debt
|
|
|
|
|
|
|
1,902
|
|
Reversal of income tax valuation
allowance applied to goodwill
|
|
|
5,307
|
|
|
|
115
|
|
Changes in operating assets and
liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(19,930
|
)
|
|
|
(30,441
|
)
|
Inventory
|
|
|
601
|
|
|
|
472
|
|
Prepaid expenses and other, net
|
|
|
(9,701
|
)
|
|
|
(2,399
|
)
|
Accounts payable
|
|
|
825
|
|
|
|
(6,147
|
)
|
Accrued expenses and other
long-term liabilities
|
|
|
3,284
|
|
|
|
10,710
|
|
Deferred revenue
|
|
|
9,926
|
|
|
|
9,430
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by continuing
operations
|
|
|
135,814
|
|
|
|
79,420
|
|
Net cash provided by discontinued
operations
|
|
|
25,985
|
|
|
|
19,681
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating
activities
|
|
|
161,799
|
|
|
|
99,101
|
|
Cash flows from investing
activities:
|
|
|
|
|
|
|
|
|
Proceeds from maturities and sales
of
available-for-sale
securities
|
|
|
831,145
|
|
|
|
336,014
|
|
Purchases of
available-for-sale
securities
|
|
|
(632,955
|
)
|
|
|
(516,109
|
)
|
Purchases of property and equipment
|
|
|
(38,231
|
)
|
|
|
(39,107
|
)
|
Proceeds received from sale of
discontinued operations
|
|
|
524,245
|
|
|
|
|
|
Cash paid in business combinations,
net of cash acquired
|
|
|
(119,635
|
)
|
|
|
(74,380
|
)
|
Other changes in equity of
discontinued operations
|
|
|
28,279
|
|
|
|
13,331
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in)
continuing operations
|
|
|
592,848
|
|
|
|
(280,251
|
)
|
Net cash used in discontinued
operations
|
|
|
(26,010
|
)
|
|
|
(23,179
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in)
investing activities
|
|
|
566,838
|
|
|
|
(303,430
|
)
|
Cash flows from financing
activities:
|
|
|
|
|
|
|
|
|
Proceeds from issuance of common
stock
|
|
|
62,768
|
|
|
|
43,384
|
|
Purchases of treasury stock
|
|
|
(71,843
|
)
|
|
|
(4,596
|
)
|
Net proceeds from issuance of
convertible debt
|
|
|
|
|
|
|
289,875
|
|
Redemption of convertible debt
|
|
|
|
|
|
|
(86,694
|
)
|
Payments of notes payable and other
|
|
|
(359
|
)
|
|
|
(495
|
)
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by
continuing operations
|
|
|
(9,434
|
)
|
|
|
241,474
|
|
Net cash (used in) provided by
discontinued operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by
financing activities
|
|
|
(9,434
|
)
|
|
|
241,474
|
|
Effect of exchange rates on cash
|
|
|
616
|
|
|
|
(1,117
|
)
|
|
|
|
|
|
|
|
|
|
Net increase in cash and cash
equivalents
|
|
|
719,819
|
|
|
|
36,028
|
|
Changes in cash attributable to
discontinued operations
|
|
|
25
|
|
|
|
3,498
|
|
Cash and cash equivalents at
beginning of period
|
|
|
155,616
|
|
|
|
39,980
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of
period
|
|
$
|
875,460
|
|
|
$
|
79,506
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
6
EMDEON
CORPORATION
(In thousands, except share and per share data,
unaudited)
|
|
1.
|
Background
and Basis of Presentation
|
Background
Emdeon Corporation (Emdeon or the
Company) is a Delaware corporation that was
incorporated in December 1995 and commenced operations in
January 1996 as Healtheon Corporation. Emdeons Common
Stock began trading on the Nasdaq National Market under the
symbol HLTH on February 11, 1999 and now trades
on the Nasdaq Global Select Market. The Company changed its name
to Healtheon/WebMD Corporation in November 1999 and to WebMD
Corporation in September 2000. In October 2005, WebMD
Corporation changed its name to Emdeon Corporation in connection
with the initial public offering of equity securities of WebMD
Health Corp. (WHC), a subsidiary that the Company
formed to act as a holding company for the business of the
Companys WebMD segment (described below) and to issue
shares in that initial public offering. Because the WebMD name
had been more closely associated with the Companys public
and private online portals than with its other businesses, the
Companys Board of Directors determined that WHC would,
following its initial public offering, have the sole right to
use the WebMD name and related trademarks.
WHCs Class A Common Stock began trading on the Nasdaq
National Market under the symbol WBMD on
September 29, 2005 and now trades on the Nasdaq Global
Select Market. As of September 30, 2006, the Company owned
48,100,000 shares of WHC Class B Common Stock, which
represents 85.6% of all outstanding WHCs Class A and
Class B Common Stock. WHC Class A Common Stock has one
vote per share, while WHC Class B Common Stock has five
votes per share. As a result, the WHC Class B Common Stock
owned by the Company represented, as of September 30, 2006,
96.6% of the combined voting power of WHCs outstanding
Common Stock.
Basis of
Presentation
The accompanying consolidated financial statements include the
consolidated accounts of Emdeon and its subsidiaries and have
been prepared in United States dollars, and in accordance with
U.S. generally accepted accounting principles
(GAAP). The consolidated accounts include 100% of
the assets and liabilities of the majority owned WHC and the
ownership interests of minority stockholders of WHC are recorded
as Minority interest in WebMD Health Corp. in the accompanying
consolidated balance sheets.
On September 14, 2006, the Company completed the sale of
its Emdeon Practice Services segment (EPS).
Accordingly, the historical results of EPS, including the gain
related to the sale, have been reclassified as discontinued
operations in the accompanying unaudited consolidated financial
statements. See Note 2 for a further description of this
transaction.
On September 26, 2006, the Company entered into a
definitive agreement for the sale of a 52% interest in its
Emdeon Business Services segment, excluding the ViPS business
unit (EBS). Accordingly, the underlying assets and
liabilities of EBS as of September 30, 2006 have been
reclassified as assets held for sale and liabilities held for
sale in the accompanying consolidated balance sheets. See
Note 3 for a further description of this transaction.
Interim
Financial Statements
The unaudited consolidated financial statements of the Company
have been prepared by management and reflect all adjustments
(consisting of only normal recurring adjustments) that, in the
opinion of management, are necessary for a fair presentation of
the interim periods presented. The results of operations for the
three and nine months ended September 30, 2006 are not
necessarily indicative of the results to be expected for any
subsequent period or for the entire year ending
December 31, 2006. Certain information and footnote
7
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
disclosures normally included in financial statements prepared
in accordance with GAAP have been condensed or omitted under the
Securities and Exchange Commissions (the SEC)
rules and regulations.
The unaudited consolidated financial statements and notes
included herein should be read in conjunction with the
Companys audited consolidated financial statements and
notes for the year ended December 31, 2005, which are
included in the Companys Annual Report on
Form 10-K
filed with the SEC.
Accounting
Estimates
The preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that
affect the amounts reported in the consolidated financial
statements and accompanying notes. The Company bases its
estimates on historical experience, current business factors,
and various other assumptions that the Company believes are
necessary to consider in order to form a basis for making
judgments about the carrying values of assets and liabilities,
the recorded amounts of revenue and expenses, and disclosure of
contingent assets and liabilities. The Company is subject to
uncertainties such as the impact of future events, economic,
environmental and political factors, and changes in the
Companys business environment; therefore, actual results
could differ from these estimates. Accordingly, the accounting
estimates used in the preparation of the Companys
financial statements will change as new events occur, as more
experience is acquired, as additional information is obtained
and as the Companys operating environment changes. Changes
in estimates are made when circumstances warrant. Such changes
in estimates and refinements in estimation methodologies are
reflected in reported results of operations; if material, the
effects of changes in estimates are disclosed in the notes to
the consolidated financial statements. Significant estimates and
assumptions by management affect: the allowance for doubtful
accounts, the carrying value of inventory, the carrying value of
prepaid advertising services, the carrying value of long-lived
assets (including goodwill and intangible assets), the
amortization and depreciation period of long-lived assets
(excluding goodwill), the carrying value, capitalization and
amortization of software development costs, the carrying value
of short-term and long-term investments, the provision for
income taxes and related deferred tax accounts, certain accrued
expenses, revenue recognition, contingencies, litigation and the
value attributed to employee stock options and other stock-based
awards.
Minority
Interest
Minority interest represents the minority stockholders
proportionate share of equity and net income or net loss of the
Companys consolidated WebMD segment. Additionally,
minority interest includes the stock-based compensation expense
related to stock options and other stock awards based on WHC
Class A Common Stock that have been expensed since the
adoption of Statement of Financial Accounting Standards
(SFAS) No. 123, (Revised 2004):
Share-Based Payment on January 1, 2006, and to a much
lesser extent, the expense associated with these awards that
were expensed in connection with APB Opinion No. 25,
Accounting for Stock Issued to Employees
(APB 25) prior to January 1, 2006. As of
September 30, 2006 and December 31, 2005, the minority
stockholders proportionate share of the equity in WHC of
$60,413 and $43,229, respectively, are reflected as Minority
interest in WebMD Health Corp. in the accompanying consolidated
balance sheets. The minority stockholders proportionate
share of net income or loss for the three and nine months ended
September 30, 2006 was income of $140 and a loss of $653,
respectively, and income of $38 for the three and nine months
ended September 30, 2005.
Net
Income Per Common Share
Basic income per common share and diluted income per common
share are presented in conformity with SFAS No. 128,
Earnings Per Share (SFAS 128). In
accordance with SFAS 128, basic income per common share has
been computed using the weighted-average number of shares of
common stock outstanding during the period, increased to give
effect to the participating rights of the convertible redeemable
exchangeable
8
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
preferred stock. Diluted income per common share has been
computed using the weighted-average number of shares of common
stock outstanding during the period, increased to give effect to
potentially dilutive securities. Additionally, for purposes of
calculating diluted income per common share of the Company, the
numerator has been adjusted to consider the effect of
potentially dilutive securities of WHC, which can dilute the
portion of WHCs net income otherwise retained by the
Company. The impact of WHCs potentially dilutive
securities on the calculation of diluted income per common share
was not material. The following table presents the calculation
of basic and diluted income per common share (shares in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
23,653
|
|
|
$
|
12,850
|
|
|
$
|
51,142
|
|
|
$
|
33,254
|
|
Income from discontinued
operations, net of tax
|
|
|
358,048
|
|
|
|
1,257
|
|
|
|
370,171
|
|
|
|
6,868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
381,701
|
|
|
$
|
14,107
|
|
|
$
|
421,313
|
|
|
$
|
40,122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock
|
|
|
277,329
|
|
|
|
345,453
|
|
|
|
276,111
|
|
|
|
328,938
|
|
Convertible redeemable
exchangeable preferred stock
|
|
|
10,638
|
|
|
|
10,638
|
|
|
|
10,638
|
|
|
|
10,638
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average
shares Basic
|
|
|
287,967
|
|
|
|
356,091
|
|
|
|
286,749
|
|
|
|
339,576
|
|
Employee stock options, restricted
stock and warrants
|
|
|
12,045
|
|
|
|
14,222
|
|
|
|
10,660
|
|
|
|
12,299
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted weighted-average shares
after assumed conversions Diluted
|
|
|
300,012
|
|
|
|
370,313
|
|
|
|
297,409
|
|
|
|
351,875
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.08
|
|
|
$
|
0.04
|
|
|
$
|
0.18
|
|
|
$
|
0.10
|
|
Income from discontinued operations
|
|
|
1.25
|
|
|
|
0.00
|
|
|
|
1.29
|
|
|
|
0.02
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1.33
|
|
|
$
|
0.04
|
|
|
$
|
1.47
|
|
|
$
|
0.12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.08
|
|
|
$
|
0.03
|
|
|
$
|
0.17
|
|
|
$
|
0.09
|
|
Income from discontinued operations
|
|
|
1.19
|
|
|
|
0.01
|
|
|
|
1.25
|
|
|
|
0.02
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1.27
|
|
|
$
|
0.04
|
|
|
$
|
1.42
|
|
|
$
|
0.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company has excluded convertible notes, as well as certain
outstanding warrants and stock options, from the calculation of
diluted income per common share because such securities were
anti-dilutive during the periods presented. The following table
presents the total number of shares that could potentially
dilute basic income per common share in the future that were not
included in the computation of diluted income per common share
during the periods presented (shares in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Options and warrants
|
|
|
46,467
|
|
|
|
56,889
|
|
|
|
56,106
|
|
|
|
59,569
|
|
Convertible notes
|
|
|
42,015
|
|
|
|
42,015
|
|
|
|
42,015
|
|
|
|
42,015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
88,482
|
|
|
|
98,904
|
|
|
|
98,121
|
|
|
|
101,584
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Products
and Services
The Companys revenue consists of product and service
revenue. Service revenue is comprised of revenue earned through
the Companys automated business and administrative
functions for healthcare payers and providers, and consulting
services to governmental agencies and commercial enterprises,
and content sponsorship, advertising and licensing of the
Companys private and public online portals. The
Companys product revenue is primarily comprised of porous
plastic products and components used in healthcare, industrial
and consumer applications which are sold through its Porex
segment. Additionally, product revenues include other
miscellaneous products, such as, medical forms and supplies,
medical reference publications and directories, as well as other
miscellaneous software products.
Sales,
Use and Value Added Tax
The Company excludes sales, use and value added tax from revenue
in the consolidated statements of operations.
Advisory
Expense
Advisory expense includes professional fees, primarily
consisting of legal, accounting and financial advisory services,
related to the pending sale transaction involving EBS.
Assets
and Liabilities Held for Sale
When specific actions to dispose of assets and liabilities
progress to the point that the plan of sale criteria included in
Statement of Financial Accounting Standards No. 144,
Accounting for the Impairment or Disposal of Long-Lived
Assets have been met, impairments to the extent they
exist, are recognized and the underlying assets and liabilities
are reflected as Assets Held for Sale and Liabilities Held for
Sale, respectively, in the accompanying consolidated balance
sheets. There was no impairment charge recorded in relation to
the pending sale of the Companys Emdeon Business Services
segment.
Recent
Accounting Pronouncements
In September 2006, the Financial Accounting Standard Board
(FASB) issued SFAS No. 157, Fair
Value Measurements (SFAS 157).
SFAS 157 defines fair value, establishes a framework for
measuring fair value and expands disclosure of fair value
measurements. SFAS 157 applies under other accounting
pronouncements that require or permit fair value measurements
and, accordingly, does not require any new fair value
measurements. SFAS 157 is effective for financial
statements issued for fiscal years beginning after
10
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
November 15, 2007. The Company is currently evaluating the
impact, if any, that this new standard will have on the
Companys results of operations, financial position or cash
flows.
In July 2006, the FASB issued FASB Interpretation No. 48,
Accounting for Uncertainty in Income Taxes,
(FIN 48), which clarifies the accounting for
uncertainty in income taxes recognized in the financial
statements in accordance with SFAS No. 109,
Accounting for Income Taxes. The interpretation
prescribes a recognition threshold and measurement attribute for
the financial statement recognition and measurement of a tax
position taken or expected to be taken in a tax return. It also
provides guidance on derecognizing, classification, interest and
penalties, accounting in interim periods, disclosure and
transition. The provisions of FIN 48 are effective for
fiscal years beginning after December 15, 2006. The Company
is currently evaluating the impact, if any, that this new
standard will have on the Companys results of operations,
financial position or cash flows.
Reclassifications
Certain reclassifications have been made to the prior period
financial statements to conform to the current year presentation.
|
|
2.
|
Discontinued
Operations
|
In February 2006, the Company announced that, in connection with
inquiries received from several third parties expressing an
interest in acquiring EPS and EBS, the Companys Board of
Directors authorized commencing a process to evaluate strategic
alternatives relating to EPS and EBS. For information regarding
a pending sale transaction involving EBS, see Note 3.
On August 8, 2006 the Company entered into a Stock Purchase
Agreement for the sale of EPS to Sage Software, Inc. (Sage
Software), an indirect wholly owned subsidiary of The Sage
Group plc. On September 14, 2006, the Company completed the
sale of Emdeon Practice Services, Inc., which together with its
subsidiaries comprised EPS (the EPS Sale).
Accordingly, the historical financial information of EPS has
been reclassified as discontinued operations in the accompanying
unaudited consolidated financial statements. The Company
received net cash proceeds of $529,466, which does not include
$35,000 being held in escrow as security for the Companys
indemnification obligations under the Stock Purchase Agreement.
One-third and two-thirds of the amount in escrow are scheduled
to be released twelve and eighteen months from the closing date,
and are included in other current assets and other assets,
respectively, in the accompanying consolidated balance sheet as
of September 30, 2006. The Company incurred approximately
$7,700 of professional fees and other expenses associated with
the EPS Sale, of which approximately $2,500 was unpaid as of
September 30, 2006 and is therefore included in accrued
expenses in the accompanying consolidated balance sheet as of
September 30, 2006. In connection with the EPS Sale, the
Company recognized a gain of $352,269, which is included in
income from discontinued operations, net of tax of $34,714, in
the accompanying consolidated statements of operations during
the three and nine months ended September 30, 2006. While
the determination of the gain on disposal is substantially
complete, the purchase price is subject to customary
post-closing adjustments, including an adjustment for working
capital, which has not been finalized. Also included in income
from discontinued operations for the three months ended
September 30,
11
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
2006 is $5,779 representing the income from operations of EPS,
net of tax, through the date of sale on September 14, 2006.
Summarized operating results for EPS through September 14,
2006 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Period
|
|
|
|
|
|
For the Period
|
|
|
|
|
|
|
July 1, 2006
|
|
|
For the Three
|
|
|
January 1, 2006
|
|
|
For the Nine
|
|
|
|
through
|
|
|
Months Ended
|
|
|
through
|
|
|
Months Ended
|
|
|
|
September 14,
|
|
|
September 30,
|
|
|
September 14,
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Revenue
|
|
$
|
59,351
|
|
|
$
|
75,499
|
|
|
$
|
212,329
|
|
|
$
|
227,113
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before taxes
|
|
|
5,958
|
|
|
|
3,942
|
|
|
|
19,469
|
|
|
|
10,980
|
|
Taxes on earnings
|
|
|
179
|
|
|
|
2,685
|
|
|
|
1,567
|
|
|
|
4,112
|
|
Gain on disposal, net of tax
|
|
|
352,269
|
|
|
|
|
|
|
|
352,269
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued
operations, net of tax
|
|
$
|
358,048
|
|
|
$
|
1,257
|
|
|
$
|
370,171
|
|
|
$
|
6,868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The assets and liabilities of EPS are reflected as discontinued
operations as of December 31, 2005 and were comprised of
the following:
|
|
|
|
|
|
|
December 31,
|
|
|
|
2005
|
|
|
Assets of discontinued operations:
|
|
|
|
|
Goodwill
|
|
$
|
179,574
|
|
Accounts receivable, net
|
|
|
37,753
|
|
Property and equipment, net
|
|
|
20,346
|
|
Other assets
|
|
|
16,574
|
|
|
|
|
|
|
Total
|
|
$
|
254,247
|
|
|
|
|
|
|
Liabilities of discontinued
operations:
|
|
|
|
|
Deferred revenue
|
|
$
|
47,450
|
|
Accounts payable and accrued
liabilities
|
|
|
20,151
|
|
Other liabilities
|
|
|
835
|
|
|
|
|
|
|
Total
|
|
$
|
68,436
|
|
|
|
|
|
|
In consideration of
EITF 03-13,
Applying the Conditions in Paragraph 42 of FASB
Statement No. 144 in Determining Whether to Report
Discontinued Operations
(EITF 03-13),
the Company will continue to generate cash flows from EPS after
the disposal date of September 14, 2006. The continuing
cash inflows will relate to revenue recognized by EBS, which
provides print-and-mail services, including postage, and
electronic data interchange services to EPSs customer base
under an agreement between EBS and EPS that continues through
2013. Also through this agreement, EBS will have continuing cash
outflows to EPS, to be included in cost of operations, related
to its obligations to pay sales commissions related to the
submission of claims. The Company believes that these continuing
cash flows will not be significant in accordance with
EITF 03-13.
The revenue and cost of operations associated with these
activities that were previously eliminated in consolidation were
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Period
|
|
|
|
For the Period
|
|
|
|
|
July 1, 2006
|
|
For the Three
|
|
January 1, 2006
|
|
For the Nine
|
|
|
through
|
|
Months Ended
|
|
through
|
|
Months Ended
|
|
|
September 14,
|
|
September 30,
|
|
September 14,
|
|
September 30,
|
|
|
2006
|
|
2005
|
|
2006
|
|
2005
|
|
Revenue
|
|
$
|
9,844
|
|
|
$
|
11,051
|
|
|
$
|
33,164
|
|
|
$
|
33,106
|
|
Cost of operations
|
|
|
1,692
|
|
|
|
2,206
|
|
|
|
5,978
|
|
|
|
6,881
|
|
The Company and Sage Software will make an IRC
Section 338(h)(10) election and will treat the EPS Sale as
a sale of assets for tax purposes. The Company will utilize a
portion of its federal net operating loss
12
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(NOL) carryforwards to offset the gain on this
transaction. Under the Companys Tax Sharing Agreement with
WHC, the Company has agreed to reimburse WHC, at the current
federal statutory tax rate of 35%, for any NOL carryforwards
attributable to WHC that are utilized by the Company in this
transaction. The Company estimates that the amount of WHCs
NOL carryforwards to be utilized in this transaction will be
approximately $240,000 to $260,000 resulting in a cash
reimbursement to WHC of $84,000 to $91,000. The estimates of the
amount of WHCs NOL carryforwards to be utilized and of the
related reimbursement are based on various assumptions and will
not be finalized until the Company completes the calculation of
its 2006 federal income taxes.
In connection with the EPS Sale, the Company entered into a
transition services agreement whereby it will provide EPS with
certain administrative services, including payroll, accounting,
purchasing and procurement, tax and human resource services, as
well as information technology (IT) support. The IT
support services are scheduled to continue to September 2008,
while the majority of the other services are scheduled to be
completed by July 2007. Sage Software may at any time terminate
any individual service prior to the scheduled end date, although
they will continue to remain liable for any costs incurred by
the Company due to early termination. The transition services
fee charged to EPS for the period from September 15, 2006
to September 30, 2006 was $341 and is included in the
Companys Corporate segment.
|
|
3.
|
Assets
and Liabilities Held For Sale
|
On September 26, 2006, the Company entered into a
definitive agreement for the sale of a 52% interest in EBS to an
affiliate of General Atlantic LLC (GA) (the
Pending EBS Transaction). At the closing of this
transaction, the Company will receive approximately $1,200,000
in cash, subject to customary post-closing adjustments including
an adjustment based on the amount of working capital at closing.
The acquisition will be financed with approximately $925,000 in
bank debt and an investment of approximately $320,000 by GA. The
Pending EBS Transaction will be structured so that the Company
and GA each own interests in a limited liability company
(Master LLC), which will own the entities comprising
EBS through a wholly owned limited liability company (EBS
LLC). The bank debt will be an obligation of EBS LLC and
will be guaranteed by Master LLC, but will not be an obligation
of or guaranteed by the Company. After the closing of the
Pending EBS Transaction, the Companys 48% ownership
interest in Master LLC will be reflected as an investment in the
Companys consolidated financial statements and will be
accounted for under the equity method. The Company has
classified the assets and liabilities of EBS as assets and
liabilities held for sale in the accompanying consolidated
balance sheet as of September 30, 2006.
The assets and liabilities of EBS as of September 30, 2006
and December 31, 2005 were comprised of the following:
13
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
Goodwill
|
|
$
|
664,350
|
|
|
$
|
681,612
|
|
Accounts receivable, net
|
|
|
119,667
|
|
|
|
108,609
|
|
Intangible assets, net
|
|
|
108,027
|
|
|
|
119,069
|
|
Property and equipment, net
|
|
|
48,031
|
|
|
|
46,667
|
|
Other assets
|
|
|
9,618
|
|
|
|
8,441
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
949,693
|
|
|
$
|
964,398
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable and accrued
liabilities
|
|
$
|
63,712
|
|
|
$
|
82,476
|
|
Deferred revenue
|
|
|
20,144
|
|
|
|
20,585
|
|
Other liabilities
|
|
|
1,735
|
|
|
|
584
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
85,591
|
|
|
$
|
103,645
|
|
|
|
|
|
|
|
|
|
|
The Company expects to recognize a taxable gain on the Pending
EBS Transaction and expects to utilize approximately $400,000 to
$450,000 of its NOL carryforwards to eliminate a significant
portion of the tax liability that would otherwise result from
this transaction. Approximately $130,000 to $150,000 of the NOL
carryforwards utilized will be NOL carryforwards attributable to
WHC. Under Emdeons Tax Sharing Agreement with WHC, Emdeon
has agreed to reimburse WHC at the current federal statutory tax
rate of 35% for any NOL carryforwards attributable to WHC that
are utilized by Emdeon in this transaction. The Company
currently estimates that the amount of the resulting cash
reimbursement to WHC will be approximately $45,000 to $52,000.
The estimates of the amounts of the utilization of the NOL
carryforwards attributable to WHC and to Emdeon and of the
related reimbursement are based on various assumptions and will
not be finalized until the Company completes the calculation of
its consolidated 2006 federal income taxes.
|
|
4.
|
Stock-Based
Compensation
|
On January 1, 2006, the Company adopted
SFAS No. 123, (Revised 2004): Share-Based
Payment (SFAS 123R), which replaces
SFAS No. 123, Accounting for Stock-Based
Compensation (SFAS 123) and supersedes
APB 25. SFAS 123R requires all share-based payments to
employees, including grants of employee stock options, to be
recognized as compensation expense over the service period
(generally the vesting period) in the consolidated financial
statements based on their fair values. The Company elected to
use the modified prospective transition method and as a result,
prior period results were not restated. Under the modified
prospective transition method, awards that were granted or
modified on or after January 1, 2006 are measured and
accounted for in accordance with SFAS 123R. Unvested stock
options and restricted stock awards that were granted prior to
January 1, 2006 will continue to be accounted for in
accordance with SFAS 123, using the same grant date fair
value and same expense attribution method used under
SFAS 123, except that all awards are recognized in the
results of operations over the remaining vesting periods. The
impact of forfeitures that may occur prior to vesting is also
estimated and considered in the amount recognized for all
stock-based compensation beginning January 1, 2006.
Prior to January 1, 2006, the Company accounted for
stock-based employee compensation using the intrinsic value
method under the recognition and measurement principles of
APB 25, and related interpretations. In accordance with
APB 25, the Company did not recognize stock-based
compensation cost with respect to stock options granted with an
exercise price equal to the market value of the underlying
common stock on the date of grant. As a result, the recognition
of stock-based compensation expense was generally limited to the
expense related to restricted stock awards and stock option
modifications, as well as the amortization of
14
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
deferred compensation related to certain acquisitions in 2000.
Additionally, all restricted stock awards and stock options
granted prior to January 1, 2006 had graded vesting, and
the Company valued these awards and recognized actual and
pro-forma expense, with respect to restricted stock awards and
stock options, as if each vesting portion of the award was a
separate award. This resulted in an accelerated attribution of
compensation expense over the vesting period. As permitted under
SFAS 123R, the Company began using a straight-line
attribution method beginning January 1, 2006 for all stock
options and restricted stock awards granted on or after
January 1, 2006, but will continue to apply the accelerated
attribution method for the remaining unvested portion of any
awards granted prior to January 1, 2006.
The Company has various stock-based compensation plans
(collectively, the Plans) under which directors,
officers and other eligible employees receive awards of options
to purchase Emdeon Common Stock and restricted shares of Emdeon
Common Stock. Additionally, the Companys majority owned
public subsidiary has a similar stock-based compensation plan
that provides for stock options and restricted stock awards
based on WHC Class A Common Stock. The Company also
maintains an Employee Stock Purchase Plan which provides
employees with the ability to buy shares of Emdeon Common Stock
at a discount. The following sections of this note summarize the
activity for each of these plans.
Emdeon
Plans
The Company had an aggregate of 8,142,996 shares of Emdeon
Common Stock available for future grants under the Plans at
September 30, 2006. In addition to the Plans, the Company
has granted options to certain directors, officers and key
employees pursuant to an individual stock option agreement. At
September 30, 2006, there were options to purchase
5,762,700 shares of Emdeon Common Stock outstanding to
these individuals. The terms of these grants are similar to the
terms of the stock options granted under the Plans and
accordingly, the stock option activity of these individuals is
included in all references to the Plans. The Company issues new
shares when stock options are exercised under the Plans.
Stock
Options
Generally, options under the Plans vest and become exercisable
ratably over a three to five year period based on their
individual grant dates subject to continued employment on the
applicable vesting dates. The majority of options granted under
the Plans expire within ten years from the date of grant.
Options are granted at prices not less than the fair market
value of Emdeons Common Stock on the date of grant. The
following table summarizes activity for the Plans for the nine
months ended September 30, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
Weighted Average
|
|
|
Aggregate
|
|
|
|
|
|
|
Exercise
|
|
|
Remaining Contractual
|
|
|
Intrinsic
|
|
|
|
Shares
|
|
|
Price Per Share
|
|
|
Life (In Years)
|
|
|
Value(1)
|
|
|
Outstanding at January 1, 2006
|
|
|
88,183,095
|
|
|
$
|
12.96
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
6,420,500
|
|
|
|
9.18
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(8,930,958
|
)
|
|
|
6.95
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(6,865,571
|
)
|
|
|
13.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at September 30,
2006
|
|
|
78,807,066
|
|
|
$
|
13.33
|
|
|
|
4.9
|
|
|
$
|
130,081
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at the end of the period
|
|
|
64,903,719
|
|
|
$
|
14.32
|
|
|
|
4.2
|
|
|
$
|
87,683
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
The aggregate intrinsic value is based on the market price of
Emdeons Common Stock on September 29, 2006, the last
trading day in September, which was $11.71, less the applicable
exercise price of the underlying option. This aggregate
intrinsic value represents the amount that would have been
realized if all of the option holders had exercised their
options as of September 29, 2006.
|
The fair value of each option granted is estimated on the date
of grant using the Black-Scholes option pricing model and using
the assumptions also noted in the following table. Expected
volatility is based on
15
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
implied volatility from traded options of Emdeons Common
Stock combined with historical volatility of Emdeons
Common Stock. Prior to January 1, 2006, only historical
volatility was considered. The expected term represents the
period of time that options are expected to be outstanding
following their grant date, and was determined using historical
exercise data. The risk-free rate is based on the
U.S. Treasury yield curve for periods equal to the expected
term of the options on the grant date.
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
|
2006
|
|
2005
|
|
Expected dividend yield
|
|
0%
|
|
0%
|
Expected volatility
|
|
0.38
|
|
0.50
|
Risk free interest rate
|
|
4.56%
|
|
3.53%
|
Expected term (years)
|
|
4.46
|
|
3.25 - 5.50
|
Weighted average fair value of
options granted during the period
|
|
$3.47
|
|
$3.81
|
Restricted
Stock Awards
Emdeon Restricted Stock consists of shares of Emdeon Common
Stock which have been awarded to employees. The grants are
restricted such that they are subject to substantial risk of
forfeiture and to restrictions on their sale or other transfer
by the employee until they vest. Generally, Emdeon Restricted
Stock awards vest ratably over a three to five year period from
their individual award dates subject to continued employment on
the applicable vesting dates. The following table summarizes the
activity of non-vested Emdeon Restricted Stock for the nine
months ended September 30, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average Grant
|
|
|
|
Shares
|
|
|
Date Fair Value
|
|
|
Beginning balance at
January 1, 2006
|
|
|
1,042,557
|
|
|
$
|
8.24
|
|
Granted
|
|
|
997,010
|
|
|
|
9.16
|
|
Vested
|
|
|
(403,703
|
)
|
|
|
8.61
|
|
Forfeited
|
|
|
(181,260
|
)
|
|
|
9.09
|
|
|
|
|
|
|
|
|
|
|
Ending balance at
September 30, 2006
|
|
|
1,454,604
|
|
|
$
|
8.66
|
|
|
|
|
|
|
|
|
|
|
Proceeds received from the exercise of options to purchase
Emdeon Common Stock were $32,317 and $62,060 for the three and
nine months ended September 30, 2006, respectively, and
$10,326 and $40,940 for the three and nine months ended
September 30, 2005, respectively. The intrinsic value
related to the exercise of these stock options, as well as the
fair value of shares of Emdeon Restricted Stock that vested was
$25,460 and $44,320 for the three and nine months ended
September 30, 2006, respectively, and $9,794 and $44,383
for the three and nine months ended September 30, 2005,
respectively. The intrinsic value of these stock options and
shares of Emdeon Restricted Stock awards is deductible for tax
purposes. However, these tax benefits were not realized as the
Company has NOL carryforwards.
WebMD
Plan
During September 2005, WHC adopted the 2005 Long-Term Incentive
Plan (the WHC Plan). The maximum number of shares of
WHC Class A Common Stock that may be subject to options or
restricted stock awards under the WHC Plan is 7,130,574, subject
to adjustment in accordance with the terms of the WHC Plan. WHC
had an aggregate of 1,374,722 shares of Class A Common
Stock available for grant under the WHC Plan at
September 30, 2006.
16
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Stock
Options
Generally, options under the WHC Plan vest and become
exercisable ratably over a four year period based on their
individual grant dates subject to continued employment on the
applicable vesting dates. The options granted under the WHC Plan
expire within ten years from the date of grant. Options are
granted at prices not less than the fair market value of
WHCs Class A Common Stock on the date of grant. The
following table summarizes activity for the WHC Plan for the
nine months ended September 30, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
Weighted Average
|
|
|
Aggregate
|
|
|
|
|
|
|
Exercise
|
|
|
Remaining Contractual
|
|
|
Intrinsic
|
|
|
|
Shares
|
|
|
Price Per Share
|
|
|
Life (In Years)
|
|
|
Value(1)
|
|
|
Outstanding at January 1, 2006
|
|
|
4,533,100
|
|
|
$
|
18.31
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
1,105,900
|
|
|
|
37.58
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(37,086
|
)
|
|
|
17.50
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(359,625
|
)
|
|
|
26.02
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at September 30,
2006
|
|
|
5,242,289
|
|
|
$
|
21.85
|
|
|
|
9.1
|
|
|
$
|
69,088
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at the end of the period
|
|
|
961,249
|
|
|
$
|
17.50
|
|
|
|
9.0
|
|
|
$
|
16,187
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
The aggregate intrinsic value is based on the market price of
WHCs Class A Common Stock on September 29, 2006,
the last trading day in September, which was $34.34, less the
applicable exercise price of the underlying option. This
aggregate intrinsic value represents the amount that would have
been realized if all of the option holders had exercised their
options as of September 29, 2006.
|
The fair value of each option granted is estimated on the date
of grant using the Black-Scholes option pricing model and using
the assumptions noted in the following table. Expected
volatility is based on implied volatility from traded options of
stock of comparable companies combined with historical stock
price volatility of comparable companies. The expected term
represents the period of time that options are expected to be
outstanding following their grant date, and was determined using
historical exercise data of WHC employees who were previously
granted Emdeon stock options. The risk-free rate is based on the
U.S. Treasury yield curve for periods equal to the expected
term of the options on the grant date.
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
Expected dividend yield
|
|
|
0
|
%
|
|
|
0
|
%
|
Expected volatility
|
|
|
0.60
|
|
|
|
0.60
|
|
Risk free interest rate
|
|
|
4.76
|
%
|
|
|
4.02
|
%
|
Expected term (years)
|
|
|
3.25
|
|
|
|
3.25 - 5.50
|
|
Weighted average fair value of
options granted during the period
|
|
$
|
17.11
|
|
|
|
$8.43
|
|
Restricted
Stock Awards
WHC Restricted Stock consists of shares of WHC Class A
Common Stock which have been awarded to employees. The grants
are restricted such that they are subject to substantial risk of
forfeiture and to restrictions on their sale or other transfer
by the employee until they vest. Generally, WHC Restricted Stock
awards vest ratably over a four year period from their
individual award dates subject to continued employment
17
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
on the applicable vesting dates. The following table summarizes
the activity of non-vested WHC Restricted Stock for the nine
months ended September 30, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average Grant
|
|
|
|
Shares
|
|
|
Date Fair Value
|
|
|
Beginning balance at
January 1, 2006
|
|
|
376,621
|
|
|
$
|
17.55
|
|
Granted
|
|
|
102,443
|
|
|
|
38.62
|
|
Vested
|
|
|
(93,988
|
)
|
|
|
17.56
|
|
Forfeited
|
|
|
(2,587
|
)
|
|
|
39.00
|
|
|
|
|
|
|
|
|
|
|
Ending balance at
September 30, 2006
|
|
|
382,489
|
|
|
$
|
23.05
|
|
|
|
|
|
|
|
|
|
|
Proceeds received from the exercise of options to purchase WHC
Class A Common Stock were $649 for the three and nine
months ended September 30, 2006. The intrinsic value
related to the exercise of these stock options, as well as the
fair value of shares of WHC Restricted Stock that vested was
$3,899 for the three and nine months ended September 30,
2006. The intrinsic value of these stock options and shares of
WHC Restricted Stock awards is deductible for tax purposes.
However, these tax benefits were not realized as the Company has
NOL carryforwards.
Other
In addition, at the time of the WHC initial public offering and
subsequently on the first anniversary, WHC issued shares of WHC
Class A Common Stock to each non-employee director with a
value equal to their annual board and committee retainers. The
Company recorded $85 and $255 of stock-based compensation
expense during the three and nine months ended
September 30, 2006, respectively, in connection with these
issuances.
Employee
Stock Purchase Plan
The Companys 1998 Employee Stock Purchase Plan, as amended
from time to time (the ESPP), allows eligible
employees the opportunity to purchase shares of Emdeon Common
Stock through payroll deductions, up to 15% of a
participants annual compensation with a maximum of
5,000 shares available per participant during each purchase
period. The purchase price of the stock is 85% of the fair
market value on the last day of each purchase period. As of
September 30, 2006, a total of 7,443,058 shares of
Emdeon Common Stock were reserved for issuance under the ESPP.
The ESPP provides for annual increases equal to the lesser of
1,500,000 shares, 0.5% of the outstanding common shares, or
a lesser amount determined by the Board of Directors. There were
167,142 and 184,074 shares issued under the ESPP during the
nine months ended September 30, 2006 and 2005,
respectively. No shares were issued during the three months
ended September 30, 2006 and 2005.
18
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Summary
of Stock-Based Compensation Expense
The following table summarizes the components and classification
of stock-based compensation expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Emdeon Plans:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options
|
|
$
|
5,413
|
|
|
$
|
44
|
|
|
$
|
17,022
|
|
|
$
|
462
|
|
Restricted stock
|
|
|
1,383
|
|
|
|
1,057
|
|
|
|
3,495
|
|
|
|
3,006
|
|
WHC Plan:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options
|
|
|
4,813
|
|
|
|
|
|
|
|
14,200
|
|
|
|
|
|
Restricted stock
|
|
|
1,037
|
|
|
|
19
|
|
|
|
3,026
|
|
|
|
19
|
|
Employee Stock Purchase Plan
|
|
|
68
|
|
|
|
|
|
|
|
363
|
|
|
|
|
|
Other
|
|
|
85
|
|
|
|
|
|
|
|
255
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation
expense
|
|
$
|
12,799
|
|
|
$
|
1,120
|
|
|
$
|
38,361
|
|
|
$
|
3,487
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations
|
|
$
|
3,010
|
|
|
$
|
|
|
|
$
|
9,353
|
|
|
$
|
|
|
Development and engineering
|
|
|
286
|
|
|
|
|
|
|
|
854
|
|
|
|
|
|
Sales, marketing, general and
administrative
|
|
|
7,930
|
|
|
|
1,073
|
|
|
|
25,028
|
|
|
|
3,631
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
11,226
|
|
|
|
1,073
|
|
|
|
35,235
|
|
|
|
3,631
|
|
Income from discontinued
operations, net of tax
|
|
|
1,573
|
|
|
|
47
|
|
|
|
3,126
|
|
|
|
(144
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total non-cash stock-based
compensation expense
|
|
$
|
12,799
|
|
|
$
|
1,120
|
|
|
$
|
38,361
|
|
|
$
|
3,487
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No tax benefits were attributed to the stock-based compensation
expense because a valuation allowance was maintained for
substantially all net deferred tax assets. As of
September 30, 2006, approximately $28,708 and $35,373 of
unrecognized stock-based compensation expense related to
unvested awards (net of estimated forfeitures) is expected to be
recognized over a weighted-average period of approximately
1.39 years and 2.01 years, related to the Plans and
the WHC Plan, respectively.
The following table summarizes pro forma net income and net
income per common share as if the Company had applied the fair
value recognition provisions of SFAS 123 to stock-based
employee compensation (including non-cash stock-based
compensation expense related to discontinued operations) for the
three and nine months ended September 30, 2005:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2005
|
|
|
2005
|
|
|
Net income as reported
|
|
$
|
14,107
|
|
|
$
|
40,122
|
|
Add: Non-cash stock-based employee
compensation expense included in reported net income
|
|
|
1,120
|
|
|
|
3,487
|
|
Deduct: Total stock-based employee
compensation expense determined under fair value based method
for all awards
|
|
|
(9,868
|
)
|
|
|
(29,236
|
)
|
|
|
|
|
|
|
|
|
|
Pro forma net income
|
|
$
|
5,359
|
|
|
$
|
14,373
|
|
|
|
|
|
|
|
|
|
|
19
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2005
|
|
|
2005
|
|
|
Net income per common share:
|
|
|
|
|
|
|
|
|
Basic as reported
|
|
$
|
0.04
|
|
|
$
|
0.12
|
|
|
|
|
|
|
|
|
|
|
Diluted as
reported
|
|
$
|
0.04
|
|
|
$
|
0.11
|
|
|
|
|
|
|
|
|
|
|
Basic pro forma
|
|
$
|
0.02
|
|
|
$
|
0.04
|
|
|
|
|
|
|
|
|
|
|
Diluted pro forma
|
|
$
|
0.01
|
|
|
$
|
0.04
|
|
|
|
|
|
|
|
|
|
|
2006
Acquisitions
On September 11, 2006, the Company acquired, through WHC,
the interactive medical education, promotion and physician
recruitment businesses of Medsite, Inc. (Medsite).
Medsite provides
e-detailing
services for pharmaceutical, medical device and healthcare
companies, including program development, targeted recruitment
and online distribution and delivery. In addition, Medsite
provides educational programs to physicians. The total purchase
consideration for Medsite was approximately $31,467, comprised
of $30,682 in cash, net of cash acquired, and $785 of estimated
acquisition costs. The acquisition was accounted for using the
purchase method of accounting and, accordingly, the purchase
price was allocated to the tangible and intangible assets
acquired and the liabilities assumed on the basis of their
respective fair values. In connection with the preliminary
allocation of the purchase price and intangible asset valuation,
goodwill of $31,758 and intangible assets subject to
amortization of $10,000 were recorded. The goodwill and
intangible assets recorded will be deductible for tax purposes.
The intangible assets are comprised of $5,500 relating to
customer relationships with estimated useful lives of three
years, $3,500 relating to acquired technology with an estimated
life of three years and $1,000 relating to a trade name with an
estimated useful life of seven years. The results of operations
of Medsite have been included in the financial statements of the
Company from September 11, 2006, the closing date of the
acquisition, and are included in the WebMD segment.
On July 18, 2006, the Company acquired Interactive Payer
Network, Inc. (IPN), a privately held provider of
healthcare electronic data interchange services. The total
purchase consideration for IPN was approximately $3,907,
comprised of $3,799 in cash, net of cash acquired, and $108 of
estimated acquisition costs. In addition, the Company has agreed
to pay up to an additional $3,000 in cash over a two-year period
beginning in August 2007 if certain financial milestones are
achieved. The acquisition was accounted for using the purchase
method of accounting and, accordingly, the purchase price was
allocated to the tangible and intangible assets acquired and the
liabilities assumed on the basis of their respective fair
values. In connection with the preliminary allocation of the
purchase price, goodwill of $3,692 was recorded. The goodwill
recorded will be deductible for tax purposes. The results of
operations of IPN have been included in the financial statements
of the Company from July 18, 2006, the closing date of the
acquisition, and are included in the Emdeon Business Services
segment.
On June 13, 2006, the Company acquired, through WHC, Summex
Corporation (Summex), a provider of health and
wellness programs that include online and offline health risk
assessments, lifestyle education and personalized telephonic
health coaching. The total purchase consideration for Summex was
approximately $30,191, comprised of $29,691 in cash, net of cash
acquired, and $500 of estimated acquisition costs. In addition,
the Company has agreed to pay up to an additional $10,000 in
cash over a two-year period if certain financial milestones are
achieved. The acquisition was accounted for using the purchase
method of accounting and, accordingly, the purchase price was
allocated to the tangible and intangible assets acquired and the
liabilities assumed on the basis of their respective fair
values. In connection with the preliminary allocation of
20
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
the purchase price and intangible asset valuation, goodwill of
$21,786 and intangible assets subject to amortization of $8,500
were recorded. The goodwill and intangible assets recorded will
not be deductible for tax purposes. The intangible assets are
comprised of $4,000 relating to customer relationships with
estimated useful lives of three years and $4,500 relating to
acquired technology with an estimated useful life of five years.
The results of operations of Summex have been included in the
financial statements of the Company from June 13, 2006, the
closing date of the acquisition, and are included in the WebMD
segment.
On January 17, 2006, the Company acquired, through WHC,
eMedicine.com, Inc. (eMedicine), a privately held
online publisher of medical reference information for physicians
and other healthcare professionals. The total purchase
consideration for eMedicine was approximately $25,382, comprised
of $24,682 in cash, net of cash acquired, and $700 of estimated
acquisition costs. The acquisition was accounted for using the
purchase method of accounting and, accordingly, the purchase
price was allocated to the tangible and intangible assets
acquired and the liabilities assumed on the basis of their
respective fair values. In connection with the preliminary
allocation of the purchase price and intangible asset valuation,
goodwill of $18,402 and an intangible asset subject to
amortization of $9,000 were recorded. The goodwill and
intangible asset recorded will not be deductible for tax
purposes. The intangible asset recorded was content with an
estimated useful life of three years. The results of operations
of eMedicine have been included in the financial statements of
the Company from January 17, 2006, the closing date of the
acquisition, and are included in the WebMD segment.
2005
Acquisitions
On December 2, 2005, the Company acquired, through WHC, the
assets of and assumed certain liabilities of Conceptis
Technologies, Inc. (Conceptis), a privately held
Montreal-based provider of online and offline medical education
and promotion aimed at physicians and other healthcare
professionals. The total purchase consideration for Conceptis
was approximately $19,859, comprised of $19,256 in cash and $603
of estimated acquisition costs. The acquisition was accounted
for using the purchase method of accounting and, accordingly,
the purchase price was allocated to the tangible and intangible
assets acquired and the liabilities assumed on the basis of
their respective fair values. In connection with the preliminary
allocation of the purchase price and intangible asset valuation,
goodwill of $14,717 and intangible assets subject to
amortization of $6,140 were recorded. The goodwill and
intangible assets recorded will be deductible for tax purposes.
The intangible assets recorded were $1,900 relating to content
with an estimated useful life of two years, $3,300 relating to
acquired technology with an estimated useful life of three years
and $940 relating to a trade name with an estimated useful life
of ten years. The results of operations of Conceptis have been
included in the financial statements of the Company from
December 2, 2005, the closing date of the acquisition, and
are included in the WebMD segment.
On March 14, 2005, the Company acquired HealthShare
Technology, Inc. (HealthShare), a privately held
company that provides online tools that compare cost and quality
measures of hospitals for use by consumers, providers and health
plans. The total purchase consideration for HealthShare was
approximately $29,985, comprised of $29,533 in cash, net of cash
acquired, and $452 of acquisition costs. The acquisition was
accounted for using the purchase method of accounting and,
accordingly, the purchase price was allocated to the tangible
and intangible assets acquired and the liabilities assumed on
the basis of their respective fair values. In connection with
the allocation of the purchase price, goodwill of $24,611 and
intangible assets subject to amortization of $8,500 were
recorded. The goodwill and intangible assets recorded will not
be deductible for tax purposes. The intangible assets are
comprised of $7,500 relating to customer relationships with
estimated useful lives of five years and $1,000 relating to
acquired technology with an estimated useful life of three
years. The results of operations of HealthShare have been
included in the financial statements of the Company from
March 14, 2005, the closing date of the acquisition, and
are included in the WebMD segment.
21
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Condensed
Balance Sheet Data
The following table summarizes the tangible and intangible
assets acquired, the liabilities assumed and the consideration
paid for each acquisition:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tangible
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
Accounts
|
|
|
Deferred
|
|
|
(Liabilities),
|
|
|
Intangible
|
|
|
|
|
|
Purchase
|
|
|
|
Receivable
|
|
|
Revenue
|
|
|
net
|
|
|
Assets
|
|
|
Goodwill
|
|
|
Price
|
|
|
2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medsite
|
|
$
|
2,664
|
|
|
$
|
(14,656
|
)
|
|
$
|
1,701
|
|
|
$
|
10,000
|
|
|
$
|
31,758
|
|
|
$
|
31,467
|
|
IPN
|
|
|
359
|
|
|
|
|
|
|
|
(144
|
)
|
|
|
|
|
|
|
3,692
|
|
|
|
3,907
|
|
Summex
|
|
|
1,064
|
|
|
|
(1,173
|
)
|
|
|
14
|
|
|
|
8,500
|
|
|
|
21,786
|
|
|
|
30,191
|
|
eMedicine
|
|
|
1,717
|
|
|
|
(2,612
|
)
|
|
|
(1,125
|
)
|
|
|
9,000
|
|
|
|
18,402
|
|
|
|
25,382
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conceptis
|
|
|
2,893
|
|
|
|
(2,866
|
)
|
|
|
(1,025
|
)
|
|
|
6,140
|
|
|
|
14,717
|
|
|
|
19,859
|
|
HealthShare
|
|
|
1,925
|
|
|
|
(4,622
|
)
|
|
|
(429
|
)
|
|
|
8,500
|
|
|
|
24,611
|
|
|
|
29,985
|
|
Pro Forma
Information
The following unaudited pro forma financial information for the
nine months ended September 30, 2006 and 2005 gives effect
to the acquisitions of Medsite, IPN, Summex, eMedicine,
Conceptis and HealthShare, including the amortization of
intangible assets, as if the acquisitions had all occurred on
January 1, 2005. The information is provided for
illustrative purposes only and is not necessarily indicative of
the operating results that would have occurred if the
transactions had been consummated on the date indicated, nor is
it necessarily indicative of future operating results of the
consolidated companies, and should not be construed as
representative of these results for any future period.
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
Revenue
|
|
$
|
884,343
|
|
|
$
|
793,383
|
|
Income from continuing operations
|
|
|
44,069
|
|
|
|
24,020
|
|
Net income
|
|
|
414,240
|
|
|
|
30,888
|
|
Basic income per common share:
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.15
|
|
|
$
|
0.07
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1.44
|
|
|
$
|
0.09
|
|
|
|
|
|
|
|
|
|
|
Diluted income per common share:
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.15
|
|
|
$
|
0.07
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1.39
|
|
|
$
|
0.09
|
|
|
|
|
|
|
|
|
|
|
Segment information has been prepared in accordance with
SFAS No. 131, Disclosures about Segments of an
Enterprise and Related Information
(SFAS 131). The accounting policies of the
segments are the same as the accounting policies for the
consolidated Company. Inter-segment revenue primarily represents
printing services provided by the Companys Emdeon Business
Services segment and certain services provided by the
Companys WebMD segment to the Companys other
operating segments. The performance of the Companys
business is monitored based on earnings before interest, taxes,
non-cash and other items. Non-cash and other items include:
legal expenses which reflect costs and expenses related to the
investigation by the
22
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
United States Attorney for the District of South Carolina and
the SEC (Legal expense); professional fees,
primarily consisting of legal, accounting and financial advisory
services, related to the Pending EBS Transaction (Advisory
expense); a charge related to the redemption of $300,000
31/4% Convertible
Subordinated Notes; minority interest in the Companys
consolidated WebMD segment; non-cash advertising expense related
to advertising acquired in exchange for the Companys
equity securities; costs and expenses related to the settlement
of the McKesson HBOC litigation; and non-cash stock-based
compensation expense, which relates to stock options issued and
assumed in connection with acquisitions and restricted stock
issued to employees and, beginning January 1, 2006,
includes the incremental non-cash stock-based compensation
expense associated with the adoption of SFAS 123R.
The Company has aligned its business into four operating
segments and one corporate segment. In connection with the
Pending EBS Transaction and the revised manner in which
management views the operations, the Company classified the ViPS
segment, formerly a business unit of the Emdeon Business
Services segment, as a separate operating segment. The following
is a description of each of the Companys operating and
corporate segments:
Emdeon Business Services provides solutions that automate
key business and administrative functions for healthcare payers
and providers, including: electronic patient eligibility and
benefit verification; electronic and paper claims processing;
electronic and paper paid-claims communication services; and
patient billing, payment and communications services. In
addition, Emdeon Business Services provides clinical
communications services that improve the delivery of healthcare
by enabling physicians to manage laboratory orders and results,
hospital reports and electronic prescriptions.
WebMD provides health information services to consumers,
physicians, healthcare professionals, employers and health plans
through public and private online portals and health-focused
publications. WebMDs public network of health portals
enables consumers and physicians to readily access health
information relevant to their specific areas of interest or
specialty. WebMDs public portals sell advertising and
sponsorship programs, including online continuing medical
education (CME) services, to companies interested in
reaching consumers and physicians online, including
pharmaceutical, biotechnology, medical device and consumer
products companies. WebMDs private portals are licensed to
employers and health plans for use by their employees and
members and provide access to personalized health and benefit
information and decision support services. WebMD provides
related services for the use of such employees and members,
including lifestyle education and personalized telephonic health
coaching. WebMD also provides physician recruitment services for
use by pharmaceutical, medical device and healthcare companies.
In addition, WebMD provides offline CME, in-person medical
education services and publishes medical reference textbooks,
healthcare provider directories and WebMD the Magazine, a
consumer magazine distributed to physician office waiting rooms.
ViPS (formerly a business unit of EBS) provides decision
support solutions, data warehousing solutions and consulting
services to governmental, Blue Cross Blue Shield and commercial
healthcare payers and performs software maintenance and
consulting services for governmental agencies involved in
healthcare.
Porex develops, manufactures and distributes proprietary
porous plastic products and components used in healthcare,
industrial and consumer applications, as well as in finished
products used in the medical device and surgical markets.
Corporate includes services shared across all operating
segments, such as executive personnel, accounting, tax,
treasury, legal, human resources, risk management and certain
information technology functions. Corporate service costs
include compensation related costs, insurance and audit fees,
leased property, facilities cost, legal and other professional
fees, software maintenance and telecommunication costs.
Additionally, in connection with the EPS Sale, the Company
entered into a transition services agreement whereby the Company
will provide EPS with certain administrative services, including
payroll, accounting, purchasing and
23
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
procurement, tax, and human resource services, as well as IT
support. These services will be provided through the Corporate
segment, and the related transition services fee the Company
charges to EPS will also be included in the Corporate segment,
offsetting the cost of providing these services. The transition
services fee charged to EPS for the period from
September 15, 2006 to September 30, 2006 was $341.
Reclassification of Segment Information. In
connection with the EPS Sale and related reclassification of
that operating segment to discontinued operations, the Company
has reclassified certain expenses related to activities that
were previously managed, and therefore reported, within the
Corporate and EBS segments, to the discontinued EPS segment, as
these expenses will not be incurred by the continuing operations
of the Company. In accordance with SFAS 144, these expenses
were reclassified for the current and comparable prior year
periods. The expenses which were reclassified to the
discontinued EPS segment aggregated $260 and $924 for the three
and nine months ended September 30, 2006, respectively, and
$550 and $1,262 for the three and nine months ended
September 30, 2005, respectively.
Summarized financial information for each of the Companys
four operating segments and corporate segment and reconciliation
to net income are presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Emdeon Business Services
|
|
$
|
187,266
|
|
|
$
|
171,396
|
|
|
$
|
557,974
|
|
|
$
|
516,941
|
|
WebMD
|
|
|
66,645
|
|
|
|
45,094
|
|
|
|
173,308
|
|
|
|
119,134
|
|
ViPS
|
|
|
24,843
|
|
|
|
24,278
|
|
|
|
73,525
|
|
|
|
66,310
|
|
Porex
|
|
|
21,298
|
|
|
|
20,410
|
|
|
|
64,544
|
|
|
|
60,663
|
|
Inter-segment eliminations
|
|
|
(320
|
)
|
|
|
(156
|
)
|
|
|
(794
|
)
|
|
|
(337
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
299,732
|
|
|
$
|
261,022
|
|
|
$
|
868,557
|
|
|
$
|
762,711
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before interest,
taxes, non-cash and other items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Emdeon Business Services
|
|
$
|
44,547
|
|
|
$
|
32,297
|
|
|
$
|
127,519
|
|
|
$
|
103,315
|
|
WebMD
|
|
|
14,633
|
|
|
|
9,077
|
|
|
|
30,759
|
|
|
|
15,100
|
|
ViPS
|
|
|
5,302
|
|
|
|
3,988
|
|
|
|
15,517
|
|
|
|
11,992
|
|
Porex
|
|
|
6,133
|
|
|
|
6,385
|
|
|
|
18,732
|
|
|
|
17,846
|
|
Corporate
|
|
|
(11,000
|
)
|
|
|
(12,509
|
)
|
|
|
(33,633
|
)
|
|
|
(35,894
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
59,615
|
|
|
|
39,238
|
|
|
|
158,894
|
|
|
|
112,359
|
|
24
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Interest, taxes, non-cash and
other items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
(18,189
|
)
|
|
|
(15,801
|
)
|
|
|
(51,964
|
)
|
|
|
(44,826
|
)
|
Non-cash stock-based compensation
|
|
|
(11,226
|
)
|
|
|
(1,073
|
)
|
|
|
(35,235
|
)
|
|
|
(3,631
|
)
|
Non-cash advertising
|
|
|
(1,660
|
)
|
|
|
(1,986
|
)
|
|
|
(4,454
|
)
|
|
|
(6,999
|
)
|
Legal expense
|
|
|
(1,023
|
)
|
|
|
(5,904
|
)
|
|
|
(1,840
|
)
|
|
|
(14,347
|
)
|
Advisory expense
|
|
|
(2,126
|
)
|
|
|
|
|
|
|
(4,198
|
)
|
|
|
|
|
Interest income
|
|
|
6,599
|
|
|
|
5,124
|
|
|
|
15,450
|
|
|
|
13,380
|
|
Interest expense
|
|
|
(4,723
|
)
|
|
|
(2,996
|
)
|
|
|
(14,082
|
)
|
|
|
(11,670
|
)
|
Income tax provision
|
|
|
(3,474
|
)
|
|
|
(1,851
|
)
|
|
|
(12,082
|
)
|
|
|
(3,567
|
)
|
Minority interest in WebMD Health
Corp., net of tax
|
|
|
(140
|
)
|
|
|
(38
|
)
|
|
|
653
|
|
|
|
(38
|
)
|
Loss on investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,642
|
)
|
Loss on redemption of convertible
debt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,902
|
)
|
Other expense
|
|
|
|
|
|
|
(1,863
|
)
|
|
|
|
|
|
|
(1,863
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
23,653
|
|
|
|
12,850
|
|
|
|
51,142
|
|
|
|
33,254
|
|
Income from discontinued
operations, net of tax
|
|
|
358,048
|
|
|
|
1,257
|
|
|
|
370,171
|
|
|
|
6,868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
381,701
|
|
|
$
|
14,107
|
|
|
$
|
421,313
|
|
|
$
|
40,122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table represents the Companys operating
segment revenue by products and services:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
|
|
September 30, 2006
|
|
|
September 30, 2005
|
|
|
|
Services
|
|
|
Products
|
|
|
Services
|
|
|
Products
|
|
|
Emdeon Business Services
|
|
$
|
185,183
|
|
|
$
|
2,083
|
|
|
$
|
169,275
|
|
|
$
|
2,121
|
|
WebMD
|
|
|
64,258
|
|
|
|
2,387
|
|
|
|
42,554
|
|
|
|
2,540
|
|
ViPS
|
|
|
24,843
|
|
|
|
|
|
|
|
24,278
|
|
|
|
|
|
Porex
|
|
|
|
|
|
|
21,298
|
|
|
|
1,200
|
|
|
|
19,210
|
|
Inter-segment eliminations
|
|
|
(126
|
)
|
|
|
(194
|
)
|
|
|
(109
|
)
|
|
|
(47
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
274,158
|
|
|
$
|
25,574
|
|
|
$
|
237,198
|
|
|
$
|
23,824
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30, 2006
|
|
|
September 30, 2005
|
|
|
|
Services
|
|
|
Products
|
|
|
Services
|
|
|
Products
|
|
|
Emdeon Business Services
|
|
$
|
552,113
|
|
|
$
|
5,861
|
|
|
$
|
509,943
|
|
|
$
|
6,998
|
|
WebMD
|
|
|
167,309
|
|
|
|
5,999
|
|
|
|
113,293
|
|
|
|
5,841
|
|
ViPS
|
|
|
73,525
|
|
|
|
|
|
|
|
66,310
|
|
|
|
|
|
Porex
|
|
|
|
|
|
|
64,544
|
|
|
|
1,200
|
|
|
|
59,463
|
|
Inter-segment eliminations
|
|
|
(438
|
)
|
|
|
(356
|
)
|
|
|
(131
|
)
|
|
|
(206
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
792,509
|
|
|
$
|
76,048
|
|
|
$
|
690,615
|
|
|
$
|
72,096
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Pending
Tender Offer
On October 20, 2006, the Company commenced a tender offer
to purchase up to 100,000,000 shares of its common stock at a
price of $12.25 per share (the Pending Tender
Offer). The Pending Tender Offer is expected to be
completed in December 2006, subject to a number of terms and
conditions, including the Companys completion of the
Pending EBS Transaction (See Note 3).
Stock
Repurchase Program
On January 23, 2006, the Company announced the
authorization of a stock repurchase program (the
Program), at which time the Company was authorized
to use up to $48,000 to purchase shares of Emdeon Common Stock,
from time to time, in the open market, through block trades or
in private transactions, depending on market conditions and
other factors. On February 8, 2006, the maximum aggregate
amount authorized for purchases under the Program was increased
to $68,000 and then further increased on March 28, 2006 to
$83,000. As of September 30, 2006, the Company had
repurchased 7,329,305 shares at a cost of approximately
$71,843 under the Program. Repurchased shares are recorded under
the cost method and are reflected as treasury stock in the
accompanying consolidated balance sheets. No shares were
repurchased during the three months ended September 30,
2006.
On November 23, 2005, the Company announced the termination
of the prior repurchase program, under which repurchases of
453,000 shares at an approximate cost of $4,596 were made
during the three and nine months ended September 30, 2005.
As of September 30, 2006 and December 31, 2005, the
Companys short-term investments consisted of certificates
of deposit, auction rate securities, U.S. Treasury Notes
and other short-term liquid investments. Marketable equity
securities consisted of equity investments in publicly traded
companies. All short-term investments and marketable equity
securities are classified as
available-for-sale.
The following table summarizes the amortized cost basis and
estimated fair value of the Companys investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2006
|
|
|
December 31, 2005
|
|
|
|
Cost Basis
|
|
|
Fair Value
|
|
|
Cost Basis
|
|
|
Fair Value
|
|
|
Cash and cash equivalents
|
|
$
|
875,460
|
|
|
$
|
875,460
|
|
|
$
|
155,616
|
|
|
$
|
155,616
|
|
Short-term investments
|
|
|
71,968
|
|
|
|
71,943
|
|
|
|
268,109
|
|
|
|
267,387
|
|
Marketable equity
securities long term
|
|
|
1,474
|
|
|
|
2,668
|
|
|
|
1,477
|
|
|
|
4,430
|
|
As of September 30, 2006, the gross unrealized losses
related to short-term debt securities are primarily due to a
decrease in the fair value of these instruments as a result of
an increase in interest rates. These securities have been in a
loss position for less than twelve months. The Company has
determined that the gross unrealized losses on its short-term
debt securities at September 30, 2006 are temporary in
nature.
Comprehensive income is comprised of net income and other
comprehensive income (loss). Other comprehensive income (loss)
includes certain changes in equity that are excluded from net
income, such as changes in unrealized holding gains (losses) on
short-term investments and marketable equity securities and
26
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
foreign currency translation adjustments. The following table
presents the components of other comprehensive income (loss) for
the three and nine months ended September 30, 2006 and 2005:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Foreign currency translation gains
(losses)
|
|
$
|
989
|
|
|
$
|
2
|
|
|
$
|
2,367
|
|
|
$
|
(2,656
|
)
|
Unrealized gains (losses) on
securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized holding gains (losses)
|
|
|
185
|
|
|
|
(873
|
)
|
|
|
(1,056
|
)
|
|
|
(2,968
|
)
|
Less: reclassification adjustment
for net losses realized in net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,642
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net unrealized gains (losses) on
securities
|
|
|
185
|
|
|
|
(873
|
)
|
|
|
(1,056
|
)
|
|
|
674
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss)
|
|
|
1,174
|
|
|
|
(871
|
)
|
|
|
1,311
|
|
|
|
(1,982
|
)
|
Net income
|
|
|
381,701
|
|
|
|
14,107
|
|
|
|
421,313
|
|
|
|
40,122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
$
|
382,875
|
|
|
$
|
13,236
|
|
|
$
|
422,624
|
|
|
$
|
38,140
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The foreign currency translation gains are not currently
adjusted for income taxes as they primarily related to permanent
investments in
non-U.S. subsidiaries.
Additionally, there were no income taxes provided for the
unrealized holdings gains (losses) on securities as a full
valuation allowance has been recorded against all domestic net
deferred tax assets.
Accumulated other comprehensive income includes the following:
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
Unrealized gains on securities
|
|
$
|
1,211
|
|
|
$
|
2,267
|
|
Foreign currency translation gains
|
|
|
7,707
|
|
|
|
5,340
|
|
|
|
|
|
|
|
|
|
|
Total accumulated other
comprehensive income
|
|
$
|
8,918
|
|
|
$
|
7,607
|
|
|
|
|
|
|
|
|
|
|
Property
and Equipment
Property and equipment consist of the following:
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2006(a)
|
|
|
2005
|
|
|
Computer equipment
|
|
$
|
21,760
|
|
|
$
|
60,336
|
|
Land and buildings
|
|
|
15,443
|
|
|
|
14,123
|
|
Office equipment, furniture and
fixtures
|
|
|
27,840
|
|
|
|
50,643
|
|
Software
|
|
|
24,312
|
|
|
|
36,487
|
|
Leasehold improvements
|
|
|
14,316
|
|
|
|
17,904
|
|
Construction in process
|
|
|
4,396
|
|
|
|
11,616
|
|
|
|
|
|
|
|
|
|
|
|
|
|
108,067
|
|
|
|
191,109
|
|
Less: accumulated depreciation
|
|
|
(41,160
|
)
|
|
|
(95,423
|
)
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
$
|
66,907
|
|
|
$
|
95,686
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
Amounts as of September 30,
2006 exclude property and equipment related to EBS, as these
amounts were reclassified to Assets Held for Sale in the
accompanying consolidated balance sheets.
|
27
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Depreciation expense was $8,427 and $23,973 for the three and
nine months ended September 30, 2006, respectively, and
$7,613 and $20,100 for the three and nine months ended
September 30, 2005, respectively.
Goodwill
and Intangible Assets
The changes in the carrying amount of goodwill for the year
ended December 31, 2005 and the nine months ended
September 30, 2006 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Emdeon
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Services
|
|
|
WebMD
|
|
|
ViPS
|
|
|
Porex
|
|
|
Total
|
|
|
Balance as of January 1, 2005
|
|
$
|
663,018
|
|
|
$
|
53,169
|
|
|
$
|
71,449
|
|
|
$
|
43,384
|
|
|
$
|
831,020
|
|
Acquisitions during the period
|
|
|
|
|
|
|
36,079
|
|
|
|
|
|
|
|
|
|
|
|
36,079
|
|
Contingent consideration for prior
period acquisitions
|
|
|
19,379
|
|
|
|
10,638
|
|
|
|
|
|
|
|
|
|
|
|
30,017
|
|
Tax reversals
|
|
|
(674
|
)
|
|
|
|
|
|
|
|
|
|
|
(600
|
)
|
|
|
(1,274
|
)
|
Adjustments to finalize purchase
price allocations
|
|
|
(111
|
)
|
|
|
783
|
|
|
|
(196
|
)
|
|
|
383
|
|
|
|
859
|
|
Effects of exchange rates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(726
|
)
|
|
|
(726
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2006
|
|
|
681,612
|
|
|
|
100,669
|
|
|
|
71,253
|
|
|
|
42,441
|
|
|
|
895,975
|
|
Acquisitions during the period
|
|
|
3,692
|
|
|
|
71,946
|
|
|
|
|
|
|
|
|
|
|
|
75,638
|
|
Contingent consideration for prior
period acquisitions(a)
|
|
|
(1,913
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,913
|
)
|
Tax reversals(b)
|
|
|
(19,040
|
)
|
|
|
(192
|
)
|
|
|
|
|
|
|
(266
|
)
|
|
|
(19,498
|
)
|
Adjustments to finalize purchase
price allocations
|
|
|
|
|
|
|
1,696
|
|
|
|
|
|
|
|
|
|
|
|
1,696
|
|
Reclassification to assets held
for sale
|
|
|
(664,351
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(664,351
|
)
|
Effects of exchange rates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
562
|
|
|
|
562
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of September 30,
2006
|
|
$
|
|
|
|
$
|
174,119
|
|
|
$
|
71,253
|
|
|
$
|
42,737
|
|
|
$
|
288,109
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
During the nine months ended
September 30, 2006, the Company adjusted goodwill by $2,539
in connection with an over accrual of contingent consideration
in the Emdeon Business Services segment. In addition, during the
nine months ended September 30, 2006, the Company made a
contingent consideration payment in the amount of $626 for a
2003 acquisition within the Emdeon Business Services segment.
|
|
(b)
|
|
Represents a reduction to goodwill
as a result of the reversal of a portion of the income tax
valuation allowances that were originally established in
connection with the purchase accounting of prior acquisitions. A
portion of these income tax valuation allowances, or $14,367,
was reversed in connection with the utilization of net operating
losses attributable to the discontinued operations, including
the gain on disposal.
|
Intangible assets subject to amortization consist of the
following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2006(b)
|
|
|
December 31, 2005
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
Gross
|
|
|
|
|
|
|
|
|
Average
|
|
|
Gross
|
|
|
|
|
|
|
|
|
Average
|
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
|
|
|
Remaining
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
|
|
|
Remaining
|
|
|
|
Amount
|
|
|
Amortization
|
|
|
Net
|
|
|
Useful Life(a)
|
|
|
Amount
|
|
|
Amortization
|
|
|
Net
|
|
|
Useful Life(a)
|
|
|
Customer relationships
|
|
$
|
60,332
|
|
|
$
|
(11,890
|
)
|
|
$
|
48,442
|
|
|
|
9.6
|
|
|
$
|
382,877
|
|
|
$
|
(242,494
|
)
|
|
$
|
140,383
|
|
|
|
11.3
|
|
Technology and patents
|
|
|
80,215
|
|
|
|
(24,653
|
)
|
|
|
55,562
|
|
|
|
16.6
|
|
|
|
176,146
|
|
|
|
(110,244
|
)
|
|
|
65,902
|
|
|
|
15.3
|
|
Trade names
|
|
|
14,927
|
|
|
|
(3,965
|
)
|
|
|
10,962
|
|
|
|
7.5
|
|
|
|
40,716
|
|
|
|
(30,435
|
)
|
|
|
10,281
|
|
|
|
8.0
|
|
Non-compete agreements, content and
other
|
|
|
17,750
|
|
|
|
(6,747
|
)
|
|
|
11,003
|
|
|
|
2.0
|
|
|
|
22,254
|
|
|
|
(3,549
|
)
|
|
|
18,705
|
|
|
|
6.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
173,224
|
|
|
$
|
(47,255
|
)
|
|
$
|
125,969
|
|
|
|
11.9
|
|
|
$
|
621,993
|
|
|
$
|
(386,722
|
)
|
|
$
|
235,271
|
|
|
|
11.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
(a)
|
|
The calculation of the weighted
average remaining useful life is based on the net book value and
the remaining amortization period (reflected in years) of each
respective intangible asset.
|
|
(b)
|
|
Amounts as of September 30,
2006 exclude intangible assets related to EBS, as these amounts
were reclassified to Assets Held for Sale in the accompanying
consolidated balance sheets.
|
Amortization expense was $9,762 and $27,991 for the three and
nine months ended September 30, 2006, respectively, and
$8,188 and $24,726 for the three and nine months ended
September 30, 2005, respectively. Aggregate amortization
expense for intangible assets is estimated to be:
|
|
|
|
|
|
|
|
|
Years ended December 31, 2006
(October 1st to December 31st)
|
|
$
|
6,796
|
|
|
|
|
|
2007
|
|
|
26,564
|
|
|
|
|
|
2008
|
|
|
23,116
|
|
|
|
|
|
2009
|
|
|
14,672
|
|
|
|
|
|
2010
|
|
|
6,131
|
|
|
|
|
|
Thereafter
|
|
|
48,690
|
|
|
|
|
|
Accrued expenses consist of the following:
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2006(a)
|
|
|
2005
|
|
|
Accrued outside services
|
|
$
|
18,200
|
|
|
$
|
11,926
|
|
Accrued acquisition contingent
consideration
|
|
|
|
|
|
|
30,122
|
|
Accrued compensation
|
|
|
21,260
|
|
|
|
35,276
|
|
Accrued customer deposits
|
|
|
143
|
|
|
|
21,570
|
|
Accrued income, sales and other
taxes
|
|
|
33,443
|
|
|
|
20,678
|
|
Other accrued liabilities
|
|
|
25,699
|
|
|
|
50,530
|
|
|
|
|
|
|
|
|
|
|
Total accrued expenses
|
|
$
|
98,745
|
|
|
$
|
170,102
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
Amounts as of September 30,
2006 exclude accrued expenses related to EBS, as these amounts
were reclassified to Liabilities Held for Sale in the
accompanying consolidated balance sheets.
|
|
|
12.
|
Commitments
and Contingencies
|
Legal
Proceedings
Ari
Weitzner, M.D., P.C. et al. v. National
Physicians Datasource LLC
As previously disclosed, on May 24, 2005, a lawsuit was
filed by Dr. Ari Weitzner individually, and as a class
action, under the Telephone Consumer Protection Act (the
TCPA), in the U.S. District Court, Eastern
District of New York against National Physicians Datasource LLC
(NPD), which is currently a subsidiary of WHC. The
lawsuit claims that faxes allegedly sent by NPD, which publishes
The Little Blue Book, were sent in violation of the TCPA.
The lawsuit potentially seeks damages in excess of $5,000. The
Court had temporarily stayed the lawsuit pending resolution of
relevant issues in a related case. On February 21, 2006,
the Court lifted the stay. The parties had been conducting
discovery until the named plaintiff in this action discontinued
this suit on November 8, 2006. However, the Company has
been advised that a suit containing the same allegations may be
brought by a different named plaintiff represented by the same
counsel. WHC expects to oppose certification as a class action
when discovery on any such matter is completed.
29
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Anthony
Vlastaris, et al. v. WebMD Publishing
Services
On September 25, 2006, Anthony Vlastaris, Brian Kressin,
and Richard Cohen filed a lawsuit individually, and as a class
action, under the TCPA, in the Ohio Court of Common Pleas,
Cuyahoga County. The lawsuit claims that the defendant sent
faxes to the plaintiffs allegedly in violation of the TCPA. The
defendant in the suit is named as WebMD Publishing
Services, an entity that does not exist. Because the suit
was served on NPD at its location in Connecticut and because NPD
is the publisher of The Little Blue Book, NPD removed the
lawsuit to the United States District Court, Northern District
of Ohio, on October 24, 2006. NPD removed the case in part
because of diversity jurisdiction and in part because the
federal Class Action Fairness Act provides federal jurisdiction
over class actions in which the potential damages exceed $5,000.
The plaintiffs counsel has sent a letter challenging the
removal on the grounds that TPCA cases are not subject to
removal. NPD intends to defend the notice of removal. The
purported class in the Vlastaris case, involving faxes
sent to three area codes in two states, is substantially a
subset of the purported nationwide class in the Weitzner
case (described above) in New York. WHC expects to oppose
class certification in this lawsuit.
Other
In the normal course of business, the Company and its
subsidiaries are involved in various other claims and legal
proceedings. While the ultimate resolution of these matters,
including those discussed in the Companys 2005 Annual
Report on the
Form 10-K
under the heading Legal Proceedings has yet to be
determined, the Company does not believe that their outcome will
have a material adverse effect on the Companys
consolidated financial position, results of operations or
liquidity.
Leases
The Company leases its offices and other facilities under
operating lease agreements that expire at various dates through
2016. Total rent expense for all operating leases was $4,197 and
$12,297 for the three and nine months ended September 30,
2006, respectively, and $4,052 and $12,375 for the three and
nine months ended September 30, 2005, respectively. Future
minimum lease commitments under non-cancelable lease agreements
at September 30, 2006 were as follows:
|
|
|
|
|
Years Ending December 31,
2006 (October 1st to December 31st)
|
|
$
|
4,593
|
|
2007
|
|
|
19,302
|
|
2008
|
|
|
17,337
|
|
2009
|
|
|
13,482
|
|
2010
|
|
|
13,134
|
|
Thereafter
|
|
|
28,242
|
|
|
|
|
|
|
Total minimum lease payments
|
|
$
|
96,090
|
|
|
|
|
|
|
On November 2, 2006, through WHC, the Company entered into
a definitive agreement to acquire all of the outstanding limited
liability company interests of Subimo, LLC (Subimo),
a privately held provider of healthcare decision support
applications to large employers, health plans and financial
institutions. The purchase price for Subimo is $60,000,
comprised of $34,000 in cash payable on the closing date and
$26,000 in WHC Class A Common Stock (WHC
Shares)
and/or cash
(the Subsequent Consideration), whichever WHC
selects at the time the acquisition closes, such Subsequent
Consideration to be paid on the second
30
EMDEON
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
anniversary of the closing except as otherwise described below.
The number of WHC Shares, if any, to be included in the
Subsequent Consideration shall be determined by dividing the
amount of the Subsequent Consideration to be paid in
WHC Shares divided by the five-day trailing average price
of the WHC Shares for a period prior to the closing date.
The purchase price is subject to adjustments, including an
adjustment based on the amounts of net working capital of Subimo
at closing, of indebtedness of Subimo at closing and of certain
transaction expenses payable on behalf of the sellers.
If the Subsequent Consideration includes WHC Shares and the
value of the Subsequent Consideration is less than $15,600 when
the WHC Shares are issued (or, in certain circumstances, when a
registration statement becomes effective), then WHC shall be
required to pay the amount by which the aggregate value of the
Subsequent Consideration is less than $15,600 minus any portion
of the Subsequent Consideration for which a right of setoff has
been applied by WHC to fulfill indemnification obligations of
the sellers. WHC will have the option of paying the amount
described in the preceding sentence in the form of cash or
additional WHC Shares. Senior management of Subimo will be
entering into long-term employment agreements with Subimo
effective as of the closing date. The portion of the Subsequent
Consideration payable to certain of those members of senior
management will be paid on the fourth anniversary of the closing
if the person is terminated for cause, under his or her
employment agreement, voluntarily terminates employment prior to
the payment of the Subsequent Consideration.
The acquisition, which is subject to customary closing
conditions, is expected to close before the end of 2006 and will
be included in the Companys WebMD segment from the date of
the closing of the acquisition.
31
|
|
ITEM 2.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
This Item 2 contains forward-looking statements with
respect to possible events, outcomes or results that are, and
are expected to continue to be, subject to risks, uncertainties
and contingencies, including those identified in this Item. See
Forward-Looking Statements on page 3.
Overview
Managements discussion and analysis of financial condition
and results of operations, or MD&A, is provided as a
supplement to the Consolidated Financial Statements and notes
thereto included elsewhere in this Quarterly Report and to
provide an understanding of our results of operations, financial
condition, and changes in financial condition. Our MD&A is
organized as follows:
|
|
|
|
|
Introduction. This section provides a general
description of our company, a brief discussion of our operating
segments, a description of certain recent developments, and
background information on certain trends, strategies and other
matters discussed in this MD&A.
|
|
|
|
Critical Accounting Policies and
Estimates. This section discusses those
accounting policies that both are considered important to our
financial condition and results of operations, and require us to
exercise subjective or complex judgments in making estimates and
assumptions. In addition, all of our significant accounting
policies, including our critical accounting policies, are
summarized in Note 1 to the Consolidated Financial
Statements contained in our 2005 Annual Report on
Form 10-K
filed with the Securities and Exchange Commission
(SEC).
|
|
|
|
Recent Accounting Pronouncements. This section
provides a summary of the most recent authoritative accounting
standards and guidance that have either been recently adopted or
may be adopted in the future.
|
|
|
|
Results of Operations and Results of Operations by Operating
Segment. These sections provide our analysis and
outlook for the significant line items on our consolidated
statements of operations, as well as other information that we
deem meaningful to understand our results of operations, on both
a company-wide and a
segment-by-segment
basis.
|
|
|
|
Liquidity and Capital Resources. This section
provides an analysis of our liquidity and cash flows, as well as
a discussion of our outstanding debt and commitments, that
existed as of September 30, 2006.
|
|
|
|
Factors That May Affect Our Future Financial Condition or
Results of Operations. This section describes
circumstances or events that could have a negative effect on our
financial condition or results of operations, or that could
change, for the worse, existing trends in some or all of our
businesses. The factors discussed in this section are in
addition to factors that may be described elsewhere in this
Quarterly Report.
|
In this MD&A, dollar amounts are in thousands, unless
otherwise noted.
Introduction
Emdeon Corporation is a Delaware corporation that was
incorporated in December 1995 and commenced operations in
January 1996 as Healtheon Corporation. Our common stock began
trading on the Nasdaq National Market under the symbol
HLTH on February 11, 1999 and now trades on the
Nasdaq Global Select Market. We changed our name to
Healtheon/WebMD Corporation in November 1999 and to WebMD
Corporation in September 2000 and to Emdeon Corporation
(Emdeon) in October 2005. The change to Emdeon was
made in connection with an initial public offering of equity
securities by WebMD Health Corp. (WHC), a subsidiary
we formed to act as a holding company for the business of our
WebMD segment and to issue shares in that initial public
offering. Because the WebMD name had been more closely
associated with our public and private online portals than with
our other businesses, our Board of Directors determined that WHC
would, following its initial public offering, have the sole
right to use the WebMD name and related trademarks.
32
As of September 30, 2006, we owned 85.6% of the aggregate
amount of outstanding shares of WHCs Class A Common
Stock and Class B Common Stock. As such, we consolidate the
minority stockholders 14.4% share of equity and net income
or loss of our WebMD segment.
On September 14, 2006, we completed the sale of our Emdeon
Practice Services segment (EPS) to Sage Software,
Inc. (the EPS Sale). Accordingly, the historical
results of EPS, including the gain related to the sale have been
reclassified as discontinued operations in our financial
statements and our discussions in the MD&A reflect EPS as
discontinued operations. For a description of the EPS Sale and
related matters, see Recent
Developments EPS Sale.
On September 26, 2006, we entered into a definitive
agreement for the sale of a 52% interest in our Emdeon Business
Services segment, excluding its ViPS business unit
(EBS) to an affiliate of General Atlantic LLC (the
Pending EBS Transaction). Accordingly, we have
classified the assets and liabilities of EBS as assets and
liabilities held for sale in our consolidated balance sheet as
of September 30, 2006. In addition, since our ViPS business
is not included in the Pending EBS Transaction, it is now being
reported as a separate operating segment.
Operating
Segments
We have aligned our business into four operating segments and
one corporate segment. In connection with the Pending EBS
Transaction and the revised manner in which management views its
operations, we have classified the ViPS segment, formerly a
business unit of the Emdeon Business Services segment, as a
separate operating segment. The following is a description of
each of our operating and corporate segments:
|
|
|
|
|
Emdeon Business Services. We provide solutions
that automate key business and administrative functions for
healthcare payers and providers, including: electronic patient
eligibility and benefit verification; electronic and paper
claims processing; electronic and paper paid-claims
communication services; and patient billing, payment and
communications services. In addition, we provide clinical
communications services that improve the delivery of healthcare
by enabling physicians to manage laboratory orders and results,
hospital reports and electronic prescriptions.
|
|
|
|
WebMD. We provide health information services
to consumers, physicians, healthcare professionals, employers
and health plans through our public and private online portals
and health-focused publications. Our public network of health
portals enables consumers and physicians to readily access
health information relevant to their specific areas of interest
or specialty. Our public portals sell advertising and
sponsorship programs, including online continuing medical
education (CME) services, to companies interested in
reaching consumers and physicians online, including
pharmaceutical, biotechnology, medical device and consumer
products companies. Our private portals are licensed to
employers and health plans for use by their employees and
members and provide access to personalized health and benefit
information and decision support services. We provide related
services for the use of such employees and members, including
lifestyle education and personalized telephonic health coaching.
WebMD also provides physician recruitment services for use by
pharmaceutical, medical device and healthcare companies. In
addition, we provide offline CME and in-person medical education
services and publish medical reference textbooks, healthcare
provider directories and WebMD the Magazine, a consumer
magazine distributed to physician office waiting rooms.
|
|
|
|
ViPS (formerly a business unit of EBS). We
provide decision support solutions, data warehousing solutions
and consulting services to governmental, Blue Cross Blue Shield
and commercial healthcare payers and perform software
maintenance and consulting services for governmental agencies
involved in healthcare.
|
|
|
|
Porex. We develop, manufacture and distribute
proprietary porous plastic products and components used in
healthcare, industrial and consumer applications, as well as in
finished products used in the medical device and surgical
markets.
|
|
|
|
Corporate. Our Corporate segment provides
shared services across all our operating segments. These
services include executive personnel, accounting, tax, treasury,
legal, human resources, risk management
|
33
|
|
|
|
|
and certain information technology functions. Corporate service
costs include compensation related costs, insurance and audit
fees, leased property, facilities cost, legal and other
professional fees, software maintenance and telecommunication
costs. Additionally, in connection with the EPS Sale, we entered
into a transition services agreement whereby we will provide EPS
with certain administrative services, including payroll,
accounting, purchasing and procurement, tax, and human resource
services, as well as information technology support. These
services will be provided through our Corporate segment, and the
related transition services fee we charge to EPS will also be
included in our Corporate segment, offsetting the cost of
providing these services. The transition services fee charged to
EPS for the period from September 15, 2006 to
September 30, 2006 was $341.
|
Recent
Developments
Pending EBS Transaction. On September 26,
2006, we entered into a definitive agreement for the sale of a
52% interest in EBS to an affiliate of General Atlantic LLC
(GA). At the closing of this transaction, we will
receive approximately $1,200,000 in cash, subject to customary
post-closing adjustments including an adjustment based on the
amount of working capital at closing. The acquisition will be
financed with approximately $925,000 in bank debt and an
investment of approximately $320,000 by GA. The Pending EBS
Transaction will be structured so that Emdeon and GA each own
interests in a limited liability company (Master
LLC), which will own the entities comprising EBS through a
wholly owned limited liability company (EBS LLC).
The bank debt will be an obligation of EBS LLC and will be
guaranteed by Master LLC, but will not be an obligation of or
guaranteed by Emdeon. After the closing of the Pending EBS
Transaction, Emdeons 48% ownership interest in Master LLC
will be reflected as an investment in Emdeons consolidated
financial statements and will be accounted for under the equity
method. We have classified the assets and liabilities of EBS as
assets and liabilities held for sale in our consolidated balance
sheet as of September 30, 2006.
We expect to recognize a taxable gain on the Pending EBS
Transaction and expect to utilize approximately $400,000 to
$450,000 of our federal net operating loss (NOL)
carryforwards to eliminate a significant portion of the tax
liability that would otherwise result from this transaction.
Approximately $130,000 to $150,000 of the NOL carryforwards
utilized will be NOL carryforwards attributable to WHC. Under
Emdeons Tax Sharing Agreement with WHC, Emdeon has agreed
to reimburse WHC at the current federal statutory tax rate of
35% for any NOL carryforwards attributable to WHC that are
utilized by Emdeon in this transaction. We currently estimate
that the amount of the resulting cash reimbursement to WHC will
be approximately $45,000 to $52,000. The estimates of the
amounts of the utilization of the NOL carryforwards attributable
to WHC and to Emdeon and of the related reimbursement are based
on various assumptions and will not be finalized until we
complete the calculation of our consolidated 2006 federal income
taxes.
Pending Tender Offer. On October 20,
2006, we commenced a tender offer to purchase up to 100,000,000
shares of our common stock at a price of $12.25 per share
(the Pending Tender Offer). The Pending Tender Offer
is expected to be completed in December 2006, subject to a
number of terms and conditions, including our completion of the
Pending EBS Transaction.
EPS Sale. On August 8, 2006, we entered
into a Stock Purchase Agreement for the sale of EPS to Sage
Software, Inc. (Sage Software), an indirect wholly
owned subsidiary of The Sage Group plc. On September 14,
2006, we completed the EPS Sale. We received net cash proceeds
of $529,466, which does not include $35,000 being held in escrow
as security for our indemnification obligations under the Stock
Purchase Agreement. One-third and two-thirds of the amount in
escrow are scheduled to be released twelve and eighteen months
from the closing date, and are included in other current assets
and other assets, respectively, in the consolidated balance
sheet as of September 30, 2006. We incurred approximately
$7,700 of professional fees and other expenses associated with
the EPS Sale, of which approximately $2,500 was unpaid as of
September 30, 2006 and is therefore included in accrued
expenses in our consolidated balance sheet as of
September 30, 2006. In connection with the EPS Sale, we
recognized a gain of $352,269, which is included in income from
discontinued operations, net of tax of $34,714, in the
consolidated statements of operations during the three and nine
months ended September 30, 2006. While the determination of
the gain on disposal is substantially complete, the purchase
price is subject to customary post-closing adjustments,
including an
34
adjustment for working capital, which has not been finalized.
Also included in income from discontinued operations for the
three and nine months ended September 30, 2006 is $5,779
and $17,902, respectively, representing the income from
operations of EPS, net of tax, through the date of sale on
September 14, 2006.
Emdeon and Sage Software will make an IRC
Section 338(h)(10) election and will treat the EPS Sale as
a sale of assets for tax purposes. We will utilize a portion of
our NOL carryforwards to offset the gain on this transaction.
Under the Tax Sharing Agreement with WHC, we have agreed to
reimburse WHC, at the current federal statutory tax rate of 35%,
for any NOL carryforwards attributable to WHC that are utilized
by us in this transaction. We estimate that the amount of
WHCs NOL carryforwards to be utilized in this transaction
will be approximately $240,000 to $260,000 resulting in a cash
reimbursement to WHC of $84,000 to $91,000. The estimates of the
amount of WHCs NOL carryforwards to be utilized and of the
related reimbursement is based on various assumptions and will
not be finalized until we complete the calculation of our
consolidated 2006 federal income taxes.
EBS has entered into an agreement with EPS pursuant to which EBS
will be the exclusive provider of electronic healthcare
transaction services and patient statement services for Emdeon
Practice Services through 2013. In addition, EPS will continue
its existing relationship with WebMD and will exclusively
integrate WebMDs personal health record with its clinical
products, including its electronic medical record.
Pending Acquisition of Subimo, LLC. On
November 2, 2006, through WHC, we entered into a definitive
agreement to acquire all of the outstanding limited liability
company interests of Subimo, LLC (Subimo), a
privately held provider of healthcare decision support
applications to large employers, health plans and financial
institutions. The purchase price for Subimo is $60,000,
comprised of $34,000 in cash payable on the closing date and
$26,000 in WHC Class A Common Stock (WHC
Shares)
and/or cash
(the Subsequent Consideration), whichever WHC
selects at the time the acquisition closes, such Subsequent
Consideration to be paid on the second anniversary of the
closing except as otherwise described below. The number of
WHC Shares, if any, to be included in the Subsequent
Consideration shall be determined by dividing the amount of the
Subsequent Consideration to be paid in WHC Shares by the
five-day trailing average price of the WHC Shares for a
period prior to the closing date. The purchase price is subject
to adjustments, including an adjustment based on the amounts of
net working capital of Subimo at closing, of indebtedness of
Subimo at closing and of certain transaction expenses payable on
behalf of the sellers.
If the Subsequent Consideration includes WHC Shares and the
value of the Subsequent Consideration is less than $15,600 when
the WHC Shares are issued (or, in certain circumstances, when a
registration statement becomes effective), then WHC shall be
required to pay the amount by which the aggregate value of the
Subsequent Consideration is less than $15,600 minus any portion
of the Subsequent Consideration for which a right of setoff has
been applied by WHC to fulfill indemnification obligations of
the sellers. WHC will have the option of paying the amount
described in the preceding sentence in the form of cash or
additional WHC Shares. Senior management of Subimo will be
entering into long-term employment agreements with Subimo
effective as of the closing date. The portion of the Subsequent
Consideration payable to certain of those members of senior
management will be paid on the fourth anniversary of the closing
if the person is terminated for cause under his or her
employment agreement or voluntarily terminates employment prior
to the payment of the Subsequent Consideration.
The acquisition, which is subject to customary closing
conditions, is expected to close before the end of 2006 and will
be included in the Companys WebMD segment from the date of
the closing of the acquisition.
Acquisition of Medsite, Inc. On
September 11, 2006, through WHC, we acquired the
interactive medical education, promotion and physician
recruitment businesses of Medsite, Inc. ( Medsite).
Medsite provides
e-detailing
services for pharmaceutical, medical device and healthcare
companies, including program development, targeted recruitment
and online distribution and delivery. In addition, Medsite
provides educational programs to physicians. The total purchase
consideration for Medsite was approximately $31,467, comprised
of $30,682 in cash, net of cash acquired, and $785 of estimated
acquisition costs. The results of operations of Medsite have
been included in our financial statements from
September 11, 2006, the closing date of the acquisition,
and are included in our WebMD segment.
35
Acquisition of Interactive Payer Network,
Inc. On July 18, 2006, we acquired
Interactive Payer Network, Inc. (IPN), a privately
held provider of healthcare electronic data interchange
services. The total purchase consideration for IPN was
approximately $3,907, comprised of $3,799 in cash, net of cash
acquired, and $108 of estimated acquisition costs. In addition,
we have agreed to pay up to an additional $3,000 in cash over a
two-year period beginning in August 2007 if certain financial
milestones are achieved. The results of operations of IPN have
been included in our financial statements from July 18,
2006, the closing date of the acquisition, and are included in
our Emdeon Business Services segment.
Acquisition of Summex Corporation. On
June 13, 2006, through WHC, we acquired Summex Corporation
(Summex), a provider of health and wellness programs
that include online and offline health risk assessments,
lifestyle education and personalized telephonic health coaching.
The Summex programs complement the online health and benefits
platform that WebMD provides to employers and health plans.
Summexs team of professional health coaches work
one-on-one
with employees and plan members to modify behaviors that may
lead to illness and high medical costs. The total purchase
consideration for Summex was approximately $30,191, comprised of
$29,691 in cash, net of cash acquired, and $500 of estimated
acquisition costs. In addition, we have agreed to pay up to an
additional $10,000 in cash over a two-year period if certain
financial milestones are achieved. The results of operations of
Summex have been included in our financial statements from
June 13, 2006, the closing date of the acquisition, and are
included in our WebMD segment.
Background
Information on Certain Trends and Strategies
Diversification of Emdeon Business
Services. Submission of claims electronically
assists healthcare payers in reducing the cost of processing and
servicing claims and can expedite the reimbursement process for
providers. However, this is just a starting point for increasing
administrative efficiency. We are continuing our efforts to
transform Emdeon Business Services from an electronic
transactions clearinghouse to a provider of more comprehensive
reimbursement cycle management services designed to provide
healthcare payers and providers not only with connectivity, but
also with the information and data necessary to ensure rapid and
accurate claim processing, remittance and payment.
|
|
|
|
|
Our services for payers now also include conversion of paper
claims to electronic ones and related document management
services, as well as paid-claims communication services. We also
act as the electronic transactions gateway for some of our payer
customers, which allows us to work more closely with them to
increase the quantity and improve the quality of the electronic
transactions coming into their systems. In addition, by
outsourcing patient encounter transaction processes to us,
payers can reduce their capital expenses and operating costs.
|
|
|
|
Our services for providers now also include systems to validate
patient insurance benefits electronically, to edit and submit
electronic claims, to manage remittance advices, to post
payments automatically and to process patient statements.
|
Increased Online Marketing and Education Spending for
Healthcare Products. Pharmaceutical,
biotechnology and medical device companies spend large amounts
each year marketing their products and educating consumers and
physicians about them, however, only a small portion of this
amount is currently spent on online services. We believe that
these companies, who comprise the majority of WebMDs
advertisers and sponsors, are becoming increasingly aware of the
effectiveness of the Internet relative to traditional media in
providing health, clinical and product-related information to
consumers and physicians. We expect that this increasing
awareness will result in increasing demand for WebMDs
services.
Changes in Health Plan Design; Health Management
Initiatives. While overall healthcare costs have
been rising at a rapid annual rate, employers costs of
providing healthcare benefits to their employees have been
increasing at an even faster rate. In response to these
increases, employers are seeking to shift a greater portion of
healthcare costs onto their employees and to redefine
traditional health benefits. Employers and health plans want to
motivate their members and employees to evaluate their
healthcare decisions more carefully in order to be more
cost-effective. As employers continue to implement high
deductible and consumer-directed healthcare plans (referred to
as CDHPs) and related Health Savings Accounts (referred to as
HSAs) to achieve these goals, we believe that WebMD will be able
to attract more employers and health
36
plans to use its private online portals. In addition, health
plans and employers have begun to recognize that encouraging the
good health of their members and employees not only benefits the
members and employees but also has financial benefits for the
health plans and employers. Accordingly, many employers and
health plans have been enhancing health management programs and
taking steps to provide healthcare information and education to
employees and members, including through online services. We
believe that WebMD is well positioned to benefit from these
trends because WebMDs private portals provide the tools
and information employees and plan members need in order to make
more informed decisions about healthcare provider, benefit and
treatment options. We believe that the pending acquisition of
Subimo (see Recent Developments
Pending Acquisition of Subimo above) will, by expanding
WebMDs suite of online health and benefit management
services, enable WebMD to better address the emerging CDHP
market.
Critical
Accounting Policies and Estimates
Our discussion and analysis of Emdeons financial condition
and results of operations are based upon our Consolidated
Financial Statements and Notes to Consolidated Financial
Statements, which were prepared in conformity with
U.S. generally accepted accounting principles. The
preparation of financial statements requires us to make
estimates and assumptions that affect the amounts reported in
the consolidated financial statements and accompanying notes. We
base our estimates on historical experience, current business
factors, and various other assumptions that we believe are
necessary to consider in order to form a basis for making
judgments about the carrying values of assets and liabilities,
the recorded amounts of revenue and expenses, and disclosure of
contingent assets and liabilities. We are subject to
uncertainties such as the impact of future events, economic,
environmental and political factors, and changes in our business
environment; therefore, actual results could differ from these
estimates. Accordingly, the accounting estimates used in
preparation of our financial statements will change as new
events occur, as more experience is acquired, as additional
information is obtained and as our operating environment
changes. Changes in estimates are made when circumstances
warrant. Such changes in estimates and refinements in estimation
methodologies are reflected in reported results of operations;
if material, the effects of changes in estimates are disclosed
in the notes to our consolidated financial statements.
We evaluate our estimates on an ongoing basis, including those
related to revenue recognition, short-term and long-term
investments, deferred tax assets, income taxes, collectibility
of customer receivables, prepaid advertising, long-lived assets
including goodwill and other intangible assets, software
development costs, inventory valuation, certain accrued
expenses, contingencies, litigation and the value attributed to
employee stock options and other stock-based awards.
We believe the following reflects our critical accounting
policies and our more significant judgments and estimates used
in the preparation of our consolidated financial statements:
|
|
|
|
|
Revenue Our revenue recognition
policies for each reportable operating segment are as follows:
|
Emdeon Business Services. Healthcare payers
and providers pay us fees for transaction services, generally on
either a per transaction basis or, in the case of some
providers, on a monthly fixed fee basis. Healthcare payers and
providers also pay us fees for document conversion, patient
statement and paid-claims communication services, typically on a
per document, per statement or per communication basis. Revenue
for transaction services, patient statement and paid-claims
communication services is recognized as the services are
provided.
WebMD. Revenue from advertising is recognized
as advertisements are delivered or as publications are
distributed. Revenue from sponsorship arrangements, content
syndication and distribution arrangements and licenses of our
healthcare management tools and private portals as well as
related health coaching services are recognized ratably over the
term of the applicable agreement. Revenue from the sponsorship
of CME is recognized over the period we substantially complete
our contractual deliverables as determined by the applicable
agreements. Subscription revenue is recognized over the
subscription period. When contractual arrangements contain
multiple elements, revenue is allocated to each element based on
its relative fair value determined using prices charged when
elements are sold separately. In certain instances where fair
value does not exist for all the elements, the amount of
37
revenue allocated to the delivered elements equals the total
consideration less the fair value of the undelivered elements.
ViPS. We provide professional consulting
services to certain governmental agencies that are typically
billed on a cost-plus fee structure. Revenue for consulting
services is recognized as the services are provided. Healthcare
payers pay us annual license fees, which are based on the number
of covered members, for use of our software and pay us time and
materials fees for providing business and information technology
consulting services to them. Additionally, payers, including
government payers, pay us fees to license decision support
software and we provide related support and maintenance for that
decision support software, and provide information technology
consulting services. Decision support software and the related
support and maintenance agreements are generally sold as bundled
time-based license agreements and, accordingly, the revenue for
both the software and related support and maintenance is
recognized ratably over the term of the license and maintenance
agreement.
Porex. We develop, manufacture and distribute
porous plastic products and components. For standard products,
we recognize revenue upon shipment of product, net of sales
returns and allowances. For sales of certain custom products, we
recognize revenue upon completion and customer acceptance.
Recognition of amounts received in advance is deferred until all
criteria have been met.
|
|
|
|
|
Assets and Liabilities Held for Sale
Our assets and liabilities held for sale consist of the
assets and liabilities of EBS. See
Introduction Recent Developments
Pending EBS Transaction above in this MD&A. We
accounted for this pending sale in accordance with Statement of
Financial Accounting Standard No. 144, Accounting for
the Impairment or Disposal of Long-Lived Assets, and, as
such, the assets and liabilities of EBS as of September 30,
2006 are shown in our consolidated balance sheets at their
carrying value. The classification of EBS as assets held for
sale did not result in an impairment. We determined that since
we will have continued involvement in the EBS operations after
the sale, and as our ownership in EBS will be accounted for as
an equity investment in our consolidated financial statements,
the disposal should not be reflected as discontinued operations.
|
|
|
|
Long-Lived Assets Our long-lived
assets consist of property and equipment, goodwill and other
intangible assets. Goodwill and other intangible assets arise
from the acquisitions we have made. The amount assigned to
intangible assets is subjective and based on our estimates of
the future benefit of the intangible asset using accepted
valuation techniques, such as discounted cash flow and
replacement cost models. Our long-lived assets, excluding
goodwill, are amortized over their estimated useful lives, which
we determined based on the consideration of several factors,
including the period of time the asset is expected to remain in
service. We evaluate the carrying value and remaining useful
lives of long-lived assets, excluding goodwill, whenever
indicators of impairment are present. We evaluate the carrying
value of goodwill annually, or whenever indicators of impairment
are present. We use a discounted cash flow approach to determine
the fair value of goodwill. There was no impairment of goodwill
noted as a result of our impairment testing in 2005.
|
|
|
|
Investments Our investments, at
September 30, 2006, consisted principally of certificates
of deposit, auction rate securities, U.S. Treasury Notes,
marketable equity securities in publicly traded companies and
other short-term liquid cash investments. Each reporting period
we evaluate the carrying value of our investments and record a
loss on investments when we believe an investment has
experienced a decline in value that is other than temporary. Our
investments are classified as
available-for-sale
and are carried at fair value. We do not recognize gains on an
investment until sold. Unrealized gains and losses are recorded
as a component of accumulated other comprehensive income. Once
realized, the gains and losses and declines in value determined
to be
other-than-temporary
are recorded. A decline in value is deemed to be
other-than-temporary
if we do not have the intent and ability to retain the
investment until any anticipated recovery in market value, the
extent and length of the time to which the market value has been
less than cost and the financial condition and near-term
prospects of the investment.
|
|
|
|
Stock-Based Compensation In December
2004, the Financial Accounting Standards Board
(FASB) issued Statement of Financial Accounting
Standards (SFAS) No. 123, (Revised 2004):
Share-Based Payment (SFAS 123R), which
replaces SFAS No. 123, Accounting for
Stock-Based Compensation,
|
38
|
|
|
|
|
(SFAS 123) and supersedes APB Opinion
No. 25, Accounting for Stock Issued to
Employees. SFAS 123R requires all share-based
payments to employees, including grants of employee stock
options, to be recognized as compensation expense over the
service period (generally the vesting period) in the
consolidated financial statements based on their fair values. We
adopted SFAS 123R on January 1, 2006 and elected to
use the modified prospective transition method and as a result,
prior period results were not restated. Under the modified
prospective method, awards that were granted or modified on or
after January 1, 2006 are measured and accounted for in
accordance with SFAS 123R. Unvested stock options and
restricted stock awards that were granted prior to
January 1, 2006 will continue to be accounted for in
accordance with SFAS 123, using the same grant date fair
value and same expense attribution method used under
SFAS 123, except that all awards are recognized in the
results of operations over the remaining vesting periods. The
impact of forfeitures that may occur prior to vesting is also
estimated and considered in the amount recognized for all
stock-based compensation beginning January 1, 2006.
|
The fair value of each option granted is estimated on the date
of grant using the Black-Scholes option pricing model. The
assumptions used in this model are expected dividend yield,
expected volatility, risk-free interest rate and expected term.
The expected volatility for stock options to purchase Emdeon
Common Stock is based on implied volatility from traded options
of Emdeon Common Stock combined with historical volatility of
Emdeons Common Stock. The expected volatility for stock
options to purchase WHC Class A Common Stock is based on
implied volatility from traded options of stock of comparable
companies combined with historical stock price volatility of
comparable companies.
|
|
|
|
|
Deferred Tax Assets Our deferred tax
assets are comprised primarily of NOL carryforwards. At
December 31, 2005, we had NOL carryforwards of
approximately $2.1 billion. These loss carryforwards may be
used to offset taxable income in future periods, reducing the
amount of taxes we might otherwise be required to pay. Valuation
allowances exist for all domestic net deferred tax assets
because of the uncertainty of realization of the deferred tax
assets due to a lack of history of generating taxable income.
Realization is dependent upon generating sufficient taxable
income prior to the expiration of the NOL carryforwards in
future periods. Although realization is not currently assured,
management evaluates the need for a valuation allowance each
quarter, and in the future, should management determine that
realization of net deferred tax assets is more likely than not,
some or all of the valuation allowance will be reversed, and our
effective tax rate will be reduced. The valuation allowance
excludes the impact of any deferred items related to certain of
our foreign operations as the realization of the deferred items
for these operations is likely.
|
|
|
|
Tax Contingencies Our tax
contingencies are recorded to address potential exposures
involving tax positions we have taken that could be challenged
by tax authorities. These potential exposures result from the
varying application of statutes, rules, regulations and
interpretations. Our estimates of tax contingencies reflect
assumptions and judgments about potential actions by taxing
jurisdictions. We believe that these assumptions and judgments
are reasonable; however, our accruals may change in the future
due to new developments in each matter and the ultimate
resolution of these matters may be greater or less than the
amount that we have accrued.
|
Recent
Accounting Pronouncements
In September 2006, the FASB issued SFAS No. 157,
Fair Value Measurements (SFAS 157).
SFAS 157 defines fair value, establishes a framework for
measuring fair value and expands disclosure of fair value
measurements. SFAS 157 applies under other accounting
pronouncements that require or permit fair value measurements
and, accordingly, does not require any new fair value
measurements. SFAS 157 is effective for financial
statements issued for fiscal years beginning after
November 15, 2007. We are currently evaluating the impact,
if any, that this new standard will have on our results of
operations, financial position or cash flows.
39
In July 2006, the FASB issued FASB Interpretation No. 48,
Accounting for Uncertainty in Income Taxes,
(FIN 48), which clarifies the accounting for
uncertainty in income taxes recognized in the financial
statements in accordance with SFAS No. 109,
Accounting for Income Taxes. The interpretation
prescribes a recognition threshold and measurement attribute for
the financial statement recognition and measurement of a tax
position taken or expected to be taken in a tax return. It also
provides guidance on derecognizing, classification, interest and
penalties, accounting in interim periods, disclosure and
transition. The cumulative effect of applying FIN 48 should
be reported as an adjustment to retained earnings at the
beginning of the period in which it is adopted. The provisions
of FIN 48 are effective for fiscal years beginning after
December 15, 2006. We are currently evaluating the impact,
if any, that this new standard will have on our results of
operations, financial position or cash flows.
Results
of Operations
The following table sets forth our consolidated statements of
operations data and expresses that data as a percentage of
revenue for the periods presented (amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
Revenue
|
|
$
|
299,732
|
|
|
|
100.0
|
|
|
$
|
261,022
|
|
|
|
100.0
|
|
|
$
|
868,557
|
|
|
|
100.0
|
|
|
$
|
762,711
|
|
|
|
100.0
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations
|
|
|
169,710
|
|
|
|
56.6
|
|
|
|
152,066
|
|
|
|
58.3
|
|
|
|
505,925
|
|
|
|
58.2
|
|
|
|
445,095
|
|
|
|
58.4
|
|
Development and engineering
|
|
|
9,243
|
|
|
|
3.1
|
|
|
|
8,912
|
|
|
|
3.4
|
|
|
|
27,164
|
|
|
|
3.1
|
|
|
|
26,595
|
|
|
|
3.5
|
|
Sales, marketing, general and
administrative
|
|
|
74,050
|
|
|
|
24.7
|
|
|
|
63,865
|
|
|
|
24.5
|
|
|
|
216,263
|
|
|
|
25.0
|
|
|
|
189,292
|
|
|
|
24.8
|
|
Depreciation and amortization
|
|
|
18,189
|
|
|
|
6.1
|
|
|
|
15,801
|
|
|
|
6.1
|
|
|
|
51,964
|
|
|
|
6.0
|
|
|
|
44,826
|
|
|
|
5.9
|
|
Legal expense
|
|
|
1,023
|
|
|
|
0.3
|
|
|
|
5,904
|
|
|
|
2.3
|
|
|
|
1,840
|
|
|
|
0.2
|
|
|
|
14,347
|
|
|
|
1.9
|
|
Advisory expense
|
|
|
2,126
|
|
|
|
0.7
|
|
|
|
|
|
|
|
|
|
|
|
4,198
|
|
|
|
0.5
|
|
|
|
|
|
|
|
|
|
Loss on investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,642
|
|
|
|
0.5
|
|
Loss on redemption of convertible
debt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,902
|
|
|
|
0.2
|
|
Interest income
|
|
|
6,599
|
|
|
|
2.2
|
|
|
|
5,124
|
|
|
|
2.0
|
|
|
|
15,450
|
|
|
|
1.8
|
|
|
|
13,380
|
|
|
|
1.8
|
|
Interest expense
|
|
|
4,723
|
|
|
|
1.6
|
|
|
|
2,996
|
|
|
|
1.1
|
|
|
|
14,082
|
|
|
|
1.6
|
|
|
|
11,670
|
|
|
|
1.5
|
|
Other expense
|
|
|
|
|
|
|
|
|
|
|
1,863
|
|
|
|
0.7
|
|
|
|
|
|
|
|
|
|
|
|
1,863
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
before income tax provision and minority interest
|
|
|
27,267
|
|
|
|
9.1
|
|
|
|
14,739
|
|
|
|
5.6
|
|
|
|
62,571
|
|
|
|
7.2
|
|
|
|
36,859
|
|
|
|
4.9
|
|
Income tax provision
|
|
|
3,474
|
|
|
|
1.2
|
|
|
|
1,851
|
|
|
|
0.7
|
|
|
|
12,082
|
|
|
|
1.4
|
|
|
|
3,567
|
|
|
|
0.5
|
|
Minority interest in WebMD Health
Corp., net of tax
|
|
|
140
|
|
|
|
|
|
|
|
38
|
|
|
|
|
|
|
|
(653
|
)
|
|
|
(0.1
|
)
|
|
|
38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
23,653
|
|
|
|
7.9
|
|
|
|
12,850
|
|
|
|
4.9
|
|
|
|
51,142
|
|
|
|
5.9
|
|
|
|
33,254
|
|
|
|
4.4
|
|
Income from discontinued
operations, net of tax
|
|
|
358,048
|
|
|
|
119.5
|
|
|
|
1,257
|
|
|
|
0.5
|
|
|
|
370,171
|
|
|
|
42.6
|
|
|
|
6,868
|
|
|
|
0.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
381,701
|
|
|
|
127.4
|
|
|
$
|
14,107
|
|
|
|
5.4
|
|
|
$
|
421,313
|
|
|
|
48.5
|
|
|
$
|
40,122
|
|
|
|
5.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue is derived from our four business segments: Emdeon
Business Services, WebMD, ViPS and Porex. Emdeon Business
Services provides solutions that automate key business and
administrative functions for healthcare payers and providers,
including: electronic patient eligibility and benefit
verification; electronic and paper claims processing; electronic
and paper paid-claims communication services; and patient
billing, payment and communications services. Emdeon Business
Services also provides clinical communications services that
enable physicians to manage laboratory orders and results,
hospital reports and electronic prescriptions. A significant
portion of Emdeon Business Services revenue is generated from
the countrys largest national and regional healthcare
payers. WebMD services include: advertising, sponsorship, CME,
40
content syndication and distribution; and licenses of private
online portals to employers, healthcare payers and others. In
addition, WebMD derives revenue from sales of, and advertising
in, its physician directories, subscriptions to its professional
medical reference textbooks, and advertisements in WebMD the
Magazine. As a result of the acquisition of the
assets of Conceptis, WebMD also generates revenue from in-person
CME programs. ViPS provides decision support solutions, data
warehousing solutions and consulting services to governmental,
Blue Cross Blue Shield and commercial healthcare payers and
performs software maintenance and consulting services for
governmental agencies involved in healthcare. Our Porex revenue
includes the sale of porous plastic components used to control
the flow of fluids and gases for use in healthcare, industrial
and consumer applications, as well as finished products used in
the medical device and surgical markets.
Cost of operations consists of costs related to services and
products we provide to customers and costs associated with the
operation and maintenance of our networks. These costs include
salaries and related expenses, including non-cash stock-based
compensation expenses, for network operations personnel and
customer support personnel, telecommunication costs, maintenance
of network equipment, cost of postage related to our automated
print-and-mail
services and paid-claims communication services, a portion of
facilities expenses, leased facilities and personnel costs,
sales commissions paid to certain distributors of our Emdeon
Business Services products and non-cash expenses related to
content and distribution services. In addition, cost of
operations includes raw materials, direct labor and
manufacturing overhead, such as fringe benefits and indirect
labor related to our Porex segment.
Development and engineering expense consists primarily of
salaries and related expenses, including non-cash stock-based
compensation expenses, associated with the development of
applications and services. Expenses include compensation paid to
development and engineering personnel, fees to outside
contractors and consultants, and the maintenance of capital
equipment used in the development process.
Sales, marketing, general and administrative expense consists
primarily of advertising, product and brand promotion, salaries
and related expenses, including non-cash stock-based
compensation expenses, for sales, administrative, finance,
legal, information technology, human resources and executive
personnel. These expenses include items related to account
management and marketing personnel, commissions, costs and
expenses for marketing programs and trade shows, and fees for
professional marketing and advertising services, as well as fees
for professional services, costs of general insurance and costs
of accounting and internal control systems to support our
operations. Also included are non-cash expenses related to
advertising and distribution services acquired in exchange for
our equity securities.
Legal expense consists of costs and expenses incurred related to
the investigation by the United States Attorney for the District
of South Carolina and the SEC.
Advisory expense includes professional fees, primarily
consisting of legal, accounting and financial advisory services,
related to the Pending EBS Transaction.
Discontinued operations consist of the historical operations of
EPS, net of tax, and the gain recognized from the EPS Sale, net
of tax.
Our discussions throughout MD&A make references to certain
non-cash expenses. We consider non-cash expenses to be those
expenses that result from the issuance of our equity
instruments. The following is a summary of our principal
non-cash expenses:
|
|
|
|
|
Non-cash advertising expense. Expense related
to the usage of our prepaid advertising inventory that we
received from News Corporation in exchange for equity
instruments we issued in connection with an agreement we entered
into with News Corporation in 1999 and subsequently amended in
2000. Our non-cash advertising expense is included in cost of
operations when we utilize prepaid advertising in conjunction
with offline advertising and sponsorship programs. Our non-cash
advertising expense is included in sales, marketing, general and
administrative expense when we utilize the prepaid advertising
for promotion of our brand or the brand of one of our
subsidiaries.
|
|
|
|
Non-cash stock-based compensation
expense. Expense for 2006 reflects the adoption
of SFAS 123R on January 1, 2006 which requires all
share-based payments to employees, including grants of
|
41
|
|
|
|
|
employee stock options, to be recognized as compensation expense
over the service period (generally the vesting period) in the
consolidated financial statements based on their fair values.
Expense for 2005 primarily related to restricted stock awards
and stock option modifications, as well as the amortization of
deferred compensation related to certain acquisitions in 2000.
Non-cash stock-based compensation expense is included in cost of
operations, development and engineering, and sales, marketing,
general and administrative expense within the accompanying
consolidated statements of operations. The following table
summarizes the non-cash stock-based compensation expense for the
three and nine months ended September 30, 2006 and 2005:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Stock-based compensation expense
included in:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations
|
|
$
|
3,010
|
|
|
$
|
|
|
|
$
|
9,353
|
|
|
$
|
|
|
Development and engineering
|
|
|
286
|
|
|
|
|
|
|
|
854
|
|
|
|
|
|
Sales, marketing, general and
administrative
|
|
|
7,930
|
|
|
|
1,073
|
|
|
|
25,028
|
|
|
|
3,631
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
11,226
|
|
|
$
|
1,073
|
|
|
$
|
35,235
|
|
|
$
|
3,631
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following discussion includes a comparison of the results of
operations for the three and nine months ended
September 30, 2006 to the three and nine months ended
September 30, 2005.
The operating results presented below reflect the
reclassification of EPS as a discontinued operation in the
current year and prior year periods. In addition, our operating
results reflect the increase in revenue and an offsetting
increase in cost of operations of $11,584 and $39,387 for the
three and nine months ended September 30, 2006,
respectively, and $13,368 and $40,181 for the three and nine
months ended September 30, 2005, respectively, related to
the intercompany activity between EPS and our other operating
segments, primarily EBS through September 14, 2006, the
date the sale was completed. This activity is primarily
comprised of
print-and-mail
services (including postage) and electronic data interchange
(EDI) services provided by EBS to the EPS customer
base and related rebates paid by EBS to EPS related to
EPSs submission of EDI transactions. These amounts had
previously been eliminated in consolidation prior to EPS being
reflected as discontinued operations.
Revenue
Revenue for the three months ended September 30, 2006 was
$299,732, compared to $261,022 in the prior year period. Our
revenue increased by $38,710 or 14.8% for the three months ended
September 30, 2006. The WebMD, Emdeon Business Services,
Porex and ViPS segments were responsible for $21,551, $15,870,
$888 and $565, respectively, of the revenue increase for the
quarter.
Revenue for the nine months ended September 30, 2006 was
$868,557, compared to $762,711 in the prior year period. Our
revenue increased by $105,846 or 13.9% for the nine months ended
September 30, 2006. The WebMD, Emdeon Business Services,
ViPS and Porex segments were responsible for $54,174, $41,033,
$7,215 and $3,881, respectively, of the revenue increase for the
nine months ended September 30, 2006.
Acquisitions completed during 2006 and 2005 within our WebMD and
EBS segments contributed $6,775 and $19,081 to the increase in
revenue for the three and nine months ended September 30,
2006, respectively. Also contributing to the increase in revenue
was increased advertising and sponsorship revenue from
WebMDs public portals and an increase in the number of
companies using WebMDs private portal platform. In
addition, revenue increased in our Emdeon Business Services
segment, primarily as a result of growth in our patient billing
and remittance and payment services and an increase in postage
rates that went into effect on January 8, 2006.
42
Costs and
Expenses
Cost of Operations. Cost of operations was
$169,710 and $505,925 for the three and nine months ended
September 30, 2006, respectively, compared to $152,066 and
$445,095 in the prior year periods. Our cost of operations
represented 56.6% and 58.2% of revenue for the three and nine
months ended September 30, 2006, compared to 58.3% and
58.4% for the three and nine months ended September 30,
2005. Included in cost of operations are non-cash stock-based
compensation expense of $3,010 and $9,353 for the three and nine
months ended September 30, 2006, with no corresponding
amount in the prior year period, as a result of the adoption of
SFAS 123R.
Cost of operations, excluding the non-cash stock-based
compensation expense, was $166,700 and $496,572 or 55.6% and
57.2% of revenue for the three and nine months ended
September 30, 2006, respectively. The increases in absolute
dollars are primarily due to higher compensation expenses in our
WebMD segment as a result of higher staffing levels, increased
expenses related to recent WebMD acquisitions, the impact of the
postal rate increase that went into effect on January 8,
2006 and increased expenses related to the delivery of our
consulting services within our ViPS operations. The decreases as
a percentage of revenue, are primarily the result of increased
revenue discussed above, without a proportionate increase in
cost. Additionally, we encountered lower direct expenses in our
EBS segment through operating efficiencies and cost savings.
These operating efficiencies and costs savings included lower
direct expenses in the areas of telecommunication charges and
paper and other direct material costs, as well as lower
personnel related costs. Partially offsetting this improvement
was the impact of the postal rate increase which had a negative
effect on cost of operations when reflected as a percentage of
revenue.
Development and Engineering. Development and
engineering expense was $9,243 and $27,164 for the three and
nine months ended September 30, 2006, compared to $8,912
and $26,595 in the prior year periods. Our development and
engineering expenses represented 3.1% of revenue for the three
and nine months ended September 30, 2006, compared to 3.4%
and 3.5% of revenue for the three and nine months ended
September 30, 2005. The increase in development and
engineering, in absolute dollars, is primarily the result of
non-cash stock-based compensation expense of $286 and $854, for
the three and nine months ended September 30, 2006, as
discussed above. Development and engineering expense, excluding
stock-based compensation expenses, was $8,957 and $26,310, or
3.0% of revenue, for the three and nine months ended
September 30, 2006, which, in absolute dollars, was
relatively consistent with the prior year.
Sales, Marketing, General and
Administrative. Sales, marketing, general and
administrative expense was $74,050 and $216,263 for the three
and nine months ended September 30, 2006, compared to
$63,865 and $189,292 in the prior year periods. Our sales,
marketing, general and administrative expenses represented 24.7%
and 25.0% of revenue for the three and nine months ended
September 30, 2006, compared to 24.5% and 24.8% of revenue
for the three and nine months ended September 30, 2005.
Included in sales, marketing, general and administrative expense
are non-cash expenses related to advertising services and
stock-based compensation expense. Non-cash stock-based
compensation expense was $7,930 and $25,028 for the three and
nine months ended September 30, 2006, compared to $1,073
and $3,631 in the prior year periods, reflecting the adoption of
SFAS 123R on January 1, 2006. We expect stock-based
compensation expense to be higher during 2006 than in prior
years due to the adoption of this accounting standard. Non-cash
expenses related to advertising services were $1,660 and $4,454
for the three and nine months ended September 30, 2006,
compared to $1,912 and $6,708 in the prior year periods.
Fluctuations in non-cash advertising expense are directly
attributable to the utilization of our prepaid advertising
inventory during the respective periods.
Sales, marketing, general and administrative expense, excluding
the non-cash stock compensation and advertising expenses
discussed above, was $64,460 and $186,781 or 21.5% of revenue
for the three and nine months ended September 30, 2006,
compared to $60,880 and $178,953 or 23.3% and 23.5% of revenue
in the prior year periods. The decrease in sales, marketing,
general and administrative expense, excluding the non-cash
expenses discussed above, as a percentage of revenue, is due to
our ability to achieve an increase in revenue without incurring
a proportionate increase in expenses, with the exception of
certain increased compensation related costs due to staffing and
sales commission expenses related to our WebMD segment,
43
which were directly attributable to the increased revenue, as
well as increased expenses related to recent acquisitions that
were not included, or only partially included in the year ago
period.
Depreciation and Amortization. Depreciation
and amortization expense was $18,189 and $51,964 for the three
and nine months ended September 30, 2006, compared to
$15,801 and $44,826 in the prior year periods. Depreciation and
amortization expense represented 6.1% and 6.0% of revenue for
the three and nine months ended September 30, 2006,
compared to 6.1% and 5.9% of revenue in the prior year periods.
The increase, in absolute dollars, for the three and nine months
ended September 30, 2006 was primarily due to depreciation
and amortization expenses relating to the acquisitions in our
WebMD segment, which were not included, or only partially
included, in the prior periods. Also contributing to the
increase in depreciation expense during the current year
periods, were capital expenditures made within EBS and WebMD
segments during the later part of 2005 and early 2006.
Legal Expense. Legal expense was $1,023 and
$1,840 for the three and nine months ended September 30,
2006, compared to $5,904 and $14,347 in the prior year periods.
Legal expense represents the external costs and expenses
incurred related to the investigation by the United States
Attorney for the District of South Carolina and the SEC. While
we cannot predict these costs and expenses with certainty and
while they may continue to be significant, we expect these costs
to continue to be lower during the remainder of 2006, as
compared to 2005, in part because existing insurance policies
became available to cover the expenses of certain former
officers and employees. In connection with the EPS Sale, we have
agreed to indemnify Sage Software with respect to this matter.
Advisory Expense. Advisory expense for the
three and nine months ended September 30, 2006 represents
costs and expenses of $2,126 and $4,198, respectively for
professional fees, primarily consisting of legal, accounting and
financial advisory services, related to the Pending EBS
Transaction. We expect that advisory expenses will continue to
be significant through the closing of the Pending EBS
Transaction, which is expected to occur during the fourth
quarter of 2006.
Loss on Investments. During the three months
ended March 31, 2005, we recorded $4,251 for unrealized
losses on marketable securities that we identified as securities
to be liquidated in the event funds were needed for redemption
of our $300,000 of
31/4% Convertible
Subordinated Notes due 2007
(31/4
Notes). Also, included in other expense for the nine
months ended September 30, 2005 is $609 related to net
gains on the sale of marketable securities.
Loss on Redemption of Convertible Notes. Loss
on redemption of convertible debt for the nine months ended
September 30, 2005, represents a loss of $1,902 related to
the redemption of the
31/4% Notes
on June 2, 2005.
Interest Income. Interest income was $6,599
and $15,450 during the three and nine months ended
September 30, 2006, compared to $5,124 and $13,380 in the
prior year periods. The increase for both the three and nine
months ended September 30, 2006 was the result of higher
average rates of return, partially offset by lower average
investment balances during the current year periods.
Interest Expense. Interest expense was $4,723
and $14,082 for the three and nine months ended
September 30, 2006, compared to $2,996 and $11,670 in the
prior year periods. The increase for both periods is due to the
issuance of our $300,000
31/8% Convertible
Notes due 2025 on August 24, 2005
(31/8
Notes) , offset by the redemption of our
31/4% Notes
on June 2, 2005. Based on the timing of the issuance and
redemption of these notes, no interest expense was incurred
during the period of June 2, 2005 to August 24, 2005.
Other Expense. Other expense for the three and
nine months ended September 30, 2005 represents a loss of
$1,863 related to the settlement of the McKesson HBOC litigation.
Income Tax Provision. The income tax provision
of $3,474 and $12,082 for the three and nine months ended
September 30, 2006 and $1,851 and $3,567 for the three and
nine months ended September 30, 2005, includes tax expense
for operations that were profitable in certain foreign, state
and other jurisdictions in which we do not have net operating
losses to offset that income. The income tax provision for the
three and
44
nine months ended September 30, 2006 also includes a
provision for federal taxes of $1,264 and $5,307, respectively,
and $46 and $115 for the three and nine months ended
September 30, 2005, respectively, that has not been reduced
by the reversal of a valuation allowance as these tax benefits
were acquired through business combinations.
Minority Interest. Minority interest expense
of $140 and income of $653 for the three and nine months ended
September 30, 2006, compared to expense of $38 for the
three and nine months ended September 30, 2005 represents
the minority stockholders proportionate share of income or
loss of our consolidated WebMD segment. The ownership interest
of minority shareholders was created as part of our initial
public offering of our WebMD segment on September 28, 2005
and fluctuates based on the net income or loss reported by our
WebMD segment.
Income from Discontinued Operations, Net of
Tax. Income from discontinued operations
represents EPSs net operating results of $5,779 and
$17,902 for the three and nine months ended September 30,
2006, compared to $1,257 and $6,868 in the prior year periods,
as well as a gain of $352,269, net of tax, recognized in
connection with the completed EPS Sale on September 14,
2006.
Results
of Operations by Operating Segment
We evaluate the performance of the business based upon earnings
before interest, taxes, non-cash and other items. Non-cash and
other items include: legal expenses which reflect costs and
expenses related to the investigation by the United States
Attorney for the District of South Carolina and the SEC
(Legal expense); professional fees, primarily
consisting of legal, accounting and financial advisory services,
related to the Pending EBS Transaction (Advisory
expense); a charge related to the redemption of the
31/4%
Notes; minority interest in our consolidated WebMD segment;
non-cash advertising expense related to advertising acquired in
exchange for our equity securities; costs and expenses related
to the settlement of the McKesson HBOC litigation; and non-cash
stock-based compensation expense, which relates to stock options
issued and assumed in connection with acquisitions and
restricted stock issued to employees and, beginning
January 1, 2006, includes the incremental non-cash
stock-based compensation expense associated with the adoption of
SFAS 123R.
Reclassification of Segment Information. In
connection with the EPS Sale and related reclassification of
that operating segment to discontinued operations, we have
reclassified certain expenses related to activities that were
previously managed, and therefore reported, within our Corporate
and EBS segments, to the discontinued EPS segment, as these
expenses will not be incurred by our continuing operations. In
accordance with SFAS 144, these expenses were reclassified
for the current and comparable prior year periods. The expenses
which were reclassified to the discontinued EPS segment
aggregated $260 and $924 for the three and nine months ended
September 30, 2006, respectively, and $550 and $1,262 for
the three and nine months ended September 30, 2005,
respectively.
Summarized financial information for each of our operating
segments and a reconciliation to net income are presented below
(amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Emdeon Business Services
|
|
$
|
187,266
|
|
|
$
|
171,396
|
|
|
$
|
557,974
|
|
|
$
|
516,941
|
|
WebMD
|
|
|
66,645
|
|
|
|
45,094
|
|
|
|
173,308
|
|
|
|
119,134
|
|
ViPS
|
|
|
24,843
|
|
|
|
24,278
|
|
|
|
73,525
|
|
|
|
66,310
|
|
Porex
|
|
|
21,298
|
|
|
|
20,410
|
|
|
|
64,544
|
|
|
|
60,663
|
|
Inter-segment eliminations
|
|
|
(320
|
)
|
|
|
(156
|
)
|
|
|
(794
|
)
|
|
|
(337
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
299,732
|
|
|
$
|
261,022
|
|
|
$
|
868,557
|
|
|
$
|
762,711
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Earnings before interest,
taxes, non-cash and other
items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Emdeon Business Services
|
|
$
|
44,547
|
|
|
$
|
32,297
|
|
|
$
|
127,519
|
|
|
$
|
103,315
|
|
WebMD
|
|
|
14,633
|
|
|
|
9,077
|
|
|
|
30,759
|
|
|
|
15,100
|
|
ViPS
|
|
|
5,302
|
|
|
|
3,988
|
|
|
|
15,517
|
|
|
|
11,992
|
|
Porex
|
|
|
6,133
|
|
|
|
6,385
|
|
|
|
18,732
|
|
|
|
17,846
|
|
Corporate
|
|
|
(11,000
|
)
|
|
|
(12,509
|
)
|
|
|
(33,633
|
)
|
|
|
(35,894
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
59,615
|
|
|
|
39,238
|
|
|
|
158,894
|
|
|
|
112,359
|
|
Interest, taxes, non-cash and
other items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
(18,189
|
)
|
|
|
(15,801
|
)
|
|
|
(51,964
|
)
|
|
|
(44,826
|
)
|
Non-cash stock-based compensation
|
|
|
(11,226
|
)
|
|
|
(1,073
|
)
|
|
|
(35,235
|
)
|
|
|
(3,631
|
)
|
Non-cash advertising
|
|
|
(1,660
|
)
|
|
|
(1,986
|
)
|
|
|
(4,454
|
)
|
|
|
(6,999
|
)
|
Legal expense
|
|
|
(1,023
|
)
|
|
|
(5,904
|
)
|
|
|
(1,840
|
)
|
|
|
(14,347
|
)
|
Advisory expense
|
|
|
(2,126
|
)
|
|
|
|
|
|
|
(4,198
|
)
|
|
|
|
|
Interest income
|
|
|
6,599
|
|
|
|
5,124
|
|
|
|
15,450
|
|
|
|
13,380
|
|
Interest expense
|
|
|
(4,723
|
)
|
|
|
(2,996
|
)
|
|
|
(14,082
|
)
|
|
|
(11,670
|
)
|
Income tax provision
|
|
|
(3,474
|
)
|
|
|
(1,851
|
)
|
|
|
(12,082
|
)
|
|
|
(3,567
|
)
|
Minority interest in WebMD Health
Corp., net of tax
|
|
|
(140
|
)
|
|
|
(38
|
)
|
|
|
653
|
|
|
|
(38
|
)
|
Loss on investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,642
|
)
|
Loss on redemption of convertible
debt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,902
|
)
|
Other expense
|
|
|
|
|
|
|
(1,863
|
)
|
|
|
|
|
|
|
(1,863
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
23,653
|
|
|
|
12,850
|
|
|
|
51,142
|
|
|
|
33,254
|
|
Income from discontinued
operations, net of tax
|
|
|
358,048
|
|
|
|
1,257
|
|
|
|
370,171
|
|
|
|
6,868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
381,701
|
|
|
$
|
14,107
|
|
|
$
|
421,313
|
|
|
$
|
40,122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following discussion is a comparison of the results of
operations for each of our operating segments for the three and
nine months ended September 30, 2006 to the three and nine
months ended September 30, 2005.
Emdeon Business Services. Revenue was $187,266
and $557,974 for the three and nine months ended
September 30, 2006, an increase of $15,870 or 9.3% and
$41,033 or 7.9%, compared to the prior year periods. The
increase in revenue for the three and nine months ended
September 30, 2006, compared to the prior year, was
primarily due to growth in our patient statement and remittance
and payment services and an increase in postage revenue which
corresponded with the increase in postage rates that went into
effect on January 8, 2006. Also contributing to the
increase in revenue for the three and nine months ended
September 30, 2006 was revenue from the IPN acquisition in
the amount of $537.
Earnings before interest, taxes, non-cash and other items was
$44,547 and $127,519 for the three and nine months ended
September 30, 2006, compared to $32,297 and $103,315 in the
prior year periods. As a percentage of revenue, earnings before
interest, taxes, non-cash and other items was 23.8% and 22.9%
for the three and nine months ended September 30, 2006,
compared to 18.8% and 20.0% for the prior year periods. The
increase in operating margin, as a percentage of revenue, was
primarily the result of higher revenue as discussed above,
without a proportionate increase in costs. This is due to a
combination of certain costs that are more fixed in nature and
do not increase proportionately with revenue including certain
personnel related costs, as well as the result of operating
efficiencies and cost savings. The operating efficiencies and
costs savings included lower direct expenses in the areas of
telecommunication expenses and other direct material
46
costs related to our patient statement and remittance and
payment service offerings, The increase in operating margin was
slightly offset by the impact of the increased postage rates
which went into effect at the beginning of the current year.
WebMD. Revenue was $66,645 and $173,308 for
the three and nine months ended September 30, 2006, an
increase of $21,551 or 47.8% and $54,174 or 45.5%, compared to
the prior year periods. The acquisitions of Healthshare,
Conceptis, eMedicine, Summex and Medsite contributed $6,238 and
$19,081 to the increases in revenue for the three and nine
months ended September 30, 2006, respectively. The
remaining increase in revenue is the result of increased
advertising and sponsorship revenue attributable to an increase
in the number of brands and sponsored programs promoted on our
sites and increased licensing revenue attributable to an
increase in the number of companies using our private portal
platform.
Earnings before interest, taxes, non-cash and other items was
$14,633 and $30,759 for the three and nine months ended
September 30, 2006, compared to $9,077 and $15,100 in the
prior year periods. As a percentage of revenue, earnings before
interest, taxes, non-cash and other items was 22.0% and 17.7%
for the three and nine months ended September 30, 2006,
compared to 20.1% and 12.7% for the prior year periods. This
increase in operating margin was primarily due to the higher
revenue discussed above without incurring a proportionate
increase in overall expenses. This increase was partially offset
by a charge of approximately $3,150 during the nine months ended
September 30, 2005 related to the resignation of our former
CEO and recruitment of our Executive Vice President of Product
and Programming and Chief Technology Officer.
ViPS. Revenue was $24,843 and $73,525 for the
three and nine months ended September 30, 2006, an increase
of $565 or 2.3% and $7,215 or 10.9%, compared to the prior year
periods, respectively. The increase in revenue for the three
months ended September 30, 2006, compared to the prior year
period, was primarily due to higher software product sales. The
increase in revenue for the nine months ended September 30,
2006, compared to the prior year, was primarily due to increased
consulting services and software product sales.
Earnings before interest, taxes, non-cash and other items was
$5,302 and $15,517 for the three and nine months ended
September 30, 2006, compared to $3,988 and $11,992 in the
prior year periods. As a percentage of revenue, earnings before
interest, taxes, non-cash and other items was 21.3% and 21.1%
for the three and nine months ended September 30, 2006,
compared to 16.4% and 18.1% for the prior year periods. The
increase in operating margin for the three and nine months ended
September 30, 2006 was primarily due to the changes in the
type of revenue we earned (which can have varying degrees of
profitability), such as the higher software revenue we earned in
the current year periods, which have higher margins than certain
types of consulting services, including the consulting services
we provide to governmental agencies.
Porex. Revenue was $21,298 and $64,544 for the
three and nine months ended September 30, 2006, an increase
of $888 or 4.4% and $3,881 or 6.4%, compared to the prior year
periods. The increase in revenue for the three and nine months
ended September 30, 2006, was primarily due to increased
sales of our healthcare, foreign industrial products and
consumer products.
Earnings before interest, taxes, non-cash and other items was
$6,133 and $18,732 for the three and nine months ended
September 30, 2006, compared to $6,385 and $17,846 in the
prior year periods. As a percentage of revenue, earnings before
interest, taxes, non-cash and other items was 28.8% and 29.0%
for the three and nine months ended September 30, 2006,
compared to 31.3% and 29.4% for the prior year periods. The
decrease in operating margin was due to higher direct costs
relating to the mix of products produced and, to a lesser
extent, higher personnel costs.
Corporate. Corporate includes expenses shared
across all segments, such as executive personnel, accounting,
tax, treasury, legal, human resources, risk management and
certain information technology functions. Corporate expenses
were $11,000 or 3.7% of revenue and $33,633 or 3.9% of revenue
for the three and nine months ended September 30, 2006,
compared to $12,509 or 4.8% of revenue and $35,894 or 4.7% of
revenue for the prior year periods. These expenses, in absolute
dollars, decreased as a result of lower personnel related costs
due to lower headcount. Additionally, our corporate expenses as
a percentage of revenue continue to decrease when compared to
the prior periods reflecting our ability to increase revenue
without a proportionate increase in corporate costs which are
generally more fixed in nature. Additionally, in connection
47
with the transition services we are providing to EPS following
the EPS Sale, we charged EPS transition services fees of $341
during the period from September 15, 2006 to
September 30, 2006. This amount is reflected within our
Corporate segment during the three and nine months ended
September 30, 2006, offsetting the cost of providing these
services.
Inter-Segment Eliminations. Inter-segment
eliminations primarily represents printing services provided by
EBS and certain services provided by our WebMD segment to our
other operating segments. Inter-segment eliminations during the
current year periods were consistent when compared to a year ago.
Liquidity
and Capital Resources
We began operations in January 1996 and, until 2004, we had
incurred net losses in each year and, as of September 30,
2006, we had an accumulated deficit of approximately
$9.7 billion. We plan to continue to invest in
acquisitions, strategic relationships, infrastructure and
product development.
As of September 30, 2006, we had approximately $947,403 in
cash and cash equivalents and short-term investments, including
$85,086 in cash and cash equivalents and short-term investments
held by WHC, and working capital of approximately $915,577,
which excludes our assets and liabilities held for sale.
Additionally, we had $2,668 in marketable equity securities. We
invest our excess cash principally in U.S. Treasury
obligations and federal agency notes and other short-term liquid
cash investments and expect to do so in the future. As of
September 30, 2006, all our marketable securities were
classified as
available-for-sale.
Cash provided by operating activities was $161,799 for the nine
months ended September 30, 2006, compared to cash provided
by operating activities of $99,101 for the nine months ended
September 30, 2005. The principal sources of the $62,698
increase in cash provided by operating activities when compared
to a year ago, were higher earnings before interest, taxes,
non-cash and other items, as well as a higher rate of
collections of receivables and lower payments related to
accounts payable, offset by higher payments of our accrued
liabilities. We expect that our cash provided by operating
activities will decrease in the future, as a direct result of
the Pending EBS Transaction.
Cash provided by investing activities was $566,838 for the nine
months ended September 30, 2006, compared to cash used in
investing activities of $303,430 for the nine months ended
September 30, 2005. Cash provided by investing activities
for the nine months ended September 30, 2006 was primarily
attributable to $524,245 of proceeds received from the EPS Sale
and $198,190 of net proceeds from maturities and sales, of
available-for-sale
securities. Cash paid in business combinations, net of cash
acquired, was $119,635 for the nine months ended
September 30, 2006, which primarily related to the
acquisition of Medsite, Summex and eMedicine, as well as
contingent consideration payments related to our acquisitions of
Advanced Business Fulfillment, Inc. (ABF) and
MedicineNet, Inc., of $17,946 and $7,250, respectively. Cash
used in investing activities for the nine months ended
September 30, 2005 included net purchases of $180,095 from
maturities and sales of
available-for-sale
securities. Cash paid in business combinations, net of cash
acquired, was $74,380 for the nine months ended
September 30, 2005, which primarily related to the ABF
contingent consideration payment and the 2005 acquisition of
HealthShare Technology, Inc. Investments in property and
equipment were $38,231 for the nine months ended
September 30, 2006, compared to $39,107 for the prior year
period.
Cash used in financing activities was $9,434 for the nine months
ended September 30, 2006, compared to cash provided by
financing activities of $241,474 for the nine months ended
September 30, 2005. Cash used in financing activities for
the nine months ended September 30, 2006 principally
related to the repurchases of our common stock of $71,843,
offset by proceeds from the issuance of our common stock,
primarily resulting from exercises of employee stock options, of
$62,768. Cash provided by financing activities for the nine
months ended September 30, 2005 consisted of $289,875
related to the net proceeds of the
31/8% Notes
in August 2005 and $43,384 related to the issuance of our common
stock, primarily resulting from exercises of employee stock
options, partially offset by cash paid of $86,694 for the
redemption of our
31/4% Notes
in June 2005 and $4,596 related to the repurchase of our common
stock.
48
Our principal commitments at September 30, 2006 were our
commitments related to the $350,000 of 1.75% Convertible
Subordinated Notes due 2023 and the
31/8% Notes
and the $100,000 of Convertible Redeemable Exchangeable
Preferred Stock. In addition, we have obligations under
operating leases of $96,090, the potential payment of contingent
consideration of up to an aggregate of $42,114 if prior
acquisitions we have made achieve certain milestones and the
future cash commitments of $34,000 related to the pending
acquisitions of Subimo.
Our liquidity will be impacted by the receipt of approximately
$1,200,000 in connection with the Pending EBS Transaction which
is expected to be completed during the quarter ended
December 31, 2006. Additionally, we recently commenced a
tender offer to purchase up to 100 million shares of our
common stock at a price of $12.25 per share, the
consummation of which would result in a use of cash of
approximately $1,225,000 if all 100 million shares are
fully tendered. The Pending Tender Offer is also expected to be
completed during the December 2006 quarter. As we previously
disclosed, the Pending Tender Offer is subject to a number of
terms and conditions, including the completion of the Pending
EBS Transaction. Because the Pending Tender Offer is subject to
the completion of the Pending EBS Transaction, the net impact of
these two transactions is not expected to have a material impact
on our liquidity, assuming all 100 million shares are fully
tendered. Our liquidity in the future will be impacted by lower
operating cash flows as a result of the Pending EBS Transaction.
While we will own a 48% interest in EBS after the Pending EBS
Transaction is completed, the debt incurred in connection with
the Pending EBS Transaction will reduce the profitability of
EBS. Additionally, our access to the cash flow of EBS will be
subject to a credit agreement to be entered into by entities
within Emdeon Business Services and that will restrict the
dividend of cash by EBS to us, as well as imposing certain other
restrictions on EBS.
We believe that, for the foreseeable future, we will have
sufficient cash resources to meet the commitments described
above and our current anticipated working capital and capital
expenditure requirements, including the capital requirements
related to the roll-out of new or updated products in 2006 and
2007. Our future liquidity and capital requirements will depend
upon numerous factors, including those discussed above regarding
the Pending EBS Transaction and the Pending Tender Offer,
retention of customers at current volume and revenue levels, our
existing and new application and service offerings, competing
technological and market developments, cost of maintaining and
upgrading the information technology platforms and
communications systems that EBS and WebMD use to provide their
services, potential future acquisitions and additional
repurchases of our common stock. We may need to raise additional
funds to support expansion, develop new or enhanced applications
and services, respond to competitive pressures, acquire
complementary businesses or technologies or take advantage of
unanticipated opportunities. If required, we may raise such
additional funds through public or private debt or equity
financing, strategic relationships or other arrangements. There
can be no assurance that such financing will be available on
acceptable terms, if at all, or that such financing will not be
dilutive to our stockholders.
Factors
That May Affect Our Future Financial Condition or Results of
Operations
This section describes circumstances or events that could have a
negative effect on our financial results or operations or that
could change, for the worse, existing trends in some or all of
our businesses. The occurrence of one or more of the
circumstances or events described below could have a material
adverse effect on our financial condition, results of operations
and cash flows or on the trading prices of the common stock and
convertible notes that we have issued or securities we may issue
in the future. The risks and uncertainties described in this
Quarterly Report are not the only ones facing us. Additional
risks and uncertainties that are not currently known to us or
that we currently believe are immaterial may also adversely
affect our business and operations.
49
Risks
Related to WebMD
WebMD has
incurred and may continue to incur losses
WebMDs operating results have fluctuated significantly in
the past from quarter to quarter and may continue to do so in
the future. WebMDs net losses from 2001 to 2003 totaled
approximately $2.6 billion. WebMDs online businesses
participate in relatively new and rapidly evolving markets. Many
companies with business plans based on providing healthcare
information through the Internet have failed to be profitable
and some have filed for bankruptcy
and/or
ceased operations. Even if demand from users exists, we cannot
assure you that WebMD will be profitable.
In addition, WebMDs online businesses have a limited
operating history and have undergone significant changes during
their short history as a result of changes in the types of
services provided, technological changes, changes in market
conditions, and changes in management, and are expected to
continue to change for similar reasons.
The
timing of WebMDs advertising and sponsorship revenue may
vary significantly from quarter to quarter
WebMDs advertising and sponsorship revenue may vary
significantly from quarter to quarter due to a number of
factors, not all of which are in WebMDs control, and any
of which may be difficult to forecast accurately. The majority
of WebMDs advertising and sponsorship contracts are for
terms of approximately four to 12 months. WebMD has
relatively few longer term advertising and sponsorship
contracts. We cannot assure you that WebMDs current
customers for these services will continue to use WebMD beyond
the terms of their existing contracts or that they will enter
into any additional contracts.
In addition, the time between the date of initial contact with a
potential advertiser or sponsor regarding a specific program and
the execution of a contract with the advertiser or sponsor for
that program may be lengthy, especially for larger contracts,
and may be subject to delays over which WebMD has little or no
control, including as a result of budgetary constraints of the
advertiser or sponsor or their need for internal approvals.
Other factors that could affect the timing of WebMDs
revenue from advertisers and sponsors include:
|
|
|
|
|
timing of Food and Drug Administration, or FDA, approval for new
products or for new approved uses for existing products;
|
|
|
|
seasonal factors relating to the prevalence of specific health
conditions and other seasonal factors that may affect the timing
of promotional campaigns for specific products; and
|
|
|
|
the scheduling of conferences for physicians and other
healthcare professionals.
|
Lengthy
sales and implementation cycles for WebMDs private online
portals make it difficult to forecast revenues from these
applications and may impact its results of operations
The period from WebMDs initial contact with a potential
client for a private online portal and the first purchase of its
solution by the client is difficult to predict. In the past,
this period has generally ranged from six to 12 months, but
in some cases has been longer. These sales may be subject to
delays due to a clients internal procedures for approving
large expenditures and other factors beyond WebMDs
control. The time it takes to implement a private online portal
is also difficult to predict and has lasted as long as six
months from contract execution to the commencement of live
operation. Implementation may be subject to delays based on the
availability of the internal resources of the client that are
needed and other factors outside of WebMDs control. As a
result, we have limited ability to forecast the timing of
revenue from new private portal clients. This, in turn, makes it
more difficult to predict WebMDs financial performance
from quarter to quarter.
During the sales cycle and the implementation period, WebMD may
expend substantial time, effort and money preparing contract
proposals, negotiating contracts and implementing the private
online portal without receiving any related revenue. In
addition, many of the expenses related to providing private
online portals are relatively fixed in the short term, including
personnel costs and technology and infrastructure costs. Even if
50
WebMDs revenue from providing private portals is lower
than expected, it may not be able to reduce its short-term
spending in response. Any shortfall in revenue would have a
direct impact on WebMDs results of operations.
If WebMD
is unable to provide content and services that attract and
retain users to The WebMD Health Network on a consistent basis,
its advertising and sponsorship revenue could be
reduced
Users of The WebMD Health Network have numerous other
online and offline sources of healthcare information services.
WebMDs ability to compete for user traffic on its public
portals depends upon its ability to make available a variety of
health and medical content, decision-support applications and
other services that meet the needs of a variety of types of
users, including consumers, physicians and other healthcare
professionals, with a variety of reasons for seeking
information. WebMDs ability to do so depends, in turn, on:
|
|
|
|
|
its ability to hire and retain qualified authors, journalists
and independent writers;
|
|
|
|
its ability to license quality content from third
parties; and
|
|
|
|
its ability to monitor and respond to increases and decreases in
user interest in specific topics.
|
We cannot assure you that WebMD will be able to continue to
develop or acquire needed content, applications and tools at a
reasonable cost. In addition, since consumer users of
WebMDs public portals may be attracted to The WebMD
Health Network as a result of a specific condition or for a
specific purpose, it is difficult for us to predict the rate at
which they will return to the public portals. Because WebMD
generates revenue by, among other things, selling sponsorships
of specific pages, sections or events on The WebMD Health
Network, a decline in user traffic levels or a reduction in
the number of pages viewed by users could cause WebMDs
revenue to decrease and could have a material adverse effect on
WebMDs results of operations.
If WebMD
is unable to provide healthcare content for its offline
publications that attracts and retains users, its revenue will
be reduced
Interest in WebMDs publications for physicians, such as
The Little Blue Book and ACP Medicine and ACS
Surgery: Principles and Practice, is based upon its ability
to make available
up-to-date
health content that meets the needs of its physician users.
Although WebMD has been able to continue to update and maintain
the physician practice information that it publishes in The
Little Blue Book, if it is unable to continue to do so for
any reason, the value of The Little Blue Book would
diminish and interest in this publication and advertising in
this publication would be adversely affected.
Similarly, WebMDs ability to maintain or increase the
subscriptions to ACP Medicine and ACS Surgery is
based upon its ability to make available
up-to-date
content which depends on its ability to retain qualified
physician authors and writers in the disciplines covered by
these publications. We cannot assure you that WebMD will be able
to retain qualified physician editors or authors to provide and
review needed content at a reasonable cost. If WebMD is unable
to provide content that attracts and retains subscribers,
subscriptions to these products will be reduced.
WebMD the Magazine was launched in April 2005 and as a
result has a very short operating history. We cannot assure you
that WebMD the Magazine will be able to attract and
retain advertisers to make this publication successful in the
long term.
A decline
in user traffic levels for The WebMD Health Network could have a
material adverse effect on its advertising and sponsorship
revenue
WebMD generates revenue by, among other things, selling
sponsorships of specific pages, sections or events on its
network of publicly available online Web sites for healthcare
providers and consumers and related
e-mailed
newsletters. WebMDs advertisers and sponsors include
pharmaceutical, biotech, medical device and consumer products
companies that are interested in communicating with and
educating WebMDs
51
audience or parts of its audience. We cannot provide assurance
that WebMD will be able to retain or increase usage of its
online public portals by consumers and physicians. There are
numerous other online and offline sources of healthcare
information services that compete with WebMD. In addition, since
users may be attracted to The WebMD Health Network as a
result of a specific condition or for a specific purpose, it is
difficult for us to predict the rate at which users will return.
A decline in user traffic levels or a reduction in the number of
pages viewed by users may cause WebMDs revenue to decrease
and could have a material adverse effect on its results of
operations.
The WebMD
Health Network includes Web sites that WebMD supplies content
to, but does not own, and the termination of its relationship
with the owners of these Web sites may negatively affect its
results of operations
Although a substantial majority of the page view traffic to
The WebMD Health Network is from Web sites that WebMD
owns, some are from Web sites owned by third parties that carry
WebMDs content (including the AOL division of Time Warner)
and, as a result, The WebMD Health Networks traffic
may vary based on the amount of traffic to Web sites of these
third parties and other factors outside its control. During the
quarter ended September 30, 2006, third party Web sites
accounted for approximately 6% of The WebMD Health
Networks aggregate page views.
WebMD does not expect its existing agreement with AOL to
continue following the expiration of that agreement in May 2007.
The monthly unique users and page view traffic from AOL was less
than 6% and 3%, respectively of The WebMD Health
Networks monthly unique users and page view traffic
for the quarter ended September 30, 2006. As a result of
the expiration, the page view traffic from AOL will no longer be
part of The WebMD Health Network. Additionally, revenues
and earnings of approximately $5 million per year related
to certain contractual guarantees will also end with the
expiration of that agreement.
In the event that any of WebMDs other relationships with
third party Web sites are terminated, The WebMD Health
Networks user page view traffic may be negatively
affected, which may negatively affect our results of operations.
WebMD may
be unsuccessful in its efforts to increase advertising and
sponsorship revenue from consumer products companies
Most of WebMDs advertising and sponsorship revenue has, in
the past, come from pharmaceutical, biotechnology and medical
device companies. More recently, WebMD has been focusing on
increasing sponsorship revenue from consumer products companies
that are interested in communicating health-related or
safety-related information about their products to WebMDs
audience. However, while a number of consumer products companies
have indicated an intent to increase the portion of their
promotional spending used on the Internet, we cannot assure you
that these advertisers and sponsors will find WebMDs
consumer Web sites to be as effective as other Web sites or
traditional media for promoting their products and services. If
WebMD encounters difficulties in competing with the other
alternatives available to consumer products companies, this
portion of its business may develop more slowly than we expect
or may fail to develop.
Failure
to maintain and enhance the WebMD brand could have a
material adverse effect on WebMDs business
We believe that the WebMD brand identity that WebMD
has developed has contributed to the success of its business and
has helped it achieve recognition as a trusted source of health
and wellness information. We also believe that maintaining and
enhancing that brand is important to expanding the user base for
WebMDs public portals, to its relationships with sponsors
and advertisers and to its ability to gain additional employer
and healthcare payer clients for its private portals. WebMD has
expended considerable resources on establishing and enhancing
the WebMD brand and its other brands, and it has
developed policies and procedures designed to preserve and
enhance its brands, including editorial procedures designed to
provide quality control of the information it publishes. WebMD
expects to continue to devote resources and efforts to maintain
and enhance its brands. However, it may not be able to
successfully maintain or enhance awareness
52
of its brands, and events outside of its control may have a
negative affect on its brands. If WebMD is unable to maintain or
enhance awareness of its brands, and do so in a cost-effective
manner, its business could be materially and adversely affected.
WebMD may
be subject to claims brought against it as a result of content
it provides
Consumers access health-related information through WebMDs
online services, including information regarding particular
medical conditions and possible adverse reactions or side
effects from medications. If WebMDs content, or content
that it obtains from third parties, contains inaccuracies, it is
possible that consumers, employees, health plan members or
others may sue WebMD for various causes of action. Although
WebMDs Web sites contain terms and conditions, including
disclaimers of liability, that are intended to reduce or
eliminate its liability, the law governing the validity and
enforceability of online agreements and other electronic
transactions is evolving. WebMD could be subject to claims by
third parties that WebMDs online agreements with consumers
and physicians that provide the terms and conditions for use of
WebMDs public or private portals are unenforceable. A
finding by a court that these agreements are invalid and that
WebMD is subject to liability could harm its business and
require costly changes to its business.
WebMD has editorial procedures in place to provide quality
control of the information that it publishes or provides.
However, we cannot assure you that WebMDs editorial and
other quality control procedures will be sufficient to ensure
that there are no errors or omissions in particular content.
Even if potential claims do not result in liability to WebMD,
investigating and defending against these claims could be
expensive and time consuming and could divert managements
attention away from operations. In addition, WebMDs
business is based on establishing the reputation of its portals
as trustworthy and dependable sources of healthcare information.
Allegations of impropriety or inaccuracy, even if unfounded,
could therefore harm WebMDs reputation and business.
WebMD
faces potential liability related to the privacy and security of
personal information it collects from consumer and healthcare
professionals through its Web sites
Internet user privacy has become a major issue both in the
United States and abroad. WebMD has privacy policies posted on
its Web sites that we believe comply with applicable laws
requiring notice to users about WebMDs information
collection, use and disclosure practices. However, whether and
how existing privacy and consumer protection laws in various
jurisdictions apply to the Internet is still uncertain and may
take years to resolve. Any legislation or regulation in the area
of privacy of personal information could affect the way WebMD
operates its Web sites and could harm its business. Further, we
can give no assurance that the privacy policies and other
statements on WebMDs Web sites, or its practices, will be
found sufficient to protect it from liability or adverse
publicity in this area.
Failure
by WebMD to maintain its CME accreditation could adversely
affect its ability to provide online CME offerings
WebMDs CME activities are planned and implemented in
accordance with the Essential Areas and Policies of the
Accreditation Council for Continuing Medical Education, or
ACCME, which oversees providers of CME credit, and other
applicable accreditation standards. In September 2004, ACCME
revised its standards for commercial support of CME. The revised
standards are intended to ensure, among other things, that CME
activities of ACCME-accredited providers are independent of
providers of healthcare goods and services that fund the
development of CME. ACCME required accredited providers to
implement these standards by May 2005. Implementation has
required additional disclosures to CME participants about those
in a position to influence content and other adjustments to the
management and operations of our CME programs. We believe we
have modified our procedures as appropriate to meet the revised
standards. However, we cannot be certain whether these
adjustments will ensure that we meet these standards or predict
whether ACCME may impose additional requirements.
In the event that ACCME concludes that WebMD has not met its
revised standards relating to CME, WebMD would not be permitted
to offer accredited ACCME activities to physicians and other
healthcare
53
professionals, and WebMD may be required, instead, to use third
parties to accredit such CME-related services on Medscape
from WebMD. In addition, any failure by WebMD to maintain
its status as an accredited ACCME provider as a result of a
failure to comply with existing or new ACCME standards could
discourage potential sponsors from engaging in CME or education
related activities with WebMD, which could have a material
adverse effect on its business.
Government
regulation and industry initiatives could adversely affect the
volume of sponsored online CME programs implemented through
WebMDs Web sites or require changes to how WebMD offers
CME
CME activities may be subject to government regulation by the
FDA, the OIG, or HHS, the federal agency responsible for
interpreting certain federal laws relating to healthcare, and by
state regulatory agencies. During the past several years,
educational programs, including CME, directed toward physicians
have been subject to increased scrutiny to ensure that sponsors
do not influence or control the content of the program. In
response to governmental and industry initiatives,
pharmaceutical companies and medical device companies have been
developing and implementing internal controls and procedures
that promote adherence to applicable regulations and
requirements. In implementing these controls and procedures,
different clients may interpret the regulations and requirements
differently and may implement procedures or requirements that
vary from client to client. These controls and procedures:
|
|
|
|
|
may discourage pharmaceutical companies from engaging in
educational activities;
|
|
|
|
may slow their internal approval for such programs;
|
|
|
|
may reduce the volume of sponsored educational programs
implemented through WebMDs Web sites to levels that are
lower than in the past; and
|
|
|
|
may require WebMD to make changes to how we offer or provide
educational programs, including CME.
|
In addition, future changes to existing regulations or to the
internal compliance programs of clients or potential clients,
may further discourage or prohibit clients or potential clients
from engaging in educational activities with WebMD, or may
require WebMD to make further changes in the way it offers or
provides educational programs.
Risks
Related to Emdeon Business Services
The
financial results of Emdeon Business Services could be adversely
affected to the extent payers conduct electronic data
interchange, or EDI, transactions without using a clearinghouse
or if their ability to do so allows them to terminate or modify
their relationships with us
There can be no assurance that healthcare payers will continue
to use Emdeon Business Services and other independent companies
to transmit healthcare transactions. Some payers currently offer
electronic data transmission services to healthcare providers
that bypass third-party EDI service providers such as Emdeon
Business Services. In addition, some payers currently offer
electronic data transmission services through affiliated
clearinghouses that compete with Emdeon Business Services. We
cannot provide assurance that Emdeon Business Services will be
able to maintain its existing relationships with payers or
develop new relationships on satisfactory terms, if at all. Any
significant increase in the utilization of links between
healthcare providers and payers without use of a third party
clearinghouse could have a material adverse effect on Emdeon
Business Services transaction volume and financial
results. In addition, any increase in the ability of payers to
bypass third party EDI service providers may adversely affect
the terms and conditions Emdeon Business Services is able to
negotiate in its agreements with them, which could also have a
material adverse impact on Emdeon Business Services
business and financial results.
54
Some of
Emdeon Business Services customers compete with it and
some, instead of using a third party provider, perform
internally some of the same services that it offers
Some of Emdeon Business Services existing payer and
provider customers compete with it or may plan to do so or
belong to alliances that compete with it or plan to do so,
either with respect to the same products and services it
provides to them or with respect to some of other lines of
business. For example, some payers currently offer, through
affiliated clearinghouses, Web portals and other means,
electronic data transmission services to healthcare providers
that allow the provider to bypass third party EDI service
providers such as Emdeon Business Services, and additional
payers may do so in the future. The ability of payers to do so
may adversely affect the terms and conditions Emdeon Business
Services is able to negotiate in its connectivity agreements
with them and its transaction volume. We cannot provide
assurance that Emdeon Business Services will be able to maintain
its existing relationships for connectivity services with payers
or develop new relationships on satisfactory terms, if at all.
In addition, some of Emdeon Business Services services
allow healthcare payers to outsource business processes that
they have been or could be performing internally and, in order
for Emdeon Business Services to be able to compete, use of its
services must be more efficient for them than use of internal
resources.
Emdeon
Business Services transaction volume and financial results
could be adversely affected if it does not maintain
relationships with practice management system vendors and large
submitters of healthcare EDI transactions
Emdeon Business Services has developed relationships with
practice management system vendors and large submitters of
healthcare claims to increase the usage of its transaction
services. In the past several years, there has been
consolidation of practice management systems vendors, including
among some of the larger such vendors, which may increase their
bargaining power in negotiations with Emdeon Business Services.
To the extent that it is not able to maintain mutually
satisfactory relationships with the larger practice management
system vendors and large submitters of healthcare EDI
transactions, Emdeon Business Services transaction volume
and financial results could be adversely affected.
New or
updated products and services of Emdeon Business Services will
not become profitable unless they achieve sufficient levels of
market acceptance
The future results of Emdeon Business Services will depend, in
part, on whether its new or updated products and services
receive sufficient customer acceptance, including:
|
|
|
|
|
the business process outsourcing services for payers that it has
developed internally and through acquisitions;
|
|
|
|
its other pre- and post-adjudication services for payers and
providers; and
|
|
|
|
its updated clinical transaction services.
|
There can be no assurance that payers and providers who use
Emdeon Business Services for sending and receiving claims will
use its other services. Providers and payers may choose to use
similar products and services offered by our competitors,
especially if they are already using products and services of
those competitors and have made investments in hardware,
software and training relating to those products and services.
Even providers and payers who are already customers of Emdeon
Business Services may not purchase new or updated products or
services, especially when they are initially offered or if they
require additional equipment or changes in workflow. Failure to
achieve broad penetration in target markets with respect to new
or updated products and services could have a material adverse
effect on the business prospects and financial results of Emdeon
Business Services.
For services that Emdeon Business Services is developing or may
develop in the future, there can be no assurance that it will
attract sufficient customers or that such services will generate
sufficient revenues to cover the costs of developing, marketing
and providing those services. In addition, the introduction of
future products and services may require or make advisable
related changes in the manner in which we market, deliver and
price our products and services, including pre-existing products
and services. There can be no assurance that
55
any pricing strategy that we implement for any new products and
services will be economically viable or acceptable to the target
markets.
Achieving
market acceptance of new or updated products and services of
Emdeon Business Services is likely to require significant
efforts and expenditures
Achieving market acceptance for new or updated products and
services of Emdeon Business Services is likely to require
substantial marketing efforts and expenditure of significant
funds to create awareness and demand by participants in the
healthcare industry. In addition, deployment of new or updated
products and services may require the use of additional
resources for training our existing sales force and customer
service personnel and for hiring and training additional
salespersons and customer service personnel. There can be no
assurance that the revenue opportunities from new or updated
products and services will justify amounts spent for their
development, marketing and roll-out.
Emdeon
Business Services ability to provide transaction services
depends on services provided by telecommunications
companies
Emdeon Business Services relies on a limited number of suppliers
to provide some of the telecommunications services necessary for
its transaction services. The telecommunications industry has
been subject to significant changes as a result of changes in
technology, regulation and the underlying economy. In the past
several years, many telecommunications companies have
experienced financial problems and some have sought bankruptcy
protection. Some of these companies have discontinued
telecommunications services for which they had contractual
obligations to Emdeon Business Services. There has also been
consolidation of telecommunications companies, further reducing
the number of telecommunications companies competing for
business. Emdeon Business Services inability to source
telecommunications services at reasonable prices due to a loss
of competitive suppliers could affect its ability to maintain
its margins until it is able to raise its prices to its
customers and, if it is not able to raise its prices, could have
a material adverse effect on its financial results.
Risks
Related to ViPS
Lengthy
sales, installation and implementation cycles for some ViPS
applications may result in unanticipated fluctuations in their
revenues
ViPS provides licensed software products and related services to
payers and information technology services to government
customers. The period from our initial contact with a potential
ViPS client and the purchase of our solution by the client is
difficult to predict. In the past, this period has generally
ranged from six to 12 months, but in some cases has
extended much longer. Sales by ViPS may be subject to delays due
to customers internal procedures for approving large
expenditures, to delays in government funding and to delays
resulting from other factors outside of our control. The time it
takes to implement a licensed software solution is also
difficult to predict and has lasted as long as 12 months
from contract execution to the commencement of live operation.
Implementation may be subject to delays based on the
availability of the internal resources of the client that are
needed and other factors outside of our control. As a result, we
have only limited ability to forecast the timing of revenue from
new ViPS sales. During the sales cycle and the implementation
period, we may expend substantial time, effort and money
preparing contract proposals and negotiating the contract
without receiving any related revenue.
ViPS
depends on CMS for a significant portion of its revenues and, if
ViPSs reputation or relationship with CMS were harmed,
ViPSs business and financial results would be adversely
affected.
ViPS is heavily dependent upon The Centers for
Medicare & Medicaid Services, or CMS, as its primary
source of revenue (directly as a prime contractor or indirectly
as a subcontractor) and we believe that the success and
development of its business will continue to depend on its
successful participation in CMS contract programs. ViPS
generated approximately 72% of its revenue from CMS (as prime
contractor or as a
56
subcontractor) in fiscal 2005. ViPSs reputation and
relationship with CMS is a key factor in maintaining and growing
revenues under contracts with CMS. Negative press reports
regarding poor contract performance, employee misconduct,
information security breaches or other aspects of our business
(including aspects of Emdeons business that are unrelated
to ViPS) could harm ViPSs reputation. If ViPSs
reputation with CMS is negatively affected, or if it is
suspended or debarred from contracting with government agencies
for any reason, such actions would decrease the amount of
business that CMS does with ViPS and its business and financial
results would be adversely affected.
ViPS
depends on being retained as a subcontractor by other CMS
contractors for a significant portion of its revenues and, if
ViPSs reputation or relationships with CMS or such
contractors was harmed, ViPSs business and financial
results would be adversely affected
ViPS depends on being retained as a subcontractor by other CMS
contractors for a significant portion of its revenues. ViPS
generated approximately 18% of its revenue in fiscal 2005 from
acting as a subcontractor for other CMS contractors. ViPSs
business and financial results could be adversely affected if
other CMS contractors eliminate or reduce their subcontracts
with ViPS (which could occur if, for example, ViPS reputation or
relationship with CMS is negatively affected as discussed above)
or if CMS terminates or reduces these other contractors
programs, does not award them new contracts or refuses to pay
under a contract.
CMS may
modify, curtail or terminate contracts prior to their completion
and, if ViPS does not replace them, its business and financial
results may suffer
Many of the CMS contracts in which ViPS participates as a
contractor or subcontractor may extend for several years. These
programs are normally funded on an annual basis. Under these
contracts, CMS generally has the right not to exercise options
to extend or expand our contracts and may modify, curtail or
terminate the contracts and subcontracts at its convenience. Any
decision by CMS not to exercise contract options or to modify,
curtail or terminate our major programs or contracts would
adversely affect the ViPS business and financial results.
ViPSs
CMS contracts may be terminated and ViPS may be liable for
penalties under a variety of procurement rules and regulations
and changes in government regulations or practices could
adversely affect its business and financial results
ViPS must comply with laws and regulations relating to the
formation, administration and performance of CMS contracts. Such
laws and regulations may potentially impose added costs on
ViPSs business and its failure to comply with them may
lead to penalties and the termination of its CMS contracts. Some
significant regulations that affect ViPS include:
|
|
|
|
|
the Federal Acquisition Regulation and supplements, which
regulate the formation, administration and performance of
U.S. Government contracts
|
|
|
|
the Truth in Negotiations Act, which requires certification and
disclosure of cost and pricing data in connection with contract
negotiations
|
|
|
|
the Cost Accounting Standards, which impose accounting
requirements that govern our right to reimbursement under
certain cost-based government contracts
|
The U.S. Government
and/or CMS
may revise procurement practices or adopt new contract rules and
regulations, such as cost accounting standards, at any time. Any
changes could impair ViPS ability to obtain new contracts or
contracts under which it currently performs when those contracts
are put up for recompetition bids. Any new contracting methods
could be costly or administratively difficult for ViPS to
implement and could adversely affect its business and financial
results.
In addition, ViPSs contracts with CMS are subject to
periodic review and investigation. If such a review or
investigation identifies improper or illegal activities, we may
be subject to civil or criminal penalties or administrative
sanctions, including the termination of contracts, forfeiture of
profits, the triggering of price
57
reduction clauses, suspension of payments, fines and suspension
or debarment from doing business with U.S. Government
agencies. We could also suffer harm to our reputation if
allegations of impropriety were made against us, which would
impair our ability to win awards of contracts in the future or
receive renewals of existing contracts. If we incur a material
penalty or administrative sanction or otherwise suffer harm to
our reputation, ViPS business and financial results could be
adversely affected.
For a description of additional risks relating to government
contracting, see Risks Applicable to Our Entire Company
and to Ownership of Our Securities Contractual
relationships with governmental customers may impose special
burdens and additional risks on us that are not generally found
in contracts with other customers
ViPS is
subject to routine audits and cost adjustments by CMS, which, if
resolved unfavorably to it, could adversely affect its
profitability
U.S. Government agencies routinely audit and review their
contractors performance on contracts, cost structure,
pricing practices and compliance with applicable laws,
regulations and standards. They also review the adequacy of, and
a contractors compliance with, its internal control
systems and policies, including the contractors
purchasing, property, estimating, compensation and management
information systems. Such audits may result in adjustments to
ViPSs contract costs, and any costs found to be improperly
allocated will not be reimbursed. ViPs records contract revenues
in based upon costs it expects to realize upon final audit.
However, we do not know the outcome of any future audits and
adjustments and, if future audit adjustments exceed our
estimates, ViPS profitability could be adversely affected.
If
subcontractors that ViPs works with fail to satisfy their
obligations to ViPS or to the customers , ViPS business and
financial results could be adversely affected
ViPS depends on subcontractors in conducting its business. There
is a risk that ViPS may have disputes with our subcontractors
arising from, among other things, the quality and timeliness of
work performed by the subcontractor, customer concerns about the
subcontractor, and ViPSs failure to extend existing task
orders or issue new task orders under a subcontract. In
addition, if any of ViPSs subcontractors fail to perform
the agreed-upon services, ViPSs ability to fulfill its
obligations may be jeopardized. If that happens, it could result
in a customer terminating a contract for default. A termination
for default could expose ViPS to liability and have an adverse
effect on ViPSs ability to compete for future contracts
and orders, especially if the customer is CMS.
Risks
Related to Porex
Porexs
success depends upon demand for its products, which in some
cases ultimately depends upon
end-user
demand for the products of its customers
Demand for our Porex products may change materially as a result
of economic or market conditions and other trends that affect
the industries in which Porex participates. In addition, because
a significant portion of our Porex products are components that
are eventually integrated into or used with products
manufactured by customers for resale to end-users, the demand
for these product components is dependent on product development
cycles and marketing efforts of these other manufacturers, as
well as variations in their inventory levels, which are factors
that we are unable to control. Accordingly, the amount of
Porexs sales to manufacturer customers can be difficult to
predict and subject to wide
quarter-to-quarter
variances.
Porexs
product offerings must meet changing customer
requirements
A significant portion of our Porex products are integrated into
end products used by manufacturing companies in various
industries, some of which are characterized by rapidly changing
technology, evolving industry standards and frequent new product
introductions. Accordingly, to satisfy its customers, Porex must
58
develop and introduce, in a timely manner, products that meet
changing customer requirements at competitive prices. To do
this, Porex must:
|
|
|
|
|
develop new uses of existing porous plastics technologies and
applications;
|
|
|
|
innovate and develop new porous plastics technologies and
applications;
|
|
|
|
commercialize those technologies and applications;
|
|
|
|
manufacture at a cost that allows it to price its products
competitively;
|
|
|
|
manufacture and deliver its products in sufficient volumes and
on time;
|
|
|
|
accurately anticipate customer needs; and
|
|
|
|
differentiate its offerings from those of its competitors.
|
We cannot assure you that Porex will be able to develop new or
enhanced products or that, if it does, those products will
achieve market acceptance. If Porex does not introduce new
products in a timely manner and make enhancements to existing
products to meet the changing needs of its customers, some of
its products could become obsolete over time, in which case
Porexs customer relationships, revenue and operating
results would be negatively impacted.
Potential
new or enhanced Porex products may not achieve sufficient sales
to be profitable or justify the cost of their
development
We cannot be certain, when we engage in Porex research and
development activities, whether potential new products or
product enhancements will be accepted by the customers for which
they are intended. Achieving market acceptance for new or
enhanced products may require substantial marketing efforts and
expenditure of significant funds to create awareness and demand
by potential customers. In addition, sales and marketing efforts
with respect to these products may require the use of additional
resources for training our existing Porex sales forces and
customer service personnel and for hiring and training
additional salespersons and customer service personnel. There
can be no assurance that the revenue opportunities from new or
enhanced products will justify amounts spent for their
development and marketing. In addition, there can be no
assurance that any pricing strategy that we implement for any
new or enhanced Porex products will be economically viable or
acceptable to the target markets.
Porex may
not be able to source the raw materials it needs or may have to
pay more for those raw materials
Some of Porexs products require high-grade plastic resins
with specific properties as raw materials. While Porex has not
experienced any material difficulty in obtaining adequate
supplies of high-grade plastic resins that meet its
requirements, it relies on a limited number of sources for some
of these plastic resins. If Porex experiences a reduction or
interruption in supply from these sources, it may not be able to
access alternative sources of supply within a reasonable period
of time or at commercially reasonable rates, which could have a
material adverse effect on its business and financial results.
In addition, the prices of some of the raw materials that Porex
uses vary, to a great extent, with the price of petroleum. As a
result, increases in the price of petroleum could have an
adverse effect on Porexs margins and on the ability of
Porexs porous plastics products to compete with products
made from other raw materials.
Disruptions
in Porexs manufacturing operations could have a material
adverse effect on its business and financial results
Any significant disruption in Porexs manufacturing
operations, including as a result of fire, power interruptions,
equipment malfunctions, labor disputes, material shortages,
earthquakes, floods, computer viruses, sabotage, terrorist acts
or other force majeure, could have a material adverse effect on
Porexs ability to deliver products to customers and,
accordingly, its financial results.
59
Porex may
not be able to keep third parties from using technology it has
developed
Porex uses proprietary technology for manufacturing its porous
plastics products and its success is dependent, to a significant
extent, on its ability to protect the proprietary and
confidential aspects of its technology. Although Porex owns
certain patents, it relies primarily on non-patented proprietary
manufacturing processes. To protect its proprietary processes,
Porex relies on a combination of trade secret laws, license
agreements, nondisclosure and other contractual provisions and
technical measures, including designing and manufacturing its
porous molding equipment and most of its molds in-house. Trade
secret laws do not afford the statutory exclusivity possible for
patented processes. There can be no assurance that the legal
protections afforded to Porex or the steps taken by Porex will
be adequate to prevent misappropriation of its technology. In
addition, these protections do not prevent independent
third-party development of competitive products or services.
The
nature of Porexs products exposes it to product liability
claims that may not be adequately covered by indemnity
agreements or insurance
The products sold by Porex, whether sold directly to end-users
or sold to other manufacturers for inclusion in the products
that they sell, expose it to potential risk of product liability
claims, particularly with respect to Porexs life sciences,
clinical, surgical and medical products. Some of Porexs
products are designed to be permanently implanted in the human
body. Design defects and manufacturing defects with respect to
such products sold by Porex or failures that occur with the
products of Porexs manufacturer customers that contain
components made by Porex could result in product liability
claims
and/or a
recall of one or more of Porexs products. Porex believes
that it carries adequate insurance coverage against product
liability claims and other risks. We cannot assure you, however,
that claims in excess of Porexs insurance coverage will
not arise. In addition, Porexs insurance policies must be
renewed annually. Although Porex has been able to obtain
adequate insurance coverage at an acceptable cost in the past,
we cannot assure you that Porex will continue to be able to
obtain adequate insurance coverage at an acceptable cost.
In most instances, Porex enters into indemnity agreements with
its manufacturing customers. These indemnity agreements
generally provide that these customers would indemnify Porex
from liabilities that may arise from the sale of their products
that incorporate Porex components to, or the use of such
products by, end-users.
While Porex generally seeks contractual indemnification from its
customers, any such indemnification is limited, as a practical
matter, to the creditworthiness of the indemnifying party. If
Porex does not have adequate contractual indemnification
available, product liability claims, to the extent not covered
by insurance, could have a material adverse effect on its
business and its financial results.
Economic,
political and other risks associated with Porexs
international sales and geographically diverse operations could
adversely affect Porexs operations and financial
results
Since Porex sells its products worldwide, its business is
subject to risks associated with doing business internationally.
In addition, Porex has manufacturing facilities in the United
Kingdom, Germany and Malaysia. Accordingly, Porexs
operations and financial results could be harmed by a variety of
factors, including:
|
|
|
|
|
changes in foreign currency exchange rates;
|
|
|
|
changes in a specific countrys or regions political
or economic conditions, particularly in emerging markets;
|
|
|
|
trade protection measures and import or export licensing
requirements;
|
|
|
|
potentially negative consequences from changes in tax laws;
|
|
|
|
differing protection of intellectual property; and
|
|
|
|
unexpected changes in regulatory requirements.
|
60
Environmental
regulation could adversely affect Porexs
business
Porex is subject to foreign and domestic environmental laws and
regulations and is subject to scheduled and random checks by
environmental authorities. Porexs business involves the
handling, storage and disposal of materials that are classified
as hazardous. Although Porexs safety procedures for
handling, storage and disposal of these materials are designed
to comply with the standards prescribed by applicable laws and
regulations, Porex may be held liable for any environmental
damages that result from Porexs operations. Porex may be
required to pay fines, remediation costs and damages, which
could have a material adverse effect on its results of
operations.
Risks
Related to the Development and Performance of the Products and
Services
of Emdeon
Business Services, ViPS and WebMD
Performance
problems with our systems or system failures, whether caused by
hardware, software or other problems, could cause us to lose
business or incur liabilities
Our customer satisfaction and our business could be harmed if we
experience transmission delays or failures or loss of data in
the systems we use to provide services to our customers,
including the transaction-related services that Emdeon Business
Services provides to healthcare payers and providers and the
online services that WebMD provides. These systems, and the
software used in these systems, are complex and, despite testing
and quality control, we cannot be certain that problems will not
occur or that they will be detected and corrected promptly if
they do occur. To operate without interruption, both we and the
service providers we use must guard against:
|
|
|
|
|
damage from fire, power loss and other natural disasters;
|
|
|
|
communications failures;
|
|
|
|
software and hardware errors, failures or crashes;
|
|
|
|
security breaches, computer viruses and similar disruptive
problems; and
|
|
|
|
other potential interruptions.
|
We have contingency plans for emergencies with the systems we
use to provide services; however, we have limited backup
facilities if these systems are not functioning. The occurrence
of a major catastrophic event or other system failure at any of
our facilities or at a third-party facility we use could
interrupt our services or result in the loss of stored data,
which could have a material adverse impact on our business or
cause us to incur material liabilities. Although we maintain
insurance for our business, we cannot guarantee that our
insurance will be adequate to compensate us for all losses that
may occur or that this coverage will continue to be available on
acceptable terms or in sufficient amounts.
We could
be subject to breach of warranty, product liability or other
claims if our software products, information technology systems
or transmission systems contain errors or experience
failures
Errors in the software we provide to customers or the software
and systems we use to provide services could cause serious
problems for our customers. For example, errors in our
transaction processing systems can result in healthcare payers
paying the wrong amount, making payments to the wrong payee or
delaying payments. In addition, since some of our products and
services relate to laboratory ordering and reporting and
electronic prescriptions, an error in our systems could result
in injury to a patient. If problems like these occur, our
customers may seek compensation from us or may seek to terminate
their agreements with us, withhold payments due to us, seek
refunds from us of part or all of the fees charged under those
agreements or initiate litigation or other dispute resolution
procedures. In addition, we may be subject to claims against us
by others affected by any such problems.
61
We attempt to limit, by contract, our liability for damages
arising from our negligence, errors or mistakes. However,
contractual limitations on liability may not be enforceable in
certain circumstances or may otherwise not provide sufficient
protection to us from liability for damages. We maintain
liability insurance coverage, including coverage for errors and
omissions. However, it is possible that claims could exceed the
amount of our applicable insurance coverage, if any, or that
this coverage may not continue to be available on acceptable
terms or in sufficient amounts. Even if these claims do not
result in liability to us, investigating and defending against
them could be expensive and time consuming and could divert
managements attention away from our operations. In
addition, negative publicity caused by these events may delay
market acceptance of our products and services, including
unrelated products and services, or may harm our reputation and
our business.
Our
ability to generate revenue could suffer if we do not continue
to update and improve our existing products and services and
develop new ones
We must introduce new healthcare information services and
technology solutions and improve the functionality of our
existing products and services in a timely manner in order to
retain existing customers and attract new ones. However, we may
not be successful in responding to technological and regulatory
developments and changing customer needs. The pace of change in
the markets we serve is rapid, and there are frequent new
product and service introductions by our competitors and by
vendors whose products and services we use in providing our own
products and services. If we do not respond successfully to
technological and regulatory changes and evolving industry
standards, our products and services may become obsolete.
Technological changes may also result in the offering of
competitive products and services at lower prices than we are
charging for our products and services, which could result in
our losing sales unless we lower the prices we charge. In
addition, there can be no assurance that the products we develop
or license will be able to compete with the alternatives
available to our customers.
Developing
and implementing new or updated products and services may take
longer and cost more than expected
We rely on a combination of internal development, strategic
relationships, licensing and acquisitions to develop our
products and services. The cost of developing new healthcare
information services and technology solutions is inherently
difficult to estimate. Our development and implementation of
proposed products and services may take longer than originally
expected, require more testing than originally anticipated and
require the acquisition of additional personnel and other
resources. If we are unable to develop new or updated products
and services on a timely basis and implement them without
significant disruptions to the existing systems and processes of
our customers, we may lose potential sales and harm our
relationships with current or potential customers.
During
times when we are making significant changes to our products and
services or to systems we use to provide services, there are
increased risks of performance problems
If we do not respond successfully to technological and
regulatory changes and evolving industry standards, our products
and services may become obsolete. The software that we sell and
that we use to provide services is inherently complex and,
despite testing and quality control, we cannot be certain that
errors will not be found in existing versions or in any
enhancements, updates and new versions that we market or use.
Even if new products and services do not have performance
problems, our technical and customer service personnel may have
difficulties in installing them or in their efforts to provide
any necessary training and support to customers.
We expect to make significant additions and changes during the
remainder of 2006 and during 2007 to some of the hardware and
software Emdeon Business Services uses to provide connectivity
services and to the systems WebMD uses to create, manage and
deliver its portals. Our implementation of additions to and
changes in these platforms may cost more than originally
expected, may take longer than originally expected, and may
require more testing than originally anticipated. While the new
hardware and software will be tested before it is used in
production, we cannot be sure that the testing will uncover all
problems that may occur in actual use. If significant problems
occur as a result of these changes, we may fail to meet our
contractual
62
obligations to customers, which could result in claims being
made against us or in the loss of customer relationships. In
addition, we cannot provide assurance that additions to or
changes in these platforms will provide the additional
functionality and other benefits that were originally expected.
If our
systems or the Internet experience security breaches or are
otherwise perceived to be insecure, our business could
suffer
A security breach could damage our reputation or result in
liability. We retain and transmit confidential information,
including patient health information, in our processing centers
and other facilities. It is critical that these facilities and
infrastructure remain secure and be perceived by the marketplace
as secure. We may be required to expend significant capital and
other resources to protect against security breaches and hackers
or to alleviate problems caused by breaches. Despite the
implementation of security measures, this infrastructure or
other systems that we interface with, including the Internet and
related systems, may be vulnerable to physical break-ins,
hackers, improper employee or contractor access, computer
viruses, programming errors,
denial-of-service
attacks or other attacks by third parties or similar disruptive
problems. Any compromise of our security, whether as a result of
our own systems or systems that they interface with, could
reduce demand for our services.
Risks
Applicable to Our Use of the Internet
Most of WebMDs services are provided through the Internet.
In addition, Emdeon Business Services provides some
Internet-based services and use the Internet to receive some
data from customers. The following risks apply to our use of the
Internet in our businesses:
Our
Internet-based services are dependent on the development and
maintenance of the Internet infrastructure
Our ability to deliver our Internet-based services is dependent
on the development and maintenance of the infrastructure of the
Internet by third parties. This includes maintenance of a
reliable network backbone with the necessary speed, data
capacity and security, as well as timely development of
complementary products such as high-speed networks and modems,
for providing reliable Internet access and services. The
Internet has experienced, and is likely to continue to
experience, significant growth in the number of users and the
amount of traffic. If the Internet continues to experience
increased usage, the Internet infrastructure may be unable to
support the demands placed on it. In addition, the reliability
and performance of the Internet may be harmed by increased usage
or by
denial-of-service
attacks.
The Internet has experienced a variety of outages and other
delays as a result of damages to portions of its infrastructure,
and it could face outages and delays in the future. These
outages and delays could reduce the level of Internet usage as
well as the availability of the Internet to us for delivery of
our Internet-based services. In addition, our customers who
utilize our Web-based services depend on Internet service
providers, online service providers and other Web site operators
for access to our Web site. All of these providers have
experienced significant outages in the past and could experience
outages, delays and other difficulties in the future due to
system failures unrelated to our systems. Any significant
interruptions in our services or increases in response time
could result in a loss of potential or existing users of and
advertisers and sponsors on our Web site and, if sustained or
repeated, could reduce the attractiveness of our services.
Delivery
of Web-based services requires uninterrupted communications and
computer service from
third-party
service providers and our own systems
Our Web-based services, including WebMDs public Web sites
and private online portals, are designed to operate
24 hours a day, seven days a week, without interruption. To
do so, we rely on internal systems as well as communications and
hosting services provided by third parties. We have experienced
periodic system interruptions in the past, and we cannot
guarantee that they will not occur again. We do not maintain
redundant systems or facilities for some of these services. In
the event of a catastrophic event at one of our
63
data centers, we may experience an extended period of system
unavailability, which could negatively impact our business. In
addition, some of our Web-based services may, at times, be
required to accommodate higher than expected volumes of traffic.
At those times, we may experience slower response times or
system failures. Any sustained or repeated interruptions or
disruptions in these systems or increase in their response times
could damage our relationships with clients, customers,
advertisers and sponsors.
Third
parties may challenge the enforceability of our online
agreements
The law governing the validity and enforceability of online
agreements and other electronic transactions is evolving. We
could be subject to claims by third parties that the online
terms and conditions for use of our Web sites, including
disclaimers or limitations of liability, are unenforceable. A
finding by a court that these terms and conditions or other
online agreements are invalid could harm our business.
Government
regulation of the Internet could adversely affect our
business
The Internet and its associated technologies are subject to
government regulation. Our failure, or the failure of our
business partners, to accurately anticipate the application of
laws and regulations affecting our products and services and the
manner in which we deliver them, or any other failure to comply
with such laws and regulations, could create liability for us,
result in adverse publicity, or negatively affect our business.
In addition, new laws and regulations, or new interpretations of
existing laws and regulations, may be adopted with respect to
the Internet or other online services covering user privacy,
patient confidentiality, consumer protection and other issues,
including pricing, content, copyrights and patents,
distribution, and characteristics and quality of products and
services. We cannot predict whether these laws or regulations
will change or how such changes will affect our business. For
more information regarding government regulation of the Internet
to which we are or may be subject, see
Business Government Regulation in our
Annual Report on
Form 10-K
for the year ended December 31, 2005.
Risks
Related to Providing Products and Services to the Healthcare
Industry
Developments
in the healthcare industry could adversely affect our
business
Almost all of the revenue of Emdeon Business Services and much
of the revenue of WebMD comes from healthcare industry
participants or from companies providing products or services to
healthcare industry participants. In addition, a significant
portion of Porexs revenue comes from products used in
healthcare or related applications. Developments that result in
a reduction of expenditures by customers or potential customers
in the healthcare industry could have a material adverse effect
on our business. General reductions in expenditures by
healthcare industry participants could result from, among other
things:
|
|
|
|
|
government regulation or private initiatives that affect the
manner in which healthcare providers interact with patients,
payers or other healthcare industry participants, including
changes in pricing or means of delivery of healthcare products
and services;
|
|
|
|
consolidation of healthcare industry participants;
|
|
|
|
reductions in governmental funding for healthcare; and
|
|
|
|
adverse changes in business or economic conditions affecting
healthcare payers or providers, pharmaceutical companies,
medical device manufacturers or other healthcare industry
participants.
|
Even if general expenditures by industry participants remain the
same or increase, developments in the healthcare industry may
result in reduced spending in some or all of the specific
markets we serve or are planning to serve. For example, use of
our products and services could be affected by:
|
|
|
|
|
changes in the billing patterns of healthcare providers;
|
|
|
|
changes in the design of health insurance plans;
|
64
|
|
|
|
|
changes in the contracting methods payers use in their
relationships with providers; and
|
|
|
|
decreases in marketing expenditures by pharmaceutical companies
or medical device manufacturers, including as a result of
governmental regulation or private initiatives that discourage
or prohibit promotional activities by pharmaceutical or medical
device companies.
|
In addition, our customers expectations regarding pending
or potential industry developments may also affect their
budgeting processes and spending plans with respect to products
and services of the types we provide.
WebMDs advertising and sponsorship revenue is particularly
dependent on pharmaceutical, biotechnology and medical device
companies. WebMDs business will be adversely impacted if,
as a result of changes in business, economic or regulatory
conditions or other factors affecting the pharmaceutical,
biotechnology or medical device industries, pharmaceutical,
biotechnology or medical device companies reduce or postpone:
|
|
|
|
|
spending on marketing and educational services;
|
|
|
|
their use of the Internet as a vehicle for marketing and
education; or
|
|
|
|
their use of any specific service or combination of services
that we provide.
|
The healthcare industry has changed significantly in recent
years and we expect that significant changes will continue to
occur. However, the timing and impact of developments in the
healthcare industry are difficult to predict. We cannot provide
assurance that the markets for our products and services will
continue to exist at current levels or that we will have
adequate technical, financial and marketing resources to react
to changes in those markets.
Governmental
and private initiatives to support adoption of healthcare
information technology may encourage additional companies to
enter our markets and may result in the development of
additional technology solutions that compete with ours
There are currently numerous federal, state and private
initiatives and studies seeking ways to increase the use of
information technology in healthcare as a means of improving
care and reducing costs. These initiatives may encourage more
companies to enter our markets and may result in the development
of additional technology solutions that compete with ours. The
effect that these kinds of governmental and private initiatives
may have on our business is difficult to predict and there can
be no assurances that we will adequately address the risks
created by these initiatives or that we will be able to take
advantage of any resulting opportunities.
Government
regulation of healthcare creates risks and challenges with
respect to our compliance efforts and our business
strategies
The healthcare industry is highly regulated and is subject to
changing political, legislative, regulatory and other
influences. Existing and new laws and regulations affecting the
healthcare industry could create unexpected liabilities for us,
cause us to incur additional costs and could restrict our
operations. Many healthcare laws are complex and their
application to specific products and services may not be clear.
In particular, many existing healthcare laws and regulations,
when enacted, did not anticipate the healthcare information
services and technology solutions that we provide. However,
these laws and regulations may nonetheless be applied to our
products and services. Our failure to accurately anticipate the
application of these laws and regulations, or other failure to
comply, could create liability for us, result in adverse
publicity and negatively affect our businesses. Some of the
risks we face from healthcare regulation are as follows:
|
|
|
|
|
because we are in the business of applying information
technology to healthcare, various aspects of HIPAA have had and
are expected to continue to have significant consequences for
Emdeon Business Services and, to a lesser extent, WebMD;
|
|
|
|
because WebMDs public portals business involves
advertising and promotion of prescription and
over-the-counter
drugs and medical devices, any increase in regulation of these
areas could make it more difficult for us to contract for
sponsorships and advertising;
|
65
|
|
|
|
|
because we provides services to healthcare providers, our sales
and promotional practices must comply with federal and state
anti-kickback laws;
|
|
|
|
our healthcare connectivity and transaction-related
administrative services must be provided in compliance with
federal and state false claims laws; and
|
|
|
|
in providing health information to consumers, we must not engage
in activities that could be deemed to be practicing medicine and
a violation of applicable laws.
|
For more information regarding the risks that healthcare
regulation creates for our businesses, see
Business Government Regulation in our
Annual Report on
Form 10-K
for the year ended December 31, 2005.
Risks
Applicable to Our Entire Company and to Ownership of Our
Securities
The
ongoing investigations by the United States Attorney for the
District of South Carolina and the SEC could negatively impact
our company and divert management attention from our business
operations
The United States Attorney for the District of South Carolina is
conducting an investigation of our company. Based on the
information available to Emdeon as of the date of this Quarterly
Report, we believe that the investigation relates principally to
issues of financial accounting improprieties for Medical Manager
Corporation, a predecessor of Emdeon (by its merger into Emdeon
in September 2000), and Medical Manager Health Systems, a former
subsidiary of Emdeon; however, we cannot be sure of the
investigations exact scope or how long it may continue. In
addition, Emdeon understands that the SEC is conducting a formal
investigation into this matter. Adverse developments in
connection with the investigations, if any, including as a
result of matters that the authorities or Emdeon may discover,
could have a negative impact on our company and on how it is
perceived by investors and potential investors and customers and
potential customers. In addition, the management effort and
attention required to respond to the investigations and any such
developments could have a negative impact on our business
operations.
Emdeon intends to continue to fully cooperate with the
authorities in this matter. While we are not able to estimate,
at this time, the amount of the expenses that we will incur in
connection with the investigations, we expect that they may
continue to be significant. In connection with the sale of
Emdeon Practice Services to Sage Software, we have agreed to
indemnify Sage Software with respect to this matter.
We have
entered into an agreement for the sale of a majority interest in
Emdeon Business Services which, if consummated, would reduce our
interest in, and control over, this business
On September 26, 2006, we entered into an agreement with
certain affiliates of General Atlantic LLC to sell a majority
interest in our Emdeon Business Services segment, excluding the
ViPS business unit. The acquisition will be financed in part
with approximately $925 million in bank debt, which will be
an obligation of the entities comprising Emdeon Business
Services. As we will retain only a 48% interest in this entity
after consummation of the sale, our interest in the future
earnings of Emdeon Business Services will be correspondingly
reduced. In addition, the debt incurred in connection with the
disposition may reduce the profitability of Emdeon Business
Services and, if Emdeon Business Services is not able to service
it with cash flow from operations, could have a material adverse
effect on the businesss results of operations and the
value of our investment. Moreover, as a holder of a minority
interest in the parent of Emdeon Business Services, we will no
longer have voting control over the entity, and will not be able
to control the affairs of the business except to the extent
specifically provided for in that entitys corporate
governance documents.
The
dispositions of Emdeon Practice Services and Emdeon Business
Services may create contractual liabilities, including for
indemnifications, as well as other risks and
liabilities
We may face significant expense as a result of ongoing
obligations in connection with the completed sale of Emdeon
Practice Services to Sage Software and the pending sale of
Emdeon Business Services to General Atlantic. The agreements we
entered into in connection with these dispositions require us to
indemnify the
66
purchasers for specified losses incurred by them or resulting
from the inaccuracy of representations made by us in connection
with the transactions. We will remain exposed to these
liabilities until the indemnification periods expire under the
agreements. In addition, we may be subject to other, unforeseen
risks and liabilities in connection with the disposed
businesses. Although our management has attempted to evaluate
and assess the potential liabilities involved in these
transactions, we cannot assure you that we have properly
ascertained all of the risks.
Our
success depends, in part, on our attracting and retaining
qualified executives and employees
The success of our business depends, in part, on our ability to
attract and retain qualified executives, writers and editors,
software developers and other technical and professional
personnel and sales and marketing personnel. We anticipate the
need to hire and retain qualified employees in these areas from
time to time. Competition for qualified personnel in the
healthcare information technology and healthcare information
services industries is intense, and we cannot assure you that we
will be able to hire or retain a sufficient number of qualified
personnel to meet our requirements, or that we will be able to
do so at salary, benefit and other compensation costs that are
acceptable to us. Failure to do so may have an adverse effect on
our business.
Recent
and pending management changes may disrupt our operations and
our ability to recruit and retain other personnel
In the past year, we have experienced changes in our senior
management. The President of our company, who was also the head
of our Emdeon Business Services segment, left in December 2005
and has not been replaced. We have also announced that we expect
to experience further changes in our senior management,
including expected changes in our Chief Executive Officer, who
we expect to change positions within our company for health
reasons, and in our Chief Financial Officer, who we announced
would be leaving that position to take a position with Sage
Software, which acquired our Emdeon Practice Services segment in
September 2006. Changes in senior management and uncertainty
regarding pending changes may disrupt the operations of our
business and may impair our ability to recruit and retain needed
personnel. Any such disruption or impairment may have an adverse
affect on our business.
We face
significant competition for our products and services
The markets in which we operate are intensely competitive,
continually evolving and, in some cases, subject to rapid
technological change.
|
|
|
|
|
Key competitors to Emdeon Business Services include: transaction
processing companies, including those providing EDI
and/or
Internet-based services and those providing services through
other means, such as paper and fax; large information technology
consulting service providers; and healthcare information system
vendors (including physician practice management system,
hospital information system and EMR system vendors), health
insurance companies, pharmacy benefit management companies and
pharmacies that provide or are developing electronic transaction
services for use by healthcare providers
and/or by
their members and customers. In addition, major software,
hardware, information systems and business process outsourcing
companies, both with and without healthcare companies as their
partners, offer or have announced their intention to offer
products or services that are competitive with those of Emdeon
Business Services.
|
|
|
|
WebMDs public portals face competition from numerous other
companies, both in attracting users and in generating revenue
from advertisers and sponsors. We compete for users with online
services and Web sites that provide health-related information,
including both commercial sites and
not-for-profit
sites. We compete for advertisers and sponsors with both
health-related Web sites and general purpose consumer online
services and portals and other high-traffic Web sites that
include both healthcare-related and non-healthcare-related
content and services. Since there are no substantial barriers to
entry
|
67
|
|
|
|
|
into the markets in which WebMDs public portals
participate, we expect that competitors will continue to enter
these markets.
|
|
|
|
|
|
WebMDs private portals compete with: providers of
healthcare decision-support tools and online health management
applications; wellness and disease management vendors; and
health information services and health management offerings of
health plans and their affiliates.
|
Many of our competitors have greater financial, technical,
product development, marketing and other resources than we do.
These organizations may be better known than we are and have
more customers than we do. We cannot provide assurance that we
will be able to compete successfully against these organizations
or any alliances they have formed or may form.
For more information about the competition we face, see
Business Healthcare Information Services and
Technology Solutions Competition for Our Healthcare
Information Services and Technology Solutions in our
Annual Report on
Form 10-K
for the year ended December 31, 2005.
Contractual
relationships with governmental customers may impose special
burdens and additional risks on us that are not generally found
in contracts with other customers
A significant portion of ViPSs revenue and a portion of
the revenue of Emdeon Business Services and WebMD comes from
customers that are governmental agencies. Government contracts
and subcontracts may be subject to some or all of the following:
|
|
|
|
|
termination when appropriated funding for the current fiscal
year is exhausted;
|
|
|
|
termination for the governmental customers convenience,
subject to a negotiated settlement for costs incurred and profit
on work completed, along with the right to place contracts out
for bid before the full contract term, as well as the right to
make unilateral changes in contract requirements, subject to
negotiated price adjustments;
|
|
|
|
most-favored pricing disclosure requirements that
are designed to ensure that the government can negotiate and
receive pricing akin to that offered commercially and
requirements to submit proprietary cost or pricing data to
ensure that government contract pricing is fair and reasonable;
|
|
|
|
commercial customer price tracking requirements that require
contractors to monitor pricing offered to a specified class of
customers and to extend price reductions offered to that class
of customers to the government;
|
|
|
|
reporting and compliance requirements related to, among other
things: conflicts of interest; equal employment opportunity,
affirmative action for veterans and for workers with
disabilities, and accessibility for the disabled;
|
|
|
|
broader audit rights than we would usually grant to
non-governmental customers; and
|
|
|
|
specialized remedies for breach and default, including setoff
rights, retroactive price adjustments, and civil or criminal
fraud penalties, as well as mandatory administrative dispute
resolution procedures instead of state contract law remedies.
|
In addition, certain violations of federal law may subject
government contractors to having their contracts terminated and,
under certain circumstances, suspension
and/or
debarment from future government contracts. We are also subject
to
conflict-of-interest
rules that may affect our eligibility for some government
contracts, including rules applicable to all
U.S. government contracts as well as rules applicable to
the specific agencies with which we have contracts or with which
we may seek to enter into contracts. Finally, some of our
government contracts are priced based on our cost of providing
products and services. Those contracts are subject to regulatory
cost-allowability standards and a specialized system of cost
accounting standards.
68
Third
parties may bring claims as a result of the activities of our
strategic partners or resellers of our products and
services
We could be subject to claims by third parties, and to
liability, as a result of the activities, products or services
of our strategic partners or resellers of our products and
services. Even if these claims do not result in liability to us,
investigating and defending these claims could be expensive,
time-consuming and result in adverse publicity that could harm
our business.
We may
not be successful in protecting our intellectual property and
proprietary rights
Our intellectual property is important to all of our businesses.
We rely on a combination of trade secret, patent and other
intellectual property laws and confidentiality procedures and
non-disclosure contractual provisions to protect our
intellectual property. We believe that our non-patented
proprietary technologies and business and manufacturing
processes are protected under trade secret, contractual and
other intellectual property rights. However, those rights do not
afford the statutory exclusivity provided by patented processes.
In addition, the steps that we take to protect our intellectual
property, proprietary information and trade secrets may prove to
be inadequate and, whether or not adequate, may be expensive.
There can be no assurance that we will be able to detect
potential or actual misappropriation or infringement of our
intellectual property, proprietary information or trade secrets.
Even if we detect misappropriation or infringement by a third
party, there can be no assurance that we will be able to enforce
our rights at a reasonable cost, or at all. In addition, our
rights to intellectual property, proprietary information and
trade secrets may not prevent independent third-party
development and commercialization of competing products or
services.
Third
parties may claim that we are infringing their intellectual
property, and we could suffer significant litigation or
licensing expenses or be prevented from selling products or
services
We could be subject to claims that we are misappropriating or
infringing intellectual property or other proprietary rights of
others. These claims, even if not meritorious, could be
expensive to defend and divert managements attention from
our operations. If we become liable to third parties for
infringing these rights, we could be required to pay a
substantial damage award and to develop non-infringing
technology, obtain a license or cease selling the products or
services that use or contain the infringing intellectual
property. We may be unable to develop non-infringing products or
services or obtain a license on commercially reasonable terms,
or at all. We may also be required to indemnify our customers if
they become subject to third-party claims relating to
intellectual property that we license or otherwise provide to
them, which could be costly.
We have
incurred losses and may incur losses in the future
We began operations in January 1996 and, until 2004, had
incurred net losses in each year since our inception. As of
September 30, 2006, we had an accumulated deficit of
approximately $9.7 billion. We currently intend to continue
to invest in infrastructure development, applications
development, marketing and acquisitions. Whether we incur losses
in a particular period will depend on, among other things, the
amount of such investments and whether those investments lead to
increased revenues.
Acquisitions,
business combinations and other transactions may be difficult to
complete and, if completed, may have negative consequences for
our business and our securityholders
We intend to seek to acquire or to engage in business
combinations with companies engaged in complementary businesses.
In addition, we may enter into joint ventures, strategic
alliances or similar arrangements with third parties. These
transactions may result in changes in the nature and scope of
our operations and changes in our financial condition. Our
success in completing these types of transactions will depend
on, among other things, our ability to locate suitable
candidates and negotiate mutually acceptable terms with them, as
well as the availability of financing. Significant competition
for these opportunities exists,
69
which may increase the cost of and decrease the opportunities
for these types of transactions. Financing for these
transactions may come from several sources, including:
|
|
|
|
|
cash and cash equivalents on hand and marketable securities;
|
|
|
|
proceeds from the incurrence of indebtedness; and
|
|
|
|
proceeds from the issuance of additional common stock, preferred
stock, convertible debt or other securities.
|
Our issuance of additional securities could:
|
|
|
|
|
cause substantial dilution of the percentage ownership of our
stockholders at the time of the issuance;
|
|
|
|
cause substantial dilution of our earnings per share;
|
|
|
|
subject us to the risks associated with increased leverage,
including a reduction in our ability to obtain financing or an
increase in the cost of any financing we obtain;
|
|
|
|
subject us to restrictive covenants that could limit our
flexibility in conducting future business activities; and
|
|
|
|
adversely affect the prevailing market price for our outstanding
securities.
|
We do not intend to seek securityholder approval for any such
acquisition or security issuance unless required by applicable
law or regulation or the terms of existing securities.
Our
business will suffer if we fail to successfully integrate
acquired businesses and technologies or to assess the risks in
particular transactions
We have in the past acquired, and may in the future acquire,
businesses, technologies, services, product lines and other
assets. The successful integration of the acquired businesses
and assets into our operations, on a cost-effective basis, can
be critical to our future performance. The amount and timing of
the expected benefits of any acquisition, including potential
synergies between Emdeon and the acquired business, are subject
to significant risks and uncertainties. These risks and
uncertainties include, but are not limited to, those relating to:
|
|
|
|
|
our ability to maintain relationships with the customers of the
acquired business;
|
|
|
|
our ability to cross-sell products and services to customers
with which we have established relationships and those with
which the acquired businesses have established relationships;
|
|
|
|
our ability to retain or replace key personnel;
|
|
|
|
potential conflicts in payer, provider, strategic partner,
sponsor or advertising relationships;
|
|
|
|
our ability to coordinate organizations that are geographically
diverse and may have different business cultures; and
|
|
|
|
compliance with regulatory requirements.
|
We cannot guarantee that any acquired businesses will be
successfully integrated with our operations in a timely or
cost-effective manner, or at all. Failure to successfully
integrate acquired businesses or to achieve anticipated
operating synergies, revenue enhancements or cost savings could
have a material adverse effect on our business, financial
condition and results of operations.
Although our management attempts to evaluate the risks inherent
in each transaction and to value acquisition candidates
appropriately, we cannot assure you that we will properly
ascertain all such risks or that acquired businesses and assets
will perform as we expect or enhance the value of our company as
a whole. In
70
addition, acquired companies or businesses may have larger than
expected liabilities that are not covered by the
indemnification, if any, that we are able to obtain from the
sellers.
We may
not be able to raise additional funds when needed for our
business or to exploit opportunities
Our future liquidity and capital requirements will depend upon
numerous factors, including the success of the integration of
our businesses, our existing and new applications and service
offerings, competing technologies and market developments,
potential future acquisitions and dispositions of companies or
businesses, and additional repurchases of our common stock. We
may need to raise additional funds to support expansion, develop
new or enhanced applications and services, respond to
competitive pressures, acquire complementary businesses or
technologies or take advantage of unanticipated opportunities.
If required, we may raise such additional funds through public
or private debt or equity financing, strategic relationships or
other arrangements. There can be no assurance that such
financing will be available on acceptable terms, if at all, or
that such financing will not be dilutive to our stockholders.
|
|
ITEM 3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
Interest
Rate Sensitivity
The primary objective of our investment activities is to
preserve principal and maintain adequate liquidity, while at the
same time maximizing the yield we receive from our investment
portfolio. This objective is accomplished by adherence to our
investment policy, which establishes the list of eligible types
of securities and credit requirements for each investment.
Changes in prevailing interest rates will cause the principal
amount of the investment to fluctuate. To minimize this risk, we
maintain our portfolio of cash equivalents, short-term
investments and marketable securities in commercial paper,
non-government debt securities, money market funds and highly
liquid United States Treasury notes. We view these high grade
securities within our portfolio as having similar market risk
characteristics. Principal amounts expected to mature in 2006
and 2007 are $70.1 million and $1.8 million,
respectively.
The
31/8% Notes
and the 1.75% Notes that we have issued have fixed interest
rates; changes in interest rates will not impact our financial
condition or results of operations.
We have not utilized derivative financial instruments in our
investment portfolio.
Exchange
Rate Sensitivity
Currently, substantially all of our sales and expenses are
denominated in United States dollars; however, Porex and WebMD
are exposed to fluctuations in foreign currency exchange rates,
primarily the rate of exchange of the United States dollar
against the Euro. This exposure arises primarily as a result of
translating the results of Porexs foreign operations to
the United States dollar at exchange rates that have fluctuated
from the beginning of the accounting period. Neither Porex nor
WebMD have engaged in foreign currency hedging activities to
date. Foreign currency translation gains were $1.0 million
and $2.4 million, during the three and nine month periods
ended September 30, 2006, respectively, and foreign
currency translation gains (losses) were $0.0 million and
$(2.7) million, during the three and nine months ended
September 30, 2005. We believe that future exchange rate
sensitivity related to Porex and WebMD will not have a material
effect on our financial condition or results of operations.
|
|
ITEM 4.
|
Controls
and Procedures
|
As required by Exchange Act
Rule 13a-15(b),
Emdeon management, including the Chief Executive Officer and
Chief Financial Officer, conducted an evaluation of the
effectiveness of Emdeons disclosure controls and
procedures, as defined in Exchange Act
Rule 13a-15(e),
as of September 30, 2006. Based on that
71
evaluation, the Chief Executive Officer and Chief Financial
Officer concluded that Emdeons disclosure controls and
procedures were effective as of September 30, 2006.
In connection with the evaluation required by Exchange Act
Rule 13a-15(d),
Emdeon management, including the Chief Executive Officer and
Chief Financial Officer, concluded that, except for the
continuing conversion by WHC to a new enterprise resource
planning system, including new accounting software, no changes
in Emdeons internal control over financial reporting, as
defined in Exchange Act Rule 13(a)-15(f), occurred during
the third quarter of 2006 that have materially affected, or are
reasonably likely to materially affect, Emdeons internal
control over financial reporting. During the third quarter of
2006, WHC continued the implementation of a new third party
enterprise resource planning system which it began to implement
earlier in 2006. As a result, certain business processes and
accounting procedures of our WebMD segment have changed. These
changes were made in accordance with WHCs plan to
implement separate systems from those of Emdeon and not in
response to any identified deficiency or weakness in WHCs
or Emdeons internal control over financial reporting.
72
PART II
OTHER INFORMATION
|
|
ITEM 1.
|
Legal
Proceedings
|
The information relating to legal proceedings contained in
Note 12 to the Consolidated Financial Statements included
in Part I, Item 1 of this Quarterly Report is
incorporated herein by this reference.
The risk factors contained in Part I, Item 2 of this
Quarterly Report under the heading Factors That May Affect
Our Future Financial Condition or Results of Operations
are incorporated herein by this reference. Those risk factors
have been substantially revised from the risk factors contained
in our Annual Report on
Form 10-K
in order to reflect the sale of Emdeon Practice Services to Sage
Software in September 2006 and other updates.
|
|
ITEM 2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
(c) The following table provides information about
purchases by Emdeon during the three months ended
September 30, 2006 of equity securities that are registered
by us pursuant to Section 12 of the Exchange Act:
Issuer
Purchases of Equity Securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum Number
|
|
|
|
|
|
|
|
|
|
|
|
|
(or Approximate
|
|
|
|
|
|
|
|
|
|
Total Number
|
|
|
Dollar Value)
|
|
|
|
|
|
|
|
|
|
of Shares
|
|
|
of Shares
|
|
|
|
|
|
|
|
|
|
Purchased as
|
|
|
that May
|
|
|
|
|
|
|
|
|
|
Part of
|
|
|
Yet Be
|
|
|
|
Total Number of
|
|
|
|
|
|
Publicly Announced
|
|
|
Purchased Under
|
|
|
|
Shares
|
|
|
Average Price
|
|
|
Plans or
|
|
|
the Plans or
|
|
Period
|
|
Purchased
|
|
|
Paid per Share
|
|
|
Programs
|
|
|
Programs
|
|
|
07/01/06 - 07/31/06
|
|
|
|
|
|
$
|
0.00
|
|
|
|
|
|
|
$
|
11,157,044
|
|
08/01/06 - 08/31/06
|
|
|
|
|
|
$
|
0.00
|
|
|
|
|
|
|
$
|
11,157,044
|
|
09/01/06 - 09/30/06
|
|
|
18,677
|
(1)
|
|
$
|
11.87
|
|
|
|
|
|
|
$
|
11,157,044
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
18,677
|
|
|
$
|
11.87
|
|
|
|
|
|
|
$
|
11,157,044
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Represents shares withheld from Emdeon Restricted Stock that
vested during September 2006 in order to satisfy withholding tax
requirements related to the vesting of the awards. The value of
these shares was determined based on the closing fair market
value of Emdeon Common Stock on the date of vesting. For
additional information, see Note 7 to the Consolidated
Financial Statements included in Part I, Item 1 of
this Quarterly Report.
|
|
|
ITEM 4.
|
Submission
of Matters to a Vote of Security Holders
|
At our Annual Meeting of Stockholders held on September 12,
2006, our stockholders voted with respect to the following
matters:
|
|
|
|
|
Proposal 1 To elect as Class II directors
to serve three year terms ending in 2009:
|
|
|
|
|
|
|
|
Paul A. Brooke
|
|
votes FOR
|
|
|
229,668,700
|
|
|
|
votes withheld
|
|
|
36,308,904
|
|
James V. Manning
|
|
votes FOR
|
|
|
260,908,863
|
|
|
|
votes withheld
|
|
|
4,468,741
|
|
Martin J. Wygod
|
|
votes FOR
|
|
|
259,941,812
|
|
|
|
votes withheld
|
|
|
5,425,792
|
|
73
|
|
|
|
|
Proposal 2 To approve an amendment to
Emdeons 2000 Long-Term Incentive Plan to increase the
number of shares reserved for issuance:
|
|
|
|
|
|
Votes FOR:
|
|
|
131,161,549
|
|
Votes AGAINST:
|
|
|
48,081,549
|
|
Abstentions:
|
|
|
819,471
|
|
Broker non-votes:
|
|
|
85,315,093
|
|
|
|
|
|
|
Proposal 3 To ratify the appointment of
Ernst & Young LLP as the independent registered public
accounting firm to serve as our independent auditor for the
fiscal year ending December 31, 2006:
|
|
|
|
|
|
Votes FOR:
|
|
|
263,796,645
|
|
Votes AGAINST:
|
|
|
6,261,555
|
|
Abstentions:
|
|
|
319,404
|
|
Broker non-votes:
|
|
|
0
|
|
As a result, Messrs. Brooke, Manning and Wygod were each
elected to serve a three year term ending in 2009 and
Proposals 2 and 3 were each approved. For each Proposal,
the totals include 10,638,297 votes cast FOR by the holder of
our Convertible Redeemable Exchangeable Preferred Stock.
In addition to the directors elected at the Annual Meeting, our
Board of Directors consists of: Mark J. Adler, M.D., Kevin
Cameron and Herman Sarkowsky, whose terms expire in 2007; and
Neil F. Dimick and Joseph E. Smith, whose terms expire in 2008.
The exhibits listed in the accompanying Exhibit Index on
page E-1
are filed or furnished as part of this Quarterly Report.
74
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
Emdeon Corporation
Andrew C. Corbin
Executive Vice President and
Chief Financial Officer
Date: November 9, 2006
75
EXHIBIT INDEX
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
2
|
.1
|
|
Stock Purchase Agreement, dated as
of August 8, 2006, between the Registrant and Sage
Software, Inc. (incorporated by reference from Exhibit 10.1
to the Registrants Current Report on
Form 8-K
filed on September 26, 2006)
|
|
2
|
.2
|
|
Merger Agreement, dated as of
September 26, 2006, among the Registrant, EBS Holdco, Inc.,
EBS Master LLC, Medifax-EDI Holding Company, EBS Acquisition
LLC, GA EBS Merger LLC and EBS Merger Co. (incorporated by
reference from Exhibit 2.1 to the Registrants Current
Report on
Form 8-K
filed on August 11, 2006)
|
|
2
|
.3
|
|
Asset Purchase Agreement, dated as
of July 19, 2006, among June Plum, Inc., Medsite, Inc.,
Medsite Acquisition Corp., MedsiteCME, LLC and Medsite
Pharmaceutical Services, LLC, (incorporated by reference from
Exhibit 10.1 to the Current Report on
Form 8-K
filed by WebMD Health Corp. on July 25, 2006)
|
|
3
|
.1
|
|
Eleventh Amended and Restated
Certificate of Incorporation of Registrant, as amended
(incorporated by reference to Exhibit 3.1 to
Registrants Quarterly Report on
Form 10-Q
for the quarter ended September 30, 2004)
|
|
3
|
.2
|
|
Certificate of Amendment of
Eleventh Amended and Restated Certificate of Incorporation of
the Registrant Changing Its Name from WebMD Corporation to
Emdeon Corporation (incorporated by reference to
Exhibit 3.1 to Registrants Current Report on
Form 8-K
dated October 17, 2005)
|
|
3
|
.3
|
|
Certificate of Designations for
Convertible Redeemable Exchangeable Preferred Stock, as amended
(incorporated by reference to Exhibit 3.2 to the
Registrants Quarterly Report on
Form 10-Q
for the quarter ended September 30, 2004)
|
|
3
|
.4
|
|
Amended and Restated Bylaws of
Registrant, as currently in effect (incorporated by reference to
Exhibit 3.2 of the Registrants Quarterly Report on
Form 10-Q
for the quarter ended June 30, 2004)
|
|
10
|
.1*
|
|
Form of Amendment to the
Registrants Equity Compensation Plans and Stock Option
Agreements**
|
|
10
|
.2
|
|
Amended and Restated Emdeon
Corporation 2000 Long-Term Incentive Plan (incorporated by
reference from Annex E to the Registrants Proxy
Statement for its 2006 Annual Meeting filed on August 14,
2006)**
|
|
10
|
.3
|
|
Amended and Restated WebMD Health
Corp. 2005 Long-Term Incentive Plan (incorporated by reference
from Annex E to WebMD Health Corp.s Proxy Statement
for its 2006 Annual Meeting filed on August 14, 2006)**
|
|
10
|
.4
|
|
Letter Agreement, dated as of
July 10, 2006, between the Registrant, Emdeon Practice
Services, Inc. and Andrew C. Corbin (incorporated by reference
from Exhibit 10.1 to the Current Report on
Form 8-K
filed by the Registrant on July 11. 2006)**
|
|
31
|
.1*
|
|
Rule 13a-14(a)/15d-14(a)
Certification of Chief Executive Officer of Registrant
|
|
31
|
.2*
|
|
Rule 13a-14(a)/15d-14(a)
Certification of Chief Financial Officer of Registrant
|
|
32
|
.1*
|
|
Section 1350 Certification of
Chief Executive Officer of Registrant
|
|
32
|
.2*
|
|
Section 1350 Certification of
Chief Financial Officer of Registrant
|
|
|
|
* |
|
Filed herewith. |
|
** |
|
Relates to executive compensation. |
E-1